Onset O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
of O O
hyperammonemic O B_DISEASE
encephalopathy O I_DISEASE
varied O O
from O O
0 O B_NUMBER[MEASURE]
. O O
5 O B_MEASURE
to O O
5 O B_MEASURE/B_ENT
days O I_MEASURE/I_ENT
( O O
mean O B_MEASURE/B_LOCATION
: O O
2 O B_MEASURE
. O O
6 O B_MEASURE
+ O I_MEASURE
/ O O
- O O
1 O B_MEASURE
. O O
3 O B_MEASURE/B_ENT
days O I_MEASURE/I_ENT
) O O
after O O
the O O
initiation O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
chemotherapy O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

The O O
effects O O
of O O
two O O
unselective O O
potassium B B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
( O O
K B B_PROTEIN[GENE]/B_LOCATION
( O O
+ O O
) O O
- O O
) O O
channel O O
blockers O O
, O O
quinine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
( O O
12 O O
. O O
5 O O
, O O
25 O O
and O O
50 O O
mg O O
/ O O
kg O O
) O O
and O O
4 B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
aminopyridine I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
1 O O
and O O
2 O O
mg O O
/ O O
kg O O
) O O
, O O
on O O
conditioned O O
place O O
preference O O
and O O
biphasic O O
changes O O
in O O
motor O O
activity O O
induced O O
by O O
morphine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
10 O O
mg O O
/ O O
kg O O
) O O
were O O
tested O O
in O O
Wistar O O
rats O O
. O O

Quinine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
is O O
known O O
to O O
block O O
voltage O O
- O O
, O O
calcium B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
- O O
and O O
ATP B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O O
sensitive O O
K B B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
+ O O
) O O
- O O
channels O O
while O O
4 B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
aminopyridine I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O O
known O O
to O O
block O O
voltage O O
- O O
sensitive O O
K B B_OTHER/B_LOCATION
( O O
+ O O
) O O
- O O
channels O O
. O O

In O O
the O O
motor O O
activity O O
test O O
measured O O
with O O
an O O
Animex O O
- O O
activity O O
meter O O
neither O O
of O O
the O O
K B B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
( O O
+ O O
) O O
- O O
channel O O
blockers O O
affected O O
morphine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
induced O O
hypoactivity O O
, O O
but O O
both O O
K B B_OTHER/B_LOCATION
( O O
+ O O
) O O
- O O
channel O O
blockers O O
prevented O O
morphine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
induced O O
secondary O O
hyperactivity O O
. O O

It O O
is O O
also O O
suggested O O
that O O
the O O
blockade O O
of O O
K B B_OTHER/B_LOCATION
( O O
+ O O
) O O
- O O
channels O O
sensitive O O
to O O
these O O
blockers O O
is O O
not O O
sufficient O O
to O O
prevent O O
morphine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
induced O O
hypoactivity O O
whereas O O
morphine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
induced O O
hyperactivity O O
seems O O
to O O
be O O
connected O O
to O O
both O O
quinine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
- O O
and O O
4 B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
aminopyridine I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
sensitive O O
K B B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
( O O
+ O O
) O O
- O O
channels O O
. O O

The O O
present O O
study O O
was O O
designed O O
to O O
investigate O O
whether O O
nociceptin B B_GENE/B_PERSON
/ O O
orphanin B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
FQ I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
nocistatin B B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
could O O
modulate O O
impairment O O
of O O
learning O O
and O O
memory O O
induced O O
by O O
scopolamine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
a O O
muscarinic O O
cholinergic O O
receptor O O
antagonist O O
, O O
using O O
spontaneous O O
alternation O O
of O O
Y O O
- O O
maze O O
and O O
step O O
- O O
down O O
type O O
passive O O
avoidance O O
tasks O O
in O O
mice O O
. O O

The O O
antipsychotic O O
agent O O
, O O
remoxipride B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
[ O O
( B B_TIME[MEASURE]/B_LOCATION
S I I_TIME[MEASURE]/I_LOCATION
) I I_TIME[MEASURE]/I_LOCATION
- I I_TIME[MEASURE]/I_LOCATION
( I I_TIME[MEASURE]/I_LOCATION
- I I_TIME[MEASURE]/I_LOCATION
) I I_TIME[MEASURE]/I_LOCATION
- I I_TIME[MEASURE]/I_LOCATION
3 I I_TIME[MEASURE]/I_LOCATION
- I I_TIME[MEASURE]/I_LOCATION
bromo I I_TIME[MEASURE]/I_LOCATION
- I I_TIME[MEASURE]/I_LOCATION
N I I_TIME[MEASURE]/I_LOCATION
- I I_TIME[MEASURE]/I_LOCATION
[ I I_TIME[MEASURE]/I_LOCATION
( I I_TIME[MEASURE]/I_LOCATION
1 I I_TIME[MEASURE]/I_LOCATION
- I I_TIME[MEASURE]/I_LOCATION
ethyl I I_TIME[MEASURE]/I_LOCATION
- I I_TIME[MEASURE]/I_LOCATION
2 I I_TIME[MEASURE]/I_LOCATION
- I I_TIME[MEASURE]/I_LOCATION
pyrrolidinyl I I_TIME[MEASURE]/I_LOCATION
) I I_TIME[MEASURE]/I_LOCATION
methyl I I_TIME[MEASURE]/I_LOCATION
] I I_TIME[MEASURE]/I_LOCATION
- I I_TIME[MEASURE]/I_LOCATION
2 I I_TIME[MEASURE]/I_LOCATION
, I I_TIME[MEASURE]/I_LOCATION
6 I I_TIME[MEASURE]/I_LOCATION
- I I_TIME[MEASURE]/I_LOCATION
dimethoxybenz I I_TIME[MEASURE]/I_LOCATION
amide I I_TIME[MEASURE]/I_LOCATION
] O O
has O O
been O O
associated O O
with O O
acquired O O
aplastic O O
anemia O O
. O O

Cells O B_BIO/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
were O O
treated O O
for O O
0 O B_MEASURE
- O O
24 O B_MEASURE
h O I_MEASURE
with O O
each O O
compound O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
0 O B_MEASURE
- O O
200 O B_MEASURE
microM O I_MEASURE
) O O
. O O

Apoptosis O O
was O O
assessed O O
by O O
fluorescence O O
microscopy O O
in O O
Hoechst B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
33342 I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
and O O
propidium B B_TIME[MEASURE]/B_COLOR
iodide I I_TIME[MEASURE]/I_COLOR
stained O O
cell O O
samples O O
. O O

In O O
research O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
towards O O
the O O
development O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
of O O
new O B_DISEASE
atypical O I_DISEASE
antipsychotic O I_DISEASE
agents O I_DISEASE
, O O
one O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
strategy O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
is O O
that O O
the O O
dopaminergic O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
system O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
can O O
be O O
modulated O O
through O O
manipulation O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
the O O
serotonergic O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
system O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
. O O

The O O
synthesis O O
and O O
preliminary O O
pharmacological O O
evaluation O O
of O O
a O O
series O O
of O O
potential O O
atypical O O
antipsychotic O O
agents O O
based O O
on O O
the O O
structure O O
of O O
1 B B_LOCATION/B_ORGANIZATION
- I I_LOCATION/I_ORGANIZATION
( I I_LOCATION/I_ORGANIZATION
1 I I_LOCATION/I_ORGANIZATION
, I I_LOCATION/I_ORGANIZATION
2 I I_LOCATION/I_ORGANIZATION
- I I_LOCATION/I_ORGANIZATION
dihydro I I_LOCATION/I_ORGANIZATION
- I I_LOCATION/I_ORGANIZATION
2 I I_LOCATION/I_ORGANIZATION
- I I_LOCATION/I_ORGANIZATION
acenaphthylenyl I I_LOCATION/I_ORGANIZATION
) I I_LOCATION/I_ORGANIZATION
piperazine I I_LOCATION/I_ORGANIZATION
( O O
7 O O
) O O
is O O
described O O
. O O

Compound O O
7e O O
, O O
5 B B_MEASURE/B_LOCATION
- I I_MEASURE/I_LOCATION
{ I I_MEASURE/I_LOCATION
2 I I_MEASURE/I_LOCATION
- I I_MEASURE/I_LOCATION
[ I I_MEASURE/I_LOCATION
4 I I_MEASURE/I_LOCATION
- I I_MEASURE/I_LOCATION
( I I_MEASURE/I_LOCATION
1 I I_MEASURE/I_LOCATION
, I I_MEASURE/I_LOCATION
2 I I_MEASURE/I_LOCATION
- I I_MEASURE/I_LOCATION
dihydro I I_MEASURE/I_LOCATION
- I I_MEASURE/I_LOCATION
2 I I_MEASURE/I_LOCATION
- I I_MEASURE/I_LOCATION
acenaphthylenyl I I_MEASURE/I_LOCATION
) I I_MEASURE/I_LOCATION
piperazinyl I I_MEASURE/I_LOCATION
] I I_MEASURE/I_LOCATION
ethyl I I_MEASURE/I_LOCATION
} I I_MEASURE/I_LOCATION
- I I_MEASURE/I_LOCATION
2 I I_MEASURE/I_LOCATION
, I I_MEASURE/I_LOCATION
3 I I_MEASURE/I_LOCATION
- I I_MEASURE/I_LOCATION
dihy I I_MEASURE/I_LOCATION
dro I I_MEASURE/I_LOCATION
- I I_MEASURE/I_LOCATION
1H I I_MEASURE/I_LOCATION
- I I_MEASURE/I_LOCATION
indol I I_MEASURE/I_LOCATION
- I I_MEASURE/I_LOCATION
2 I I_MEASURE/I_LOCATION
- I I_MEASURE/I_LOCATION
one I I_MEASURE/I_LOCATION
, O O
from O O
this O O
series O O
showed O O
significant O O
affinities O O
at O O
the O O
5 O O
- O O
HT1A O O
and O O
5 O O
- O O
HT2A O O
receptors O O
and O O
moderate O O
affinity O O
at O O
the O O
D2 O O
receptor O O
. O O

OBJECTIVE O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O O
To O O
determine O O
whether O O
pharmacological O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
stress O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
leads O O
to O O
prolonged O O
but O O
reversible O B_DISEASE_ADJECTIVE[DISEASE]
left O O
ventricular O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
dysfunction O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O O
patients O B_PERSON
with O O
coronary O B_DISEASE
artery O I_DISEASE
disease O I_DISEASE
, O O
similar O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
that O O
seen O O
after O O
exercise O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
. O O

BACKGROUND O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
: O O
The O O
use O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_ORGANISM_FUNCTION
of O O
appetite O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
suppressants O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
Europe O B_LOCATION/B_PERSON
has O O
been O O
associated O O
with O O
the O O
development O B_DISEASE_ADJECTIVE[DISEASE]
of O O
primary O B_DISEASE
pulmonary O I_DISEASE
hypertension O I_DISEASE
( O O
PPH O B_DISEASE/B_GENE
) O O
. O O

The O O
use O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
anorexigens O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
was O O
common O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
in O O
both O O
groups O B_ORGANIZATION/B_LOCATION
. O O

An O O
unexpectedly O O
high O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
( O O
11 O B_MEASURE
. O O
4 O B_MEASURE/B_PERSON
% O I_MEASURE/I_PERSON
) O O
number O B_MEASURE/B_PERSON
of O O
patients O B_PERSON
with O O
SPH O B_DISEASE/B_GENE
had O O
used O O
anorexigens O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
. O O

The O O
high O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
prevalence O B_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
anorexigen O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
use O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
patients O B_PERSON/B_LOCATION
with O O
SPH O B_DISEASE/B_GENE
also O O
raises O O
the O O
possibility O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
that O O
these O O
drugs O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
precipitate O O
pulmonary O B_DISEASE
hypertension O I_DISEASE
in O O
patients O B_PERSON/B_ORGANIZATION
with O O
underlying O B_DISEASE/B_GENE
conditions O I_DISEASE
associated O O
with O O
SPH O B_DISEASE/B_GENE
. O O

However O O
, O O
only O O
longer O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
experience O I_PERSON/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
will O O
more O O
clearly O O
define O O
the O O
incidence O B_DISEASE_ADJECTIVE[DISEASE]
of O O
each O O
side O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
effect O I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O O
low O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
molecular O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
weight O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
preparations O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

PURPOSE O O
: O O
To O O
report O O
a O O
case O O
of O O
bilateral O O
optic O O
neuropathy O O
in O O
a O O
patient O O
receiving O O
tacrolimus B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
FK B B_PERSON/B_LOCATION
506 I B_PERSON/I_LOCATION
, O O
Prograf O O
; O O
Fujisawa O O
USA O O
, O O
Inc O O
, O O
Deerfield O O
, O O
Illinois O O
) O O
for O O
immunosuppression O O
after O O
orthotropic O O
liver O O
transplantation O O
. O O

Hypercalcemia O B_DISEASE
, O O
arrhythmia O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
, O O
and O O
mood O B_DISEASE
stabilizers O I_DISEASE
. O O

Patients O B_PERSON
in O O
group O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
B O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
were O O
not O O
comparable O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
those O O
in O O
group O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
A O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
, O O
as O O
the O O
latter O B_NUMBER[MEASURE]/B_PERSON
were O O
medically O O
compromised O O
and O O
were O O
receiving O O
multiple O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
pharmacotherapies O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Patterns O O
of O O
sulfadiazine B B_DISEASE_ADJECTIVE[DISEASE]/B_BACTERIUM[BIO]
acute O O
nephrotoxicity O O
. O O

Sulfadiazine B B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
acute O O
nephrotoxicity O O
is O O
reviving O O
specially O O
because O O
of O O
its O O
use O O
in O O
toxoplasmosis O O
in O O
HIV O O
- O O
positive O O
patients O O
. O O

Four O B_NUMBER[MEASURE]
of O O
44 O B_NUMBER[MEASURE]/B_PERSON
patients O I_NUMBER[MEASURE]/I_PERSON
( O O
9 O B_MEASURE/B_PERSON
% O I_MEASURE/I_PERSON
) O O
evaluable O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O O
response O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
exhibited O O
objective O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
subjective O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
evidence O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
an O O
antineoplastic O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
effect O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
of O O
therapy O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

The O O
Olanzipine B B_LOCATION
HGGW O O
Study O O
Group O O
. O O

Tests O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
basic O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
visual O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
function O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
included O O
high O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
- O O
and O O
low O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
- O O
contrast O B_MEASURE
visual O I_MEASURE
acuity O I_MEASURE
( O O
HCVA O B_LOCATION/B_ORGANIZATION
and O O
LCVA O B_LOCATION/B_ORGANIZATION
) O O
, O O
Pelli O B_PERSON
- O O
Robson O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
contrast O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
threshold O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
( O O
CT O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
) O O
and O O
Goldmann O B_MEASURE
perimetry O I_MEASURE
( O O
FIELDS O B_LOCATION/B_ORGANIZATION
) O O
. O O

The O O
mean O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
differences O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
in O O
the O O
pre O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
and O O
post O B_LOCATION/B_DISEASE
- O O
dilatation O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
measurements O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O O
tested O O
for O O
statistical O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
significance O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
at O O
the O O
95 O B_MEASURE/B_LOCATION
% O I_MEASURE/I_LOCATION
level O I_MEASURE/I_LOCATION
using O O
one O B_NUMBER[MEASURE]/B_BODY_PART_OR_ORGAN_COMPONENT
- O O
tail O B_BODY_PART_OR_ORGAN_COMPONENT/B_MEASURE
paired O O
t O B_OTHER/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
tests O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
. O O

RESULTS O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
: O O
Pupillary O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
dilation O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
resulted O O
in O O
a O O
statistically O O
significant O B_DISEASE_ADJECTIVE[DISEASE]
deterioration O I_DISEASE_ADJECTIVE[DISEASE]
in O O
CT O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
and O O
HCVA O B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
only O O
. O O

The O O
aim O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O O
the O O
study O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
was O O
to O O
evaluate O O
the O O
potential O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
role O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O O
a O O
selective O B_PROTEIN[GENE]/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
alpha1 O I_PROTEIN[GENE]/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
adrenoceptor O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
agonist O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
the O O
treatment O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
urinary O B_DISEASE/B_LOCATION
stress O I_DISEASE/I_LOCATION
incontinence O I_DISEASE/I_LOCATION
. O O

The O O
results O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
indicate O O
that O O
the O O
clinical O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
usefulness O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
direct O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
, O O
peripherally O O
acting O O
sub O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
- O O
type O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
- O O
selective O B_PROTEIN[GENE]/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
alpha1 O I_PROTEIN[GENE]/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
adrenoceptor O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
agonists O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
in O O
the O O
medical O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
treatment O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
stress O B_DISEASE/B_LOCATION
incontinence O I_DISEASE/I_LOCATION
may O O
be O O
limited O O
by O O
associated O O
piloerection O B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
and O O
cardiovascular O B_DISEASE
side O I_DISEASE
effects O I_DISEASE
. O O

Doses O B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
more O B_MEASURE
than O O
90 O B_NUMBER[MEASURE]/B_LOCATION
% O I_NUMBER[MEASURE]/I_LOCATION
of O O
randomized O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
patients O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
in O O
the O O
high O B_MEASURE/B_LOCATION
- O O
and O O
low O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
- O O
dose O B_MEASURE/B_LOCATION
groups O B_MEASURE/I_LOCATION
were O O
titrated O O
to O O
their O O
assigned O O
target O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
, O O
and O O
the O O
mean O B_MEASURE/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
doses O B_MEASURE/I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
blinded O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
medication O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
both O O
groups O B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
remained O O
similar O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
throughout O O
the O O
study O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

OBJECTIVES O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
: O O
Simultaneous O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
abuse O B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
cocaine O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
ethanol O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
affects O O
12 O B_PERSON/B_ENT
million O I_PERSON/I_ENT
Americans O I_PERSON/I_ENT
annually O O
. O O

In O O
combination O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
these O O
substances O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
are O O
substantially O O
more O O
toxic O B_DISEASE_ADJECTIVE[DISEASE]
than O O
either O O
drug O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
alone O O
. O O

Hemodynamic O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
measurements O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
, O O
electrocardiograms O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
, O O
and O O
serum O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
drug O I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
concentrations O I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O O
obtained O O
at O O
baseline O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
, O O
and O O
then O O
at O O
fixed O O
time O B_MEASURE/B_LOCATION
intervals O I_MEASURE/I_LOCATION
after O O
each O O
drug O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
administered O O
. O O

Co O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
- O O
administration O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
resulted O O
in O O
prolonged O B_DISEASE
cardiac O I_DISEASE
toxicity O I_DISEASE
and O O
was O O
dysrhythmogenic O B_DISEASE_ADJECTIVE[DISEASE]
. O O

Viracept B B_DISEASE_ADJECTIVE[DISEASE]/B_BACTERIUM[BIO]
and O O
irregular O O
heartbeat O O
warning O O
. O O

The O O
symptoms O B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
ceased O O
after O O
switching O O
to O O
another O O
drug O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
combination O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Finally O O
, O O
resting O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
and O O
peak O B_MEASURE
exercise O O
abnormal O B_DISEASE
left O I_DISEASE
ventricular O I_DISEASE
filling O I_DISEASE
was O O
detected O O
in O O
38 O B_MEASURE
and O O
35 O B_MEASURE/B_PERSON
% O I_MEASURE/I_PERSON
of O O
patients O B_PERSON/B_BIO
as O O
compared O O
to O O
19 O B_MEASURE
and O O
9 O B_MEASURE/B_PERSON
% O I_MEASURE/I_PERSON
of O O
controls O B_PERSON/B_BIO
, O O
respectively O O
( O O
p O B_PROTEIN[GENE]/B_LOCATION
= O O
0 O B_MEASURE
. O O
11 O B_MEASURE
and O O
0 O B_MEASURE
. O O
02 O B_MEASURE
, O O
respectively O O
) O O
. O O

Phase O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
2 O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
early O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
afterdepolarization O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
as O O
a O O
trigger O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
polymorphic O B_DISEASE
ventricular O I_DISEASE
tachycardia O I_DISEASE
in O O
acquired O O
long O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
- O O
QT O B_DISEASE/B_LOCATION
syndrome O I_DISEASE/I_LOCATION
: O O
direct O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
evidence O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
from O O
intracellular O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
recordings O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
the O O
intact O B_BODY_PART_OR_ORGAN_COMPONENT
left O O
ventricular O B_BODY_PART_OR_ORGAN_COMPONENT
wall O I_BODY_PART_OR_ORGAN_COMPONENT
. O O

We O O
therefore O O
hypothesized O O
that O O
overexpression O O
of O O
Cu B B_LOCATION
/ O O
Zn B B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
- O O
superoxide B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
dismutase O O
( O O
h O O
- O O
SOD1 O O
) O O
should O O
protect O O
transgenic O O
mice O O
from O O
ototoxicity O O
. O O

OBJECTIVE O O
: O O
To O O
assess O O
whether O O
prednisone B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
PDN B B_DISEASE/B_PROTEIN[GENE]
) O O
produces O O
anxiety O O
and O O
/ O O
or O O
cerebral O O
glial O O
changes O O
in O O
rats O O
. O O

Anxiety O B_DISEASE
was O O
assessed O O
using O O
an O O
open O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
field O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
and O O
elevated O O
plus O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
- O O
maze O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
devices O I_LOCATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Stained O O
microglia O B_BIO/B_DISEASE_ADJECTIVE[DISEASE]
cells O I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
were O O
significantly O O
more O O
numerous O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
striatum O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
and O O
hippocampus O B_BODY_PART_OR_ORGAN_COMPONENT
in O O
the O O
high O B_MEASURE/B_LOCATION
- O O
dose O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
group O I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
compared O O
to O O
controls O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
. O O

Antimicrobial O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
induced O O
mania O B_DISEASE
( O O
antibiomania O B_DISEASE/B_MEASURE
) O O
: O O
a O O
review O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
spontaneous O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
reports O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

The O O
authors O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
reviewed O O
reported O O
cases O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
antibiotic O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
induced O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
manic O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
episodes O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
by O O
means O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
a O O
MEDLINE O B_ORGANIZATION
and O O
PsychLit O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
search O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
for O O
reports O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
of O O
antibiotic O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
induced O O
mania O B_DISEASE
. O O

Twenty O B_NUMBER[MEASURE]/B_LOCATION
- O O
one O B_NUMBER[MEASURE]/B_ORGANIZATION
reports O I_NUMBER[MEASURE]/I_ORGANIZATION
of O O
antimicrobial O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
induced O O
mania O B_DISEASE
were O O
found O O
in O O
the O O
literature O B_PERSON/B_LOCATION
. O O

Patients O B_PERSON/B_BIO
have O O
an O O
increased O O
risk O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
of O O
developing O O
mania O B_DISEASE
while O O
being O O
treated O O
with O O
antimicrobials O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Further O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
research O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
clearly O O
is O O
required O O
to O O
determine O O
the O O
incidence O B_MEASURE
of O O
antimicrobial O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
induced O O
mania O B_DISEASE
, O O
the O O
relative O B_MEASURE
risk O I_MEASURE
factors O I_MEASURE
of O O
developing O O
an O O
antimicrobial O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
induced O O
manic O B_DISEASE
episode O I_DISEASE
among O O
various O B_PERSON
demographic O I_PERSON
populations O I_PERSON
, O O
and O O
the O O
incidence O B_MEASURE
of O O
patients O B_PERSON
who O O
continue O O
to O O
have O O
persistent O B_DISEASE
affective O I_DISEASE
disorders O I_DISEASE
once O O
the O O
initial O B_DISEASE
episode O I_DISEASE
, O O
which O O
occurs O O
while O O
the O O
patient O B_PERSON/B_BODY_PART_OR_ORGAN_COMPONENT
is O O
taking O O
antibiotics O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
subsides O B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
. O O

The O O
aim O O
of O O
the O O
present O O
study O O
was O O
to O O
determine O O
the O O
efficacy O O
of O O
glyceryl B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
trinitrate I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
GTN B B_ORGANIZATION/B_LOCATION
) O O
, O O
an O O
NO B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
donor O O
, O O
in O O
the O O
resolution O O
of O O
primary O O
dysmenorrhea O O
in O O
comparison O O
with O O
diclofenac B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
DCF B B_LOCATION/B_ORGANIZATION
) O O
. O O

In O O
the O O
subsequent O B_TIME[MEASURE]/B_LOCATION
cycle O I_TIME[MEASURE]/I_LOCATION
the O O
other O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
treatment O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
was O O
used O O
. O O

The O O
participants O B_PERSON
recorded O O
menstrual O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
symptoms O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
and O O
possible O B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
side O B_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
effects O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
at O O
different O B_MEASURE/B_ENT
times O I_MEASURE/I_ENT
( O O
0 O B_MEASURE
, O O
30 O B_MEASURE
, O O
60 O B_MEASURE
, O O
120 O B_MEASURE/B_ENT
minutes O I_MEASURE/I_ENT
) O O
after O O
the O O
first O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
dose O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
of O O
medication O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
on O O
the O O
first O B_SEQUENCE[MEASURE]/B_LOCATION
day O I_SEQUENCE[MEASURE]/I_LOCATION
of O O
the O O
cycle O B_TIME[MEASURE]
, O O
with O O
both O O
drugs O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
. O O

Both O O
treatments O O
significantly O O
reduced O O
DPI O O
by O O
the O O
30th O O
minute O O
( O O
GTN B B_LOCATION
, O O
- O O
12 O O
. O O
8 O O
+ O O
/ O O
- O O
17 O O
. O O
9 O O
; O O
DCF B B_LOCATION/B_ORGANIZATION
, O O
- O O
18 O O
. O O
9 O O
+ O O
/ O O
- O O
16 O O
. O O
6 O O
) O O
. O O

However O O
, O O
DCF B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
continued O O
to O O
be O O
effective O O
in O O
reducing O O
pelvic O O
pain O O
for O O
two O O
hours O O
, O O
whereas O O
GTN B B_DISEASE/B_MEASURE
scores O O
remained O O
more O O
or O O
less O O
stable O O
after O O
30 O O
min O O
and O O
significantly O O
higher O O
than O O
those O O
for O O
DFC O O
( O O
after O O
one O O
hour O O
: O O
GTN B B_LOCATION/B_PROTEIN[GENE]
, O O
- O O
12 O O
. O O
8 O O
+ O O
/ O O
- O O
17 O O
. O O
9 O O
; O O
DFC O O
, O O
- O O
18 O O
. O O
9 O O
+ O O
/ O O
- O O
16 O O
. O O
6 O O
and O O
after O O
two O O
hours O O
: O O
GTN B B_LOCATION/B_PROTEIN[GENE]
, O O
- O O
23 O O
. O O
7 O O
+ O O
/ O O
- O O
20 O O
. O O
5 O O
; O O
DFC O O
, O O
- O O
59 O O
. O O
7 O O
+ O O
/ O O
- O O
17 O O
. O O
9 O O
, O O
p O O
= O O
0 O O
. O O
0001 O O
) O O
. O O

Headache O O
was O O
significantly O O
increased O O
by O O
GTN B B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
but O O
not O O
by O O
DCF B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

These O O
findings O O
indicate O O
that O O
GTN B B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
has O O
a O O
reduced O O
efficacy O O
and O O
tolerability O O
by O O
comparison O O
with O O
DCF B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
the O O
treatment O O
of O O
primary O O
dysmenorrhea O O
. O O

Temocapril B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
a O O
long O O
- O O
acting O O
non O O
- O O
SH O O
group O O
angiotensin B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
converting O O
enzyme O O
inhibitor O O
, O O
modulates O O
glomerular O O
injury O O
in O O
chronic O O
puromycin B B_DISEASE_ADJECTIVE[DISEASE]
aminonucleoside I I_DISEASE_ADJECTIVE[DISEASE]
nephrosis O O
. O O

The O O
purpose O O
of O O
the O O
present O O
study O O
was O O
to O O
determine O O
whether O O
chronic O O
administration O O
of O O
temocapril B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
a O O
long O O
- O O
acting O O
non O O
- O O
SH O O
group O O
angiotensin B B_GENE
converting O O
enzyme O O
( O O
ACE O O
) O O
inhibitor O O
, O O
reduced O O
proteinuria O O
, O O
inhibited O O
glomerular O O
hypertrophy O O
and O O
prevented O O
glomerulosclerosis O O
in O O
chronic O O
puromycin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
aminonucleoside I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
( O O
PAN B B_DISEASE
) O O
- O O
induced O O
nephrotic O O
rats O O
. O O

Systolic O O
BP O O
in O O
the O O
PAN B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
group O O
was O O
significantly O O
high O O
at O O
4 O O
, O O
14 O O
and O O
20 O O
weeks O O
, O O
but O O
was O O
normal O O
in O O
the O O
PAN B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
/ O O
temocapril B B_LOCATION
group O O
. O O

The O O
ratio O O
of O O
glomerular O O
tuft O O
area O O
to O O
the O O
area O O
of O O
Bowman O O
' O O
s O O
capsules O O
( O O
GT O O
/ O O
BC O O
) O O
in O O
the O O
PAN B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
group O O
was O O
significantly O O
increased O O
, O O
but O O
it O O
was O O
significantly O O
lower O O
in O O
the O O
PAN B B_LOCATION/B_ORGANIZATION
/ O O
temocapril B B_LOCATION/B_ORGANIZATION
group O O
. O O

It O O
appears O O
that O O
temocapril B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
was O O
effective O O
in O O
retarding O O
renal O O
progression O O
and O O
protected O O
renal O O
function O O
in O O
PAN B B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
neprotic O O
rats O O
. O O

BACKGROUND O O
: O O
The O O
24 O O
- O O
hour O O
continuous O O
infusion O O
of O O
5 B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
fluorouracil I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
5 B B_LOCATION/B_PROTEIN[GENE]
- I I_LOCATION/I_PROTEIN[GENE]
FU I I_LOCATION/I_PROTEIN[GENE]
) O O
and O O
folinic B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
acid I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
FA B B_LOCATION
) O O
as O O
part O O
of O O
several O O
new O O
multidrug O O
chemotherapy O O
regimens O O
in O O
advanced O O
gastric O O
cancer O O
( O O
AGC O O
) O O
has O O
shown O O
to O O
be O O
effective O O
, O O
with O O
low O O
toxicity O O
. O O

In O O
order O O
to O O
improve O O
this O O
MMC B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
- O O
dependent O O
schedule O O
we O O
initiated O O
a O O
phase O O
II O O
study O O
with O O
high O O
- O O
dose O O
5 B B_LOCATION/B_PERSON
- I I_LOCATION/I_PERSON
FU I I_LOCATION/I_PERSON
/ O O
FA B B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
3 O O
- O O
weekly O O
bolus O O
MMC B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Treatment O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_GENE
given O O
on O O
an O O
outpatient O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_LOCATION
basis O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_LOCATION
, O O
using O O
portable O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
pump O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
systems O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
was O O
repeated O O
on O O
day O B_TIME[MEASURE]/B_LOCATION
57 O I_TIME[MEASURE]/I_LOCATION
. O O

CONCLUSIONS O O
: O O
High O O
- O O
dose O O
5 B B_LOCATION/B_PERSON
- I I_LOCATION/I_PERSON
FU I I_LOCATION/I_PERSON
/ O O
FA B B_LOCATION
/ O O
MMC B B_LOCATION/B_ORGANIZATION
is O O
an O O
effective O O
and O O
well O O
- O O
tolerated O O
outpatient O O
regimen O O
for O O
AGC O O
( O O
objective O O
response O O
rate O O
54 O O
. O O
6 O O
% O O
) O O
. O O

These O O
well O O
- O O
documented O O
side O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
effects O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
have O O
restricted O O
the O O
use O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
of O O
this O O
potent O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
protease O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
inhibitor O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
children O B_PERSON/B_DISEASE
. O O

The O O
cumulative O O
incidence O O
of O O
serum O O
creatinine B B_MEASURE/B_GENE
levels O O
> O O
50 O O
% O O
above O O
normal O O
was O O
33 O O
% O O
after O O
96 O O
weeks O O
. O O

Children O O
with O O
persistent O O
sterile O O
leukocyturia O O
more O O
frequently O O
had O O
serum O O
creatinine B B_MEASURE/B_GENE
levels O O
of O O
50 O O
% O O
above O O
normal O O
than O O
those O O
children O O
without O O
persistent O O
sterile O O
leukocyturia O O
. O O

We O O
report O O
a O O
case O O
of O O
acute O O
interstitial O O
nephritis O O
( O O
AIN O O
) O O
due O O
to O O
nicergoline B B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
Sermion B B_PROTEIN[GENE]/B_BACTERIUM[BIO]
) O O
. O O

Paw O B_PERSON/B_DISEASE
preference O I_PERSON/I_DISEASE
was O O
assessed O O
by O O
a O O
food O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
reaching O O
test O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
. O O

In O O
normal O O
rats O O
, O O
the O O
whole O O
brain O O
sections O O
exhibited O O
complete O O
staining O O
with O O
TTC B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
. O O

The O O
selective O O
blockade O O
of O O
A2 O O
adenosine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
receptor O O
by O O
DMPX B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
( O O
3 B B_TIME[MEASURE]/B_LOCATION
, I B_TIME[MEASURE]/I_LOCATION
7 I B_TIME[MEASURE]/I_LOCATION
- I B_TIME[MEASURE]/I_LOCATION
dimethyl I B_TIME[MEASURE]/I_LOCATION
- I B_TIME[MEASURE]/I_LOCATION
1 I B_TIME[MEASURE]/I_LOCATION
- I B_TIME[MEASURE]/I_LOCATION
propargylxanthine I B_TIME[MEASURE]/I_LOCATION
) O O
significantly O O
enhanced O O
cocaine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O O
induced O O
locomotor O O
activity O O
of O O
animals O O
. O O

Using O O
a O O
nested O B_PERSON/B_MEASURE
case O I_PERSON/I_MEASURE
- O O
control O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
design O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
, O O
477 O B_PERSON/B_MEASURE
cases O I_PERSON/I_MEASURE
of O O
bradyarrhythmia O B_DISEASE
requiring O O
a O O
permanent O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
pacemaker O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
were O O
matched O O
( O O
1 O B_MEASURE
: O O
4 O B_MEASURE
) O O
to O O
1 O B_MEASURE
, O O
908 O B_MEASURE/B_PERSON
controls O I_MEASURE/I_PERSON
. O O

Nonsteroidal O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
anti O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
- O O
inflammatory O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
drug O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
- O O
induced O O
cystitis O B_DISEASE
is O O
a O O
poorly O O
recognized O O
and O O
under O O
- O O
reported O O
condition O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

The O O
true O B_MEASURE/B_LOCATION
incidence O B_MEASURE/I_LOCATION
of O O
nonsteroidal O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
anti O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
- O O
inflammatory O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
drug O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
- O O
induced O O
cystitis O B_DISEASE
in O O
humans O B_PERSON/B_BIO
must O O
be O O
clarified O O
by O O
prospective O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
clinical O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
trials O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
. O O

BACKGROUND O B_TIME[MEASURE]/B_LOCATION
AND O O
OBJECTIVES O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
: O O
Central O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
nervous O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
system O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
and O O
cardiac O B_DISEASE
toxicity O I_DISEASE
following O O
the O O
administration O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
of O O
local O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
anesthetics O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
is O O
a O O
recognized O O
complication O B_DISEASE
of O O
regional O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
anesthesia O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

PURPOSE O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
: O O
Apnea O B_DISEASE
is O O
known O O
to O O
occur O O
during O O
seizures O B_DISEASE/B_LOCATION
, O O
but O O
systematic O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
studies O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
of O O
ictal O B_DISEASE
respiratory O I_DISEASE
changes O I_DISEASE
in O O
adults O B_PERSON/B_BIO
are O O
few O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

METHODS O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
: O O
Twelve O B_PERSON/B_BIO
rats O I_PERSON/I_BIO
( O O
six O B_NUMBER[MEASURE]
chronically O O
epileptic O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
animals O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
and O O
six O B_NUMBER[MEASURE]/B_PERSON
controls O I_NUMBER[MEASURE]/I_PERSON
) O O
were O O
anesthetized O O
, O O
given O O
tracheotomies O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
, O O
and O O
subjected O O
to O O
hyperventilation O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
or O O
hypoventilation O B_DISEASE
conditions O I_DISEASE
. O O

Although O O
VE O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
had O O
a O O
similar O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
decrease O B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
in O O
both O O
groups O B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
in O O
the O O
epileptic O B_TIME[MEASURE]/B_ORGANIZATION
group O I_TIME[MEASURE]/I_ORGANIZATION
, O O
the O O
decrease O B_DISEASE_ADJECTIVE[DISEASE]
in O O
VE O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
was O O
due O O
to O O
a O O
significant O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
( O O
p O O
< O B_MEASURE
0 O B_MEASURE
. O O
05 O B_MEASURE
) O O
increase O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
in O O
TE O B_MEASURE/B_LOCATION
peak O I_MEASURE/I_LOCATION
in O O
relation O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
to O O
that O O
of O O
the O O
control O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
animals O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
. O O

The O O
hypoventilation O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
maneuver O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
led O O
to O O
an O O
increase O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O O
the O O
arterial O B_PROTEIN[GENE]/B_BODY_PART_OR_ORGAN_COMPONENT
Paco2 O I_PROTEIN[GENE]/I_BODY_PART_OR_ORGAN_COMPONENT
, O O
followed O O
by O O
an O O
increase O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O O
VE O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
. O O

In O O
the O O
epileptic O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
group O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
the O O
increase O B_DISEASE_ADJECTIVE[DISEASE]
in O O
VE O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
was O O
mediated O O
by O O
a O O
significant O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
( O O
p O B_OTHER/B_MEASURE
< O B_MEASURE
0 O B_MEASURE
. O O
05 O B_MEASURE
) O O
decrease O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O O
TE O B_MEASURE/B_LOCATION
peak O I_MEASURE/I_LOCATION
compared O O
with O O
the O O
control O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
group O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
. O O

Systemic O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
application O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
of O O
KCN O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
, O O
to O O
evaluate O O
the O O
effects O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
peripheral O B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
chemoreception O B_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
activation O B_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O O
ventilation O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_PROTEIN[GENE]
, O O
led O O
to O O
a O O
similar O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
increase O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
in O O
VE O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
for O O
both O O
groups O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
. O O

There O O
was O O
a O O
significant O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
decrease O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
in O O
the O O
time O B_TIME[MEASURE]/B_DISEASE
to O O
onset O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
arrhythmia O B_DISEASE
as O O
compared O O
with O O
control O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
nonprogesterone O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
treated O O
rats O B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
6 O B_MEASURE
. O O
2 O B_MEASURE/B_LOCATION
+ O I_MEASURE/I_LOCATION
/ O O
- O O
1 O B_MEASURE
. O O
3 O B_MEASURE/B_SPORT[ENT]
vs O I_MEASURE/I_SPORT[ENT]
. O O
30 O B_MEASURE
. O O
8 O B_MEASURE
+ O I_MEASURE
/ O O
- O O
2 O B_MEASURE
. O O
5 O B_TIME[MEASURE]
min O I_TIME[MEASURE]
, O O
mean O O
+ O B_OTHER/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
/ O O
- O O
SE O B_DISEASE/B_PROTEIN[GENE]
) O O
. O O

Serum O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
levels O I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O O
tumor O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
necrosis O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
factor O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- O O
alpha O B_PROTEIN[GENE]
and O O
interferon O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O O
gamma O B_PROTEIN[GENE]/B_MEASURE
were O O
also O O
determined O O
by O O
ELISA O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

AIM O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
: O O
We O O
studied O O
the O O
effect O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
high O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
frequency O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
STN O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
stimulation O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
in O O
23 O B_PERSON/B_BIO
patients O I_PERSON/I_BIO
. O O

CONCLUSION O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
: O O
Bilateral O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
subthalamic O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
nucleus O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
stimulation O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
is O O
an O O
effective O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
treatment O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
for O O
advanced O B_DISEASE/B_LOCATION
Parkinson O I_DISEASE/I_LOCATION
' O I_DISEASE/I_LOCATION
s O I_DISEASE/I_LOCATION
disease O I_DISEASE/I_LOCATION
. O O

Due O O
to O O
an O O
accidental O B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
malfunctioning O I_DISEASE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
the O O
infusion O B_PRODUCT[OBJECT]/B_LOCATION
pump O I_PRODUCT[OBJECT]/I_LOCATION
, O O
the O O
patient O B_PERSON/B_BODY_PART_OR_ORGAN_COMPONENT
was O O
inadvertently O O
administered O O
a O O
toxic O B_MEASURE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
dosage O B_MEASURE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
the O O
drug O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
which O O
caused O O
renal O B_DISEASE
insufficiency O I_DISEASE
. O O

Given O O
the O O
progressive O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
deterioration O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
of O O
the O O
symptoms O B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
of O O
the O O
laboratory O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
values O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
despite O O
adequate O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
medical O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
treatment O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
, O O
a O O
decision O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
was O O
made O O
to O O
introduce O O
haemodialytical O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
therapy O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
order O B_MEASURE/B_PERSON
to O O
remove O O
the O O
drug O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
and O O
therapy O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
reduce O O
the O O
nephrotoxicity O B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

From O O
the O O
results O O
obtained O O
, O O
haemodialysis O O
can O O
therefore O O
be O O
suggested O O
as O O
a O O
useful O O
therapy O O
in O O
rare O O
cases O O
of O O
progressive O O
acute O O
renal O O
failure O O
caused O O
by O O
desferrioxamine B B_DISEASE
. O O

Seven O B_NUMBER[MEASURE]
( O O
54 O B_NUMBER[MEASURE]/B_PERSON
% O I_NUMBER[MEASURE]/I_PERSON
) O O
of O O
the O O
13 O B_PERSON
patients O I_PERSON
experienced O O
visual O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
recovery O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
after O O
stopping O O
the O O
drug O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

A O O
low O B_DISEASE_ADJECTIVE[DISEASE]/B_TIME[MEASURE]
dose O I_DISEASE_ADJECTIVE[DISEASE]/I_TIME[MEASURE]
and O O
prompt O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
discontinuation O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
of O O
the O O
drug O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O O
recommended O O
particularly O O
in O O
individuals O B_PERSON/B_LOCATION
with O O
diabetes O B_DISEASE
mellitus O I_DISEASE
, O O
glaucoma O B_DISEASE
or O O
who O O
are O O
heavy O B_DISEASE/B_PERSON
smokers O I_DISEASE/I_PERSON
. O O

Gustatory O B_DISEASE
hyperhidrosis O I_DISEASE
is O O
facial O B_DISEASE_ADJECTIVE[DISEASE]/B_TIME[MEASURE]
sweating O B_DISEASE_ADJECTIVE[DISEASE]/I_TIME[MEASURE]
usually O O
associated O O
with O O
the O O
eating O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_ORGANISM_FUNCTION
of O O
hot O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
spicy O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
food O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
or O O
even O O
smelling O O
this O O
food O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
. O O

In O O
rodents O O
, O O
the O O
effect O O
of O O
the O O
beta B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
carboline I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
derivative O O
isopropyl B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
6 I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
benzyloxy I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
4 I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
methoxymethyl I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
beta I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
carboline I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
3 I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
carboxylate I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
abecarrnil B B_LOCATION/B_PROTEIN[GENE]
) O O
, O O
a O O
new O O
ligand O O
for O O
benzodiazepine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
receptors O O
possessing O O
anxiolytic O O
and O O
anticonvulsant O O
properties O O
, O O
was O O
evaluated O O
on O O
the O O
function O O
of O O
central O O
gamma B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
aminobutyric I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
acid I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
( O O
GABA B B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
A O O
receptor O O
complex O O
, O O
both O O
in O O
vitro O O
and O O
in O O
vivo O O
. O O

Bromocriptine B B_PERSON
has O O
been O O
implicated O O
in O O
several O O
previous O O
case O O
reports O O
of O O
myocardial O O
infarction O O
in O O
the O O
puerperium O O
. O O

There O O
are O O
very O O
few O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
reports O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
about O O
asterixis O B_DISEASE/B_BIO
as O O
a O O
side O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
effect O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
treatment O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
with O O
psychopharmacologic O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
agents O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Baseline O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
blood O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
pressures O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
were O O
higher O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
in O O
fluctuating O O
patients O B_PERSON/B_LOCATION
; O O
a O O
higher O B_MEASURE
baseline O I_MEASURE
blood O I_MEASURE
pressure O I_MEASURE
correlated O O
with O O
greater O B_DISEASE
hypotensive O I_DISEASE
effects O I_DISEASE
. O O

Angiotensin B B_GENE
- O O
converting O O
enzyme O O
( O O
ACE O O
) O O
inhibitors O O
should O O
be O O
used O O
first O O
as O O
they O O
are O O
safer O O
, O O
do O O
not O O
require O O
blood O O
level O O
monitoring O O
, O O
modify O O
progression O O
of O O
disease O O
, O O
relieve O O
symptoms O O
, O O
improve O O
exercise O O
tolerance O O
and O O
reduce O O
mortality O O
. O O

Dosage O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
increased O O
from O O
2 O B_MEASURE
. O O
5 O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
mg O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
b O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
. O O
d O B_TIME[MEASURE]/B_DISEASE
. O O
to O O
5 O B_MEASURE
mg O I_MEASURE
b O O
. O O
d O B_TIME[MEASURE]/B_DISEASE
. O O
at O O
4 O B_TIME[MEASURE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
weeks O I_TIME[MEASURE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O O
patients O B_PERSON/B_BIO
with O O
diastolic O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
blood O B_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
pressure O B_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
greater O B_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
than O O
90 O B_MEASURE/B_LOCATION
mmHg O I_MEASURE/I_LOCATION
and O O
their O O
further O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
response O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
was O O
greater O B_MEASURE
than O O
those O O
remaining O O
on O O
2 O B_NUMBER[MEASURE]
. O O
5 O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
mg O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
b O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
. O O
d O B_TIME[MEASURE]/B_DISEASE
. O O

Plasma O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
concentrations O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
did O O
not O O
differ O O
significantly O O
between O O
the O O
two O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
formulations O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Although O O
both O O
formulations O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
had O O
similar O B_DRUG_ADJECTIVE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
pharmacokinetic O I_DRUG_ADJECTIVE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
and O O
pharmacodynamic O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
profiles O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
the O O
new O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
formulation O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
is O O
not O O
suitable O B_DISEASE_ADJECTIVE[DISEASE]
for O O
clinical O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_PERSON
use O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_PERSON
due O O
to O O
the O O
high O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
incidence O B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
of O O
thrombophlebitis O B_DISEASE
produced O O
. O O

After O O
withdrawal O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
of O O
the O O
pharmacon O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
all O O
symptoms O B_DISEASE
disappeared O O
spontaneously O O
. O O

Several O O
cases O O
of O O
cardiac O O
adverse O O
reactions O O
related O O
to O O
vinorelbine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
VNR B B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
) O O
have O O
been O O
reported O O
in O O
the O O
literature O O
. O O

The O O
risk O O
of O O
VNR B B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
cardiac O O
events O O
was O O
similar O O
to O O
vindesine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
VDS B B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
) O O
and O O
other O O
cardiotoxic O O
drugs O O
[ O O
fluorouracil B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
anthracyclines B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
, O O
gemcitabine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
GEM B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
) O O
em O O
leader O O
] O O
. O O

Even O O
if O O
it O O
did O O
not O O
reach O O
statistical O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
significance O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
because O O
of O O
a O O
few O B_MEASURE/B_PERSON
number O I_MEASURE/I_PERSON
of O O
cases O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
the O O
risk O B_DISEASE/B_MEASURE
was O O
lower O B_MEASURE
in O O
trials O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
excluding O O
patients O B_PERSON
with O O
cardiac O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
history O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
and O O
seemed O O
to O O
be O O
higher O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
in O O
trials O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
including O O
patients O B_PERSON
with O O
pre O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
existing O O
cardiac O B_DISEASE
diseases O I_DISEASE
. O O

Within O O
2 O B_NUMBER[MEASURE]/B_LOCATION
to O O
3 O B_TIME[MEASURE]/B_ENT
weeks O I_TIME[MEASURE]/I_ENT
of O O
initially O O
effective O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
and O O
well O O
- O O
tolerated O O
treatment O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
3 O B_NUMBER[MEASURE]/B_PERSON
patients O I_NUMBER[MEASURE]/I_PERSON
with O O
a O O
history O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_EDU[ORGANIZATION]
of O O
rosacea O B_DISEASE
and O O
1 O B_NUMBER[MEASURE]/B_PERSON
with O O
a O O
history O B_ORGANIZATION/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
acne O B_DISEASE
experienced O O
sudden O B_DISEASE_ADJECTIVE[DISEASE]
worsening O O
with O O
pustular O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
rosaceiform O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
lesions O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O O

MA B B_LOCATION/B_DISEASE
may O O
selectively O O
damage O O
the O O
medial O O
temporal O O
lobe O O
and O O
, O O
consistent O O
with O O
metabolic O O
studies O O
, O O
the O O
cingulate O O
- O O
limbic O O
cortex O O
, O O
inducing O O
neuroadaptation O O
, O O
neuropil O O
reduction O O
, O O
or O O
cell O O
death O O
. O O

Many O B_NUMBER[MEASURE]/B_PERSON
of O O
these O O
genes O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
are O O
regulated O O
by O O
the O O
peroxisome O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
proliferator O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- O O
activated O O
receptor O B_GENE
- O O
alpha O B_PROTEIN[GENE]
( O O
PPARalpha O B_GENE
) O O
, O O
a O O
ligand O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O O
activated O O
nuclear O B_GENE
hormone O I_GENE
receptor O I_GENE
transcription O I_GENE
factor O I_GENE
. O O

A O O
significant O B_MEASURE
decrease O I_MEASURE
was O O
observed O O
in O O
the O O
activity O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
the O O
myocardial O B_ENZYME[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
marker O I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
enzymes O I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
with O O
a O O
concomitant O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
increase O I_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O O
their O O
activity O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
in O O
serum O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
. O O

Whilst O B_NUMBER[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
using O O
the O O
device O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
she O O
gradually O O
became O O
anxious O B_DISEASE_ADJECTIVE[DISEASE]
, O O
the O O
feeling O B_PERSON/B_DISEASE
worsening O O
after O O
each O O
bolus O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
. O O

We O O
feel O O
that O O
, O O
although O O
the O O
dramatic O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
extrapyramidal O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
side O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
effects O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O O
dopaminergic O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
antiemetics O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
are O O
well O O
known O O
, O O
more O O
subtle O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
manifestations O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
may O O
easily O O
be O O
overlooked O O
. O O

A O O
2 O B_MEASURE/B_PROTEIN[GENE]
g O I_MEASURE/I_PROTEIN[GENE]
/ O O
dL O B_MEASURE
decrease O I_MEASURE
in O O
hemoglobin O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
concentrations O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
in O O
patients O B_PERSON/B_BIO
with O O
anemia O B_DISEASE
was O O
observed O O
at O O
week O B_TIME[MEASURE]/B_LOCATION
2 O I_TIME[MEASURE]/I_LOCATION
after O O
the O O
start O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
treatment O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O O

Patients O B_PERSON
who O O
experience O O
a O O
fall O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
in O O
hemoglobin O B_MEASURE/B_DISEASE
concentrations O I_MEASURE/I_DISEASE
of O O
2 O B_MEASURE/B_PROTEIN[GENE]
g O I_MEASURE/I_PROTEIN[GENE]
/ O O
dL O B_TIME[MEASURE]/B_PROTEIN[GENE]
or O O
more O B_MEASURE
at O O
week O B_TIME[MEASURE]/B_LOCATION
2 O I_TIME[MEASURE]/I_LOCATION
after O O
the O O
start O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
treatment O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
should O O
be O O
monitored O O
with O O
particular O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_PERSON
care O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_PERSON
. O O

The O O
animals O B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
killed O O
on O O
day O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
30 O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
also O O
presented O O
fibrosis O B_DISEASE
in O O
the O O
renal O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
cortex O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
despite O O
the O O
recovery O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
of O O
renal O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
function O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
. O O

Glucose B B_BODY_PART_OR_ORGAN_COMPONENT
metabolism O O
in O O
patients O O
with O O
schizophrenia O O
treated O O
with O O
atypical O O
antipsychotic O O
agents O O
: O O
a O O
frequently O O
sampled O O
intravenous O O
glucose B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
tolerance O O
test O O
and O O
minimal O O
model O O
analysis O O
. O O

CONCLUSION O O
: O O
The O O
timing O O
of O O
renal O O
injury O O
strongly O O
suggests O O
melphalan B B_DISEASE/B_VIRUS[BIO]
as O O
the O O
causative O O
agent O O
. O O

Part O B_MEASURE/B_LOCATION
B O I_MEASURE/I_LOCATION
, O O
for O O
eight O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
different O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
rats O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
in O O
each O O
group O B_BODY_PART_OR_ORGAN_COMPONENT/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
blood O I_BODY_PART_OR_ORGAN_COMPONENT/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
brain O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
barrier O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
permeability O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
was O O
evaluated O O
by O O
measuring O O
the O O
amount O B_MEASURE/B_LOCATION
and O O
extent O B_MEASURE/B_LOCATION
of O O
extravasation O B_DISEASE/B_PHYSIOLOGIC_FUNCTION[ORGANISM_FUNCTION]
of O O
Evans O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Blue O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
dye O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

BACKGROUND O O
: O O
Acetaminophen B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
paracetamol B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
- O O
- O O
P B B_OTHER/B_LOCATION
) O O
and O O
Nimesulide B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
N B B_OTHER/B_LOCATION
) O O
are O O
widely O O
used O O
analgesic O O
- O O
antipyretic O O
/ O O
anti O O
- O O
inflammatory O O
drugs O O
. O O

The O O
rate O B_MEASURE
of O O
adverse O B_DISEASE_ADJECTIVE[DISEASE]
hypersensitivity O I_DISEASE_ADJECTIVE[DISEASE]
reactions O I_DISEASE_ADJECTIVE[DISEASE]
to O O
these O O
agents O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O O
generally O O
low O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
. O O

On O O
the O O
contrary O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_NUMBER[MEASURE]
non O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_NUMBER[MEASURE]
- O O
steroidal O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
anti O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
- O O
inflammatory O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
drugs O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
( O O
NSAIDs O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
) O O
are O O
commonly O O
involved O O
in O O
such O B_DISEASE/B_LOCATION
reactions O I_DISEASE/I_LOCATION
. O O

OBJECTIVE O O
: O O
We O O
evaluated O O
the O O
tolerability O O
of O O
CE B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
in O O
a O O
group O O
of O O
patients O O
with O O
documented O O
history O O
of O O
adverse O O
cutaneous O O
reactions O O
to O O
P B B_OTHER/B_LOCATION
and O O
N B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
associated O O
or O O
not O O
to O O
classic O O
NSAIDs O O
. O O

METHODS O O
: O O
We O O
studied O O
9 O O
patients O O
with O O
hypersensitivity O O
to O O
P B B_OTHER/B_LOCATION
and O O
N B B_OTHER/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O O
or O O
without O O
associated O O
reactions O O
to O O
classic O O
NSAIDs O O
. O O

The O O
diagnosis O O
of O O
P B B_LOCATION
and O O
N B B_OTHER/B_LOCATION
- O O
induced O O
skin O O
reactions O O
was O O
based O O
in O O
vivo O O
challenge O O
. O O

After O O
2 O B_NUMBER[MEASURE]/B_LOCATION
- O O
3 O B_TIME[MEASURE]/B_ENT
days O I_TIME[MEASURE]/I_ENT
, O O
a O O
single O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
dose O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O O
200 O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mg O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
administered O O
. O O

Thus O O
, O O
we O O
conclude O O
that O O
CE B B_LOCATION/B_PERSON
is O O
a O O
reasonably O O
safe O O
alternative O O
to O O
be O O
used O O
in O O
subjects O O
who O O
do O O
not O O
tolerate O O
P B B_OTHER/B_LOCATION
and O O
N B B_OTHER/B_LOCATION
. O O

Case O B_PERSON/B_TIME[MEASURE]
- O O
control O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
study O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
of O O
regular O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
analgesic O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
and O O
nonsteroidal O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
anti O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
- O O
inflammatory O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
use O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
end O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
stage O B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
renal O I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
disease O I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
. O O

Long O B_TIME[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
- O O
term O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
use O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
any O O
analgesic O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
associated O O
with O O
an O O
overall O B_MEASURE
odds O I_MEASURE
ratio O I_MEASURE
of O O
1 O B_MEASURE
. O O
22 O B_MEASURE
( O O
95 O B_MEASURE
% O I_MEASURE
CI O I_MEASURE
, O O
0 O B_MEASURE
. O O
89 O B_MEASURE
- O O
1 O B_MEASURE
. O O
66 O B_MEASURE
) O O
. O O

CONCLUSION O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
: O O
Our O O
data O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
indicate O O
that O O
long O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
- O O
term O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
use O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
nonaspirin O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
analgesic O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
drugs O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
and O O
NSAIDs O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O O
not O O
associated O O
with O O
an O O
increased O O
risk O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
of O O
ESRD O B_DISEASE
. O O

To O O
investigate O O
how O O
GAP43 O O
expression O O
( O O
GAP43 O O
- O O
ir O O
) O O
correlates O O
with O O
MFS O O
, O O
we O O
assessed O O
the O O
intensity O O
( O O
densitometry O O
) O O
and O O
extension O O
( O O
width O O
) O O
of O O
GAP43 O O
- O O
ir O O
in O O
the O O
inner O O
molecular O O
layer O O
of O O
the O O
dentate O O
gyrus O O
( O O
IML O O
) O O
of O O
rats O O
subject O O
to O O
status O O
epilepticus O O
induced O O
by O O
pilocarpine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
Pilo B B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
, O O
previously O O
injected O O
or O O
not O O
with O O
cycloheximide B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
CHX B B_LOCATION/B_ORGANIZATION
) O O
, O O
which O O
has O O
been O O
shown O O
to O O
inhibit O O
MFS O O
. O O

However O O
, O O
the O O
results O O
of O O
the O O
width O O
of O O
the O O
GAP43 O O
- O O
ir O O
band O O
in O O
the O O
IML O O
showed O O
that O O
CHX B B_DISEASE
+ O O
Pilo B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
and O O
control O O
animals O O
had O O
a O O
significantly O O
larger O O
band O O
( O O
p O O
= O O
0 O O
. O O
03 O O
) O O
as O O
compared O O
with O O
that O O
in O O
the O O
Pilo B B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
group O O
. O O

The O O
elevated O B_LOCATION/B_DISEASE_ADJECTIVE[DISEASE]
plus O I_LOCATION/I_DISEASE_ADJECTIVE[DISEASE]
- O O
maze O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
( O O
EPM O B_LOCATION/B_DISEASE
) O O
test O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
was O O
used O O
to O O
evaluate O O
the O O
effects O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
drugs O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O O
anxiety O B_DISEASE
. O O

Locomotor O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
activity O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
was O O
recorded O O
for O O
individual O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
groups O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
by O O
using O O
the O O
same O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
treatment O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
protocol O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O O
the O O
EPM O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
test O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
. O O

Administration O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
of O O
each O O
drug O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
and O O
their O O
combinations O B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
did O O
not O O
produce O O
any O O
effect O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O O
locomotor O B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
activity O I_DISEASE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

BACKGROUND O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O O
Hormone O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
therapy O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
( O O
HT O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_PROTEIN[GENE]
) O O
is O O
widely O O
used O O
for O O
controlling O O
menopausal O B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
symptoms O I_DISEASE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

In O O
relatively O O
healthy O B_PERSON/B_TIME[MEASURE]
women O I_PERSON/I_TIME[MEASURE]
, O O
combined O O
continuous O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
HT O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
significantly O O
increased O O
the O O
risk O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
of O O
venous O B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
thromboembolism O I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
or O O
coronary O B_DISEASE/B_LOCATION
event O I_DISEASE/I_LOCATION
( O O
after O O
one O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
year O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
' O O
s O O
use O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
) O O
, O O
stroke O B_DISEASE
( O O
after O O
3 O B_NUMBER[MEASURE]/B_ENT
years O I_NUMBER[MEASURE]/I_ENT
) O O
, O O
breast O B_DISEASE
cancer O I_DISEASE
( O O
after O O
5 O B_TIME[MEASURE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
years O I_TIME[MEASURE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
) O O
and O O
gallbladder O B_DISEASE
disease O I_DISEASE
. O O

Overall O O
, O O
the O O
only O B_NUMBER[MEASURE]/B_ORGANIZATION
statistically O O
significant O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
benefits O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O O
HT O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
were O O
a O O
decreased O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
incidence O I_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
fractures O B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
and O O
colon O B_DISEASE
cancer O I_DISEASE
with O O
long O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
- O O
term O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
use O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
. O O

Among O O
relatively O O
healthy O B_PERSON
women O I_PERSON
over O O
65 O B_NUMBER[MEASURE]/B_ENT
years O I_NUMBER[MEASURE]/I_ENT
taking O O
continuous O B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
combined O O
HT O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
there O O
was O O
a O O
statistically O O
significant O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
increase O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
in O O
the O O
incidence O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
of O O
dementia O B_DISEASE
. O O

Among O O
women O B_PERSON
with O O
cardiovascular O B_DISEASE
disease O I_DISEASE
, O O
long O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
- O O
term O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
use O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
of O O
combined O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
continuous O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
HT O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
significantly O O
increased O O
the O O
risk O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
of O O
venous O B_DISEASE/B_LOCATION
thromboembolism O I_DISEASE/I_LOCATION
. O O

The O O
only O B_SEQUENCE[MEASURE]/B_ORGANIZATION
significantly O O
increased O O
risk O B_DISEASE_ADJECTIVE[DISEASE]
reported O O
was O O
for O O
venous O B_DISEASE
thromboembolism O I_DISEASE
in O O
women O B_PERSON/B_BIO
taking O O
combined O O
continuous O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
HT O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
; O O
their O O
absolute O B_MEASURE/B_DISEASE
risk O I_MEASURE/I_DISEASE
remained O O
very O O
low O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
. O O

AUTHORS O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
' O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
CONCLUSIONS O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O O
HT O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
is O O
not O O
indicated O O
for O O
the O O
routine O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
management O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
chronic O B_DISEASE/B_PROTEIN[GENE]
disease O B_DISEASE/I_PROTEIN[GENE]
. O O

We O O
need O O
more O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
evidence O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
on O O
the O O
safety O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
HT O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
for O O
menopausal O B_PERSON/B_DISEASE
symptom O I_PERSON/I_DISEASE
control O I_PERSON/I_DISEASE
, O O
though O O
short O B_MEASURE
- O O
term O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
use O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
appears O O
to O O
be O O
relatively O O
safe O B_DISEASE_ADJECTIVE[DISEASE]/B_TIME[MEASURE]
for O O
healthy O B_PERSON
younger O I_PERSON
women O I_PERSON
. O O

Drug O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
induced O O
liver O B_DISEASE
injury O I_DISEASE
: O O
an O O
analysis O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
461 O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
incidences O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
submitted O O
to O O
the O O
Spanish O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
registry O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
over O O
a O O
10 O B_NUMBER[MEASURE]
- O O
year O B_TIME[MEASURE]
period O I_TIME[MEASURE]
. O O

BACKGROUND O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
& O O
AIMS O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
: O O
Progress O B_DISEASE_ADJECTIVE[DISEASE]
in O O
the O O
understanding O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
susceptibility O B_DISEASE_ADJECTIVE[DISEASE]
factors O I_DISEASE_ADJECTIVE[DISEASE]
to O O
drug O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
induced O O
liver O B_DISEASE
injury O I_DISEASE
( O O
DILI O B_DISEASE
) O O
and O O
outcome O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
predictability O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
are O O
hampered O O
by O O
the O O
lack O B_DISEASE_ADJECTIVE[DISEASE]
of O O
systematic O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
programs O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
to O O
detect O O
bona O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
fide O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cases O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

CONCLUSIONS O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O O
Patients O B_PERSON/B_BIO
with O O
drug O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
induced O O
hepatocellular O B_DISEASE
jaundice O I_DISEASE
have O O
11 O B_MEASURE
. O O
7 O B_MEASURE/B_PERSON
% O I_MEASURE/I_PERSON
chance O I_MEASURE/I_PERSON
of O O
progressing O O
to O O
death O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
or O O
transplantation O B_DISEASE/B_SURGICAL_AND_MEDICAL_PROCEDURES[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

The O O
aims O O
of O O
this O O
study O O
were O O
to O O
examine O O
vancomycin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
VCM B B_LOCATION/B_ORGANIZATION
) O O
- O O
induced O O
oxidative O O
stress O O
that O O
promotes O O
production O O
of O O
reactive O O
oxygen B B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
species O O
( O O
ROS O O
) O O
and O O
to O O
investigate O O
the O O
role O O
of O O
erdosteine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
an O O
expectorant O O
agent O O
, O O
which O O
has O O
also O O
antioxidant O O
properties O O
, O O
on O O
kidney O O
tissue O O
against O O
the O O
possible O O
VCM B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
- O O
induced O O
renal O O
impairment O O
in O O
rats O O
. O O

VCM B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
administration O O
to O O
control O O
rats O O
significantly O O
increased O O
renal O O
malondialdehyde B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
MDA B B_LOCATION
) O O
and O O
urinary O O
N O O
- O O
acetyl O O
- O O
beta O O
- O O
d O O
- O O
glucosaminidase O O
( O O
NAG O O
, O O
a O O
marker O O
of O O
renal O O
tubular O O
injury O O
) O O
excretion O O
but O O
decreased O O
superoxide B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
dismutase O O
( O O
SOD O O
) O O
and O O
catalase O O
( O O
CAT O O
) O O
activities O O
. O O

Because O O
ideal O O
lipid O O
targets O O
were O O
not O O
reached O O
( O O
low O O
- O O
density O O
lipoprotein O O
( O O
LDL O O
) O O
cholesterol B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
less O O
than O O
130 O O
mg O O
/ O O
dl O O
, O O
high O O
- O O
density O O
lipoprotein O O
( O O
HDL O O
) O O
cholesterol B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
greater O O
than O O
35 O O
mg O O
/ O O
dl O O
, O O
or O O
total O O
cholesterol B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
/ O O
HDL O O
cholesterol B B_MEASURE/B_LOCATION
less O O
than O O
4 O O
. O O
5 O O
mg O O
/ O O
dl O O
) O O
with O O
diet O O
plus O O
a O O
single O O
drug O O
, O O
gemfibrozil B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
( O O
1 O O
. O O
2 O O
g O O
/ O O
day O O
) O O
- O O
lovastatin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
( O O
primarily O O
20 O O
or O O
40 O O
mg O O
) O O
treatment O O
was O O
given O O
. O O

AIM O B_MEASURE
: O O
To O O
study O O
the O O
change O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
lipid O B_DISEASE/B_GENE
metabolism O B_DISEASE/I_GENE
by O O
antiandrogen O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
therapy O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
in O O
patients O B_PERSON/B_BIO
with O O
prostate O B_DISEASE/B_LOCATION
cancer O I_DISEASE/I_LOCATION
. O O

MATERIALS O O
AND O O
METHODS O O
: O O
We O O
studied O O
with O O
a O O
2 O O
. O O
5 O O
years O O
follow O O
- O O
up O O
the O O
changes O O
in O O
plasma O O
cholesterols B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
( O O
C B B_OTHER/B_LOCATION
) O O
, O O
triglycerides B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
TG B B_LOCATION
) O O
, O O
lipoproteins O O
( O O
LP O O
) O O
, O O
and O O
apolipoproteins O O
( O O
Apo O O
) O O
B O O
- O O
100 O O
, O O
A O O
- O O
I O O
, O O
and O O
A O O
- O O
II O O
pro O O
fi O O
les O O
in O O
24 O O
patients O O
of O O
mean O O
age O O
60 O O
years O O
with O O
low O O
risk O O
prostate O O
cancer O O
( O O
stage O O
: O O
T1cN0M0 O O
, O O
Gleason O O
score O O
: O O
2 O O
- O O
5 O O
) O O
during O O
treatment O O
with O O
cyproterone B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
acetate I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
CPA B B_LOCATION/B_ORGANIZATION
) O O
without O O
surgical O O
management O O
or O O
radiation O O
therapy O O
. O O

We O O
herein O O
report O O
the O O
case O O
of O O
a O O
70 O O
- O O
year O O
- O O
old O O
man O O
with O O
5 B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
FU I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
induced O O
cardiotoxicity O O
, O O
in O O
whom O O
a O O
high O O
serum O O
level O O
of O O
alpha B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
fluoro I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
beta I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
alanine I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
FBAL B B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
) O O
was O O
observed O O
. O O

The O O
serum O O
FBAL B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
concentration O O
subsequently O O
decreased O O
to O O
352 O O
ng O O
/ O O
ml O O
, O O
the O O
same O O
as O O
the O O
value O O
measured O O
on O O
the O O
first O O
day O O
of O O
S O O
- O O
1 O O
administration O O
. O O

The O O
patient O B_PERSON/B_BIO
achieved O O
a O O
partial O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
response O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
6 O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
months O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
after O O
the O O
initiation O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
the O O
S O B_DISEASE/B_GENE
- O O
1 O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
treatment O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

The O O
experience O O
of O O
this O O
case O O
, O O
together O O
with O O
a O O
review O O
of O O
the O O
literature O O
, O O
suggests O O
that O O
FBAL B B_DISEASE/B_GENE
is O O
related O O
to O O
5 B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
FU I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
induced O O
cardiotoxicity O O
. O O

Because O O
of O O
the O O
relatively O O
short O O
final O O
half O O
- O O
life O O
of O O
monoHER B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
( O O
about O O
30 O O
min O O
) O O
, O O
it O O
is O O
expected O O
that O O
the O O
time O O
interval O O
between O O
monoHER B B_LOCATION/B_ORGANIZATION
and O O
DOX B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
might O O
be O O
of O O
influence O O
on O O
the O O
cardioprotective O O
effect O O
of O O
monoHER B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

BACKGROUND O O
: O O
Bepridil B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
hydrochloride I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
Bpd B B_ORGANIZATION/B_LOCATION
) O O
has O O
attracted O O
attention O O
as O O
an O O
effective O O
drug O O
for O O
atrial O O
fibrillation O O
( O O
AF O O
) O O
and O O
atrial O O
flutter O O
( O O
AFL O O
) O O
. O O

Bpd B B_DISEASE/B_PROTEIN[GENE]
was O O
administered O O
to O O
459 O O
patients O O
( O O
361 O O
males O O
, O O
63 O O
+ O O
/ O O
- O O
12 O O
years O O
old O O
) O O
comprising O O
378 O O
AF O O
and O O
81 O O
AFL O O
cases O O
. O O

In O O
this O O
study O O
we O O
aimed O O
at O O
studying O O
the O O
involvement O O
of O O
the O O
brain O O
RAS O O
in O O
the O O
cardiac O O
reactivity O O
to O O
the O O
beta O O
- O O
adrenoceptor O O
( O O
beta O O
- O O
AR O O
) O O
agonist O O
isoproterenol B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
Iso B B_ORGANIZATION/B_LOCATION
) O O
. O O

These O O
results O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
indicate O O
that O O
TGR O B_PERSON/B_BIO
are O O
more O O
sensitive O B_DISEASE_ADJECTIVE[DISEASE]
to O O
beta O O
- O O
AR O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
agonist O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
induced O O
cardiac O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
inotropic O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
response O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
and O O
hypertrophy O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O O
possibly O O
due O B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
to O O
chronically O O
low O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
sympathetic O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
outflow O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
directed O O
to O O
the O O
heart O B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
. O O

BACKGROUND O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
: O O
Drug O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
induced O O
long O B_DISEASE
QT O I_DISEASE
syndrome O I_DISEASE
is O O
a O O
serious O B_DISEASE_ADJECTIVE[DISEASE]
adverse O I_DISEASE_ADJECTIVE[DISEASE]
drug O I_DISEASE_ADJECTIVE[DISEASE]
reaction O I_DISEASE_ADJECTIVE[DISEASE]
. O O

These O O
include O O
augmented O O
endothelin O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O O
1 O B_TIME[MEASURE]
( O O
ET O B_PROTEIN[GENE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
- O O
1 O B_NUMBER[MEASURE]
) O O
release O B_ENT/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
increased O O
sympathetic O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
nervous O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
system O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
activity O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
and O O
elevated O O
tissue O B_DISEASE
oxidative O I_DISEASE
stress O I_DISEASE
. O O

We O O
hypothesized O O
that O O
increased O O
venous O O
smooth O O
muscle O O
( O O
venomotor O O
) O O
tone O O
plays O O
a O O
role O O
in O O
Nomega B B_BODY_PART_OR_ORGAN_COMPONENT/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_BODY_PART_OR_ORGAN_COMPONENT/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
nitro I I_BODY_PART_OR_ORGAN_COMPONENT/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_BODY_PART_OR_ORGAN_COMPONENT/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
L I I_BODY_PART_OR_ORGAN_COMPONENT/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_BODY_PART_OR_ORGAN_COMPONENT/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
arginine I I_BODY_PART_OR_ORGAN_COMPONENT/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
LNNA B B_LOCATION/B_DISEASE
) O O
hypertension O O
through O O
these O O
mechanisms O O
. O O

Maximal O O
contraction O O
to O O
norepinephrine B B_LOCATION
was O O
modestly O O
reduced O O
in O O
arteries O O
from O O
LNNA B B_DISEASE/B_GENE
compared O O
with O O
control O O
rats O O
whereas O O
the O O
maximum O O
contraction O O
to O O
ET O O
- O O
1 O O
was O O
significantly O O
reduced O O
( O O
54 O O
% O O
control O O
) O O
. O O

Mean O O
circulatory O O
filling O O
pressure O O
, O O
an O O
in O O
vivo O O
measure O O
of O O
venomotor O O
tone O O
, O O
was O O
not O O
elevated O O
in O O
LNNA B B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
hypertension O O
at O O
1 O O
or O O
2 O O
weeks O O
after O O
LNNA B B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
. O O

The O O
superoxide B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
scavenger O O
tempol B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
( O O
30 O O
, O O
100 O O
, O O
and O O
300 O O
micromol O O
kg O O
( O O
- O O
1 O O
) O O
, O O
IV O O
) O O
did O O
not O O
change O O
arterial O O
pressure O O
in O O
control O O
rats O O
but O O
caused O O
a O O
dose O O
- O O
dependent O O
decrease O O
in O O
LNNA B B_DISEASE
rats O O
( O O
- O O
18 O O
+ O O
/ O O
- O O
8 O O
, O O
- O O
26 O O
+ O O
/ O O
- O O
15 O O
, O O
and O O
- O O
54 O O
+ O O
/ O O
- O O
11 O O
mm O O
Hg O O
) O O
. O O

Similarly O O
, O O
ganglionic O O
blockade O O
with O O
hexamethonium B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BACTERIUM[BIO]
caused O O
a O O
significantly O O
greater O O
fall O O
in O O
LNNA B B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
hypertensive O O
rats O O
( O O
76 O O
+ O O
/ O O
- O O
9 O O
mm O O
Hg O O
) O O
compared O O
with O O
control O O
rats O O
( O O
35 O O
+ O O
/ O O
- O O
10 O O
mm O O
Hg O O
) O O
. O O

Carotid O O
arteries O O
, O O
vena O O
cava O O
, O O
and O O
sympathetic O O
ganglia O O
from O O
LNNA B B_DISEASE
rats O O
had O O
higher O O
basal O O
levels O O
of O O
superoxide B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
compared O O
with O O
those O O
from O O
control O O
rats O O
. O O

AIM O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
: O O
Extrapyramidal O B_DISEASE
syndrome O I_DISEASE
( O O
EPS O B_DISEASE
) O O
is O O
most O O
commonly O O
affected O O
by O O
typical O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
antipsychotic O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
drugs O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
that O O
have O O
a O O
high O B_LOCATION/B_MEASURE
affinity O I_LOCATION/I_MEASURE
with O O
the O O
D2 O B_GENE
receptor O I_GENE
. O O

Recently O O
, O O
many O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
research O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
groups O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
have O O
reported O O
on O O
the O O
positive O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
relationship O I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
between O O
the O O
genetic O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
variations O B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
in O O
the O O
DRD2 O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
gene O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and O O
the O O
therapeutic O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
response O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
schizophrenia O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
patients O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
as O O
a O O
result O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
the O O
role O B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
variations O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]
in O O
the O O
receptor O B_GENE/B_LOCATION
in O O
modulating O O
receptor O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
expression O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
. O O

All O O
these O O
behavioral O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
parameters O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
showed O O
statistically O O
significant O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
changes O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
suggesting O O
that O O
regular O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
physical O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
exercises O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
decrease O O
susceptibility O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
to O O
subsequently O O
induced O O
seizures O B_DISEASE
and O O
ameliorate O O
the O O
course O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
of O O
experimentally O O
induced O O
status O B_DISEASE
epilepticus O I_DISEASE
. O O

We O O
here O O
probed O O
how O O
selective O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
tonic O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
dopaminergic O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
stimulation O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
affects O O
associative O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
learning O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
. O O

Forty O B_PERSON
healthy O I_PERSON
subjects O I_PERSON
were O O
trained O O
in O O
a O O
novel O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
vocabulary O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O O
45 O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
concrete O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
nouns O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
over O O
the O O
course O B_LOCATION/B_TIME[MEASURE]
of O O
5 O B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
consecutive O B_TIME[MEASURE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
training O B_TIME[MEASURE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
days O B_TIME[MEASURE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
a O O
prospective O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
, O O
randomized O O
, O O
double O B_MEASURE/B_COLOR
- O O
blind O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
placebo O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
- O O
controlled O O
design O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
. O O

This O O
learning O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
decrement O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
persisted O O
up O O
to O O
the O O
last O B_MEASURE/B_PERSON
follow O O
- O O
up O O
4 O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
weeks O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
post O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
- O O
training O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
. O O

Differential O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
diagnosis O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O O
drug O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
induced O O
disease O B_DISEASE
is O O
invaluable O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
even O O
for O O
patients O B_PERSON/B_BIO
with O O
classical O B_DISEASE
polyarteritis O I_DISEASE
nodosa O I_DISEASE
. O O

BACKGROUND O O
: O O
Combined O O
hepatitis O O
B O O
immune O O
globulin O O
( O O
HBIg O O
) O O
and O O
lamivudine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
prophylaxis O O
of O O
the O O
recurrence O O
of O O
hepatitis O O
B O O
after O O
liver O O
transplantation O O
has O O
significantly O O
improved O O
the O O
survival O O
of O O
HBsAg B B_DISEASE/B_GENE
positive O O
patients O O
. O O

HBIg O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
was O O
administered O O
intravenously O O
during O O
the O O
first O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
week O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
and O O
intramuscularly O O
thereafter O O
. O O

A O O
daily O O
oral O O
dose O O
of O O
100 O O
mg O O
lamivudine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O O
2 O O
weeks O O
before O O
transplantation O O
for O O
10 O O
patients O O
enabled O O
57 O O
. O O
1 O O
% O O
( O O
4 O O
/ O O
7 O O
) O O
and O O
62 O O
. O O
5 O O
% O O
( O O
5 O O
/ O O
8 O O
) O O
of O O
HBV O O
- O O
DNA O O
and O O
HBeAg B B_GENE/B_DISEASE
positive O O
patients O O
respectively O O
to O O
convert O O
to O O
be O O
negative O O
. O O

Eslicarbazepine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
acetate I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
( O O
BIA B B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
2 I B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
- I B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
093 I B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
, O O
S B B_MEASURE/B_PERSON
- I I_MEASURE/I_PERSON
( I I_MEASURE/I_PERSON
- I I_MEASURE/I_PERSON
) I I_MEASURE/I_PERSON
- I I_MEASURE/I_PERSON
10 I I_MEASURE/I_PERSON
- I I_MEASURE/I_PERSON
acetoxy I I_MEASURE/I_PERSON
- I I_MEASURE/I_PERSON
10 I I_MEASURE/I_PERSON
, I I_MEASURE/I_PERSON
11 I I_MEASURE/I_PERSON
- I I_MEASURE/I_PERSON
dihydro I I_MEASURE/I_PERSON
- I I_MEASURE/I_PERSON
5H I I_MEASURE/I_PERSON
- I I_MEASURE/I_PERSON
dibenzo I I_MEASURE/I_PERSON
/ I I_MEASURE/I_PERSON
b I I_MEASURE/I_PERSON
, I I_MEASURE/I_PERSON
f I I_MEASURE/I_PERSON
/ I I_MEASURE/I_PERSON
azepine I I_MEASURE/I_PERSON
- I I_MEASURE/I_PERSON
5 I I_MEASURE/I_PERSON
- I I_MEASURE/I_PERSON
carboxamide I I_MEASURE/I_PERSON
) O O
is O O
a O O
novel O O
antiepileptic O O
drug O O
, O O
now O O
in O O
Phase O O
III O O
clinical O O
trials O O
, O O
designed O O
with O O
the O O
aim O O
of O O
improving O O
efficacy O O
and O O
safety O O
in O O
comparison O O
with O O
the O O
structurally O O
related O O
drugs O O
carbamazepine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
CBZ B B_LOCATION/B_ORGANIZATION
) O O
and O O
oxcarbazepine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
OXC B B_LOCATION/B_ORGANIZATION
) O O
. O O

Pre O O
- O O
treatment O O
with O O
a O O
dose O O
of O O
30 O O
mg O O
/ O O
kg O O
2h O O
before O O
picrotoxin B B_BIO/B_BODY_PART_OR_ORGAN_COMPONENT
microperfusion O O
prevented O O
seizures O O
in O O
the O O
75 O O
% O O
of O O
the O O
rats O O
. O O

Lower O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
doses O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
( O O
3 O B_NUMBER[MEASURE]
and O O
10mg O B_MEASURE
/ O O
kg O B_MEASURE
) O O
did O O
not O O
suppress O O
seizures O B_DISEASE
, O O
however O O
, O O
after O O
administration O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_ORGANISM_FUNCTION
of O O
10mg O B_MEASURE
/ O O
kg O B_MEASURE
, O O
significant O B_DISEASE_ADJECTIVE[DISEASE]
reductions O I_DISEASE_ADJECTIVE[DISEASE]
in O O
seizures O B_MEASURE/B_DISEASE
duration O I_MEASURE/I_DISEASE
( O O
24 O B_MEASURE
. O O
3 O B_MEASURE
+ O I_MEASURE
/ O O
- O O
6 O B_MEASURE
. O O
8s O B_MEASURE
) O O
and O O
seizure O B_MEASURE/B_DISEASE
number O I_MEASURE/I_DISEASE
( O O
1 O B_MEASURE
. O O
6 O B_MEASURE
+ O I_MEASURE
/ O O
- O O
0 O B_MEASURE
. O O
34 O B_MEASURE
) O O
were O O
found O O
. O O

Chinese B B_PERSON/B_ORGANIZATION
herbal I I_PERSON/I_ORGANIZATION
medicine O O
preparations O O
are O O
widely O O
available O O
and O O
often O O
regarded O O
by O O
the O O
public O O
as O O
natural O O
and O O
safe O O
remedies O O
for O O
a O O
variety O O
of O O
medical O O
conditions O O
. O O

Chloroacetaldehyde B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
( O O
CAA B B_LOCATION
) O O
is O O
a O O
metabolite O O
of O O
the O O
alkylating O O
agent O O
ifosfamide B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
IFO B B_DISEASE/B_PROTEIN[GENE]
) O O
and O O
putatively O O
responsible O O
for O O
renal O O
damage O O
following O O
anti O O
- O O
tumor O O
therapy O O
with O O
IFO B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
. O O

This O O
effect O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
can O O
be O O
reduced O O
by O O
acidification O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
. O O

Therefore O O
, O O
urinary O O
acidification O O
could O O
be O O
an O O
option O O
to O O
prevent O O
IFO B B_DISEASE_ADJECTIVE[DISEASE]
nephropathy O O
in O O
patients O O
. O O

The O O
number O B_MEASURE
of O O
hilar O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
neurons O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
immunoreactive O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O O
Prox O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O O
1 O B_NUMBER[MEASURE]
, O O
a O O
granule O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
- O O
cell O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_LOCATION
- O O
specific O B_PROTEIN[GENE]/B_MEASURE
marker O I_PROTEIN[GENE]/I_MEASURE
, O O
was O O
estimated O O
using O O
the O O
optical O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
fractionator O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
method O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
. O O

Of O O
the O O
262 O B_PERSON/B_DISEASE
patients O I_PERSON/I_DISEASE
, O O
14 O B_MEASURE
( O O
18 O B_MEASURE/B_PERSON
% O I_MEASURE/I_PERSON
) O O
of O O
76 O B_NUMBER[MEASURE]/B_PERSON
who O O
had O O
stopped O O
treatment O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
at O O
the O O
time O B_TIME[MEASURE]/B_LOCATION
of O O
the O O
study O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
experienced O O
documented O O
adverse O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
effects O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

CONCLUSIONS O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
: O O
The O O
current O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
study O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
used O O
a O O
protocol O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
visual O B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
acuity O I_MEASURE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
color O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
vision O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
assessment O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
, O O
funduscopy O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
, O O
and O O
Humphrey O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
10 O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
- O O
2 O B_MEASURE
visual O I_MEASURE
field O I_MEASURE
testing O I_MEASURE
and O O
shows O O
that O O
visual O B_DISEASE_ADJECTIVE[DISEASE]
field O I_DISEASE_ADJECTIVE[DISEASE]
defects O I_DISEASE_ADJECTIVE[DISEASE]
appeared O O
before O O
any O O
corresponding O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
changes O I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
any O O
other O B_TIME[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
tested O O
clinical O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
parameters O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
; O O
the O O
defects O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
were O O
reproducible O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
the O O
test O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
parameters O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
were O O
reliable O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

This O O
had O O
been O O
apparently O O
uncomplicated O B_DISEASE_ADJECTIVE[DISEASE]
and O O
she O O
had O O
maintained O O
a O O
remarkably O O
high O B_MEASURE/B_LOCATION
level O I_MEASURE/I_LOCATION
of O O
physical O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
activity O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
. O O

Second O B_PERSON
degree O I_PERSON
Mobitz O I_PERSON
type O I_PERSON
II O I_PERSON
atrioventricular O I_PERSON
block O I_PERSON
was O O
diagnosed O O
on O O
electrocardiogram O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
and O O
temporary O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
transvenous O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
ventricular O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
pacing O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
instituted O O
in O O
the O O
peri O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
operative O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_LOCATION
period O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_LOCATION
. O O

We O O
suggest O O
that O O
patients O B_PERSON
who O O
have O O
received O O
chemotherapy O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
at O O
any O O
time O B_MEASURE/B_LOCATION
should O O
have O O
a O O
pre O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
operative O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
electrocardiogram O I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
even O O
if O O
they O O
are O O
asymptomatic O B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
. O O

Risks O O
and O O
benefits O O
of O O
COX B B_DISEASE_ADJECTIVE[DISEASE]
- I I_DISEASE_ADJECTIVE[DISEASE]
2 I I_DISEASE_ADJECTIVE[DISEASE]
inhibitors I I_DISEASE_ADJECTIVE[DISEASE]
vs O O
non O O
- O O
selective O O
NSAIDs O O
: O O
does O O
their O O
cardiovascular O O
risk O O
exceed O O
their O O
gastrointestinal O O
benefit O O
? O O

During O O
the O O
follow O O
- O O
up O O
of O O
our O O
patient O O
, O O
penicillamine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
was O O
interrupted O O
after O O
the O O
appearance O O
of O O
a O O
lichenoid O O
dermatitis O O
, O O
and O O
zinc B B_LOCATION
acetate I I_LOCATION
permitted O O
to O O
continue O O
the O O
successful O O
treatment O O
of O O
the O O
patient O O
without O O
side O O
- O O
effects O O
. O O

The O O
patient O O
' O O
s O O
observations O O
were O O
within O O
normal O O
limits O O
, O O
he O O
was O O
administered O O
oxygen B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
via O O
a O O
face O O
mask O O
and O O
glyceryl B B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_BODY_PART_OR_ORGAN_COMPONENT
trinitrate I B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_BODY_PART_OR_ORGAN_COMPONENT
( O O
GTN B B_DISEASE/B_LOCATION
) O O
. O O

No O O
significant O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
heart O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
rate O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
differences O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O O
observed O O
between O O
the O O
sham O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
and O O
lesioned O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
groups O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
. O O

A O O
7 O B_NUMBER[MEASURE]
- O O
year O B_TIME[MEASURE]
- O O
old O B_PERSON
girl O I_PERSON
with O O
an O O
unusual O B_DISEASE
reaction O I_DISEASE
to O O
induction O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
chemotherapy O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O O
precursor O B_BODY_PART_OR_ORGAN_COMPONENT/B_GENE
B O I_BODY_PART_OR_ORGAN_COMPONENT/I_GENE
- O O
cell O B_DISEASE
acute O I_DISEASE
lymphoblastic O I_DISEASE
leukemia O I_DISEASE
( O O
ALL O B_DISEASE
) O O
is O O
described O O
. O O

BACKGROUND O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O O
One O B_MEASURE/B_PERSON
third O I_MEASURE/I_PERSON
of O O
patients O B_PERSON/B_BIO
treated O O
for O O
hypertension O B_DISEASE
attain O O
adequate O B_DISEASE
blood O I_DISEASE
pressure O I_DISEASE
( O O
BP O B_PROTEIN[GENE]/B_DISEASE
) O O
control O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
, O O
and O O
multidrug O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
regimens O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
are O O
often O O
required O O
. O O

Given O O
the O O
lifelong O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
nature O I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
hypertension O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O O
there O O
is O O
a O O
need O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
to O O
evaluate O O
the O O
long O B_TIME[MEASURE]/B_LOCATION
- O O
term O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
efficacy O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
and O O
tolerability O B_DISEASE_ADJECTIVE[DISEASE]
of O O
higher O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
doses O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_MEASURE
of O O
combination O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
anti O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
- O O
hypertensive O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
therapies O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

OBJECTIVE O O
: O O
This O O
study O O
investigated O O
the O O
efficacy O O
and O O
tolerability O O
of O O
valsartan B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
VAL B B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
or O O
hydrochlorothiazide B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
HCTZ B B_LOCATION/B_ORGANIZATION
) O O
- O O
monotherapy O O
and O O
higher O O
- O O
dose O O
combinations O O
in O O
patients O O
with O O
essential O O
hypertension O O
. O O

VAL B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
/ O O
HCTZ B B_MEASURE/B_PROTEIN[GENE]
320 O O
/ O O
12 O O
. O O
5 O O
and O O
320 O O
/ O O
25 O O
mg O O
were O O
further O O
investigated O O
in O O
a O O
54 O O
- O O
week O O
, O O
open O O
- O O
label O O
extension O O
. O O

All O O
active O O
treatments O O
were O O
associated O O
with O O
significantly O O
reduced O O
MSSBP O O
and O O
MSDBP O O
during O O
the O O
core O O
8 O O
- O O
week O O
study O O
, O O
with O O
each O O
monotherapy O O
significantly O O
contributing O O
to O O
the O O
overall O O
effect O O
of O O
combination O O
therapy O O
( O O
VAL B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
and O O
HCTZ B B_LOCATION
, O O
P O O
< O O
0 O O
. O O
001 O O
) O O
. O O

Each O O
combination O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
was O O
associated O O
with O O
significantly O O
greater O B_DISEASE_ADJECTIVE[DISEASE]
reductions O I_DISEASE_ADJECTIVE[DISEASE]
in O O
MSSBP O B_DISEASE/B_GENE
and O O
MSDBP O B_DISEASE/B_GENE
compared O O
with O O
the O O
monotherapies O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
and O O
placebo O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
( O O
all O O
, O O
P O B_MEASURE/B_PROTEIN[GENE]
< O O
0 O B_MEASURE
. O O
001 O B_MEASURE
) O O
. O O

The O O
mean O O
reduction O O
in O O
MSSBP O O
/ O O
MSDBP O O
with O O
VAL B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
/ O O
HCTZ B B_MEASURE/B_PROTEIN[GENE]
320 O O
/ O O
25 O O
mg O O
was O O
24 O O
. O O
7 O O
/ O O
16 O O
. O O
6 O O
mm O O
Hg O O
, O O
compared O O
with O O
5 O O
. O O
9 O O
/ O O
7 O O
. O O
0 O O
mm O O
Hg O O
with O O
placebo O O
. O O

The O O
reduction O O
in O O
MSSBP O O
was O O
significantly O O
greater O O
with O O
VAL B B_LOCATION/B_ORGANIZATION
/ O O
HCTZ B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
320 O O
/ O O
25 O O
mg O O
compared O O
with O O
VAL B B_LOCATION/B_ORGANIZATION
/ O O
HCTZ B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
160 O O
/ O O
12 O O
. O O
5 O O
mg O O
( O O
P O O
< O O
0 O O
. O O
002 O O
) O O
. O O

Rates O B_MEASURE
of O O
response O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
BP O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
control O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O O
significantly O O
higher O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
in O O
the O O
groups O B_ORGANIZATION/B_PERSON
that O O
received O O
combination O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
treatment O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
compared O O
with O O
those O O
that O O
received O O
monotherapy O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
. O O

The O O
incidence O O
of O O
hypokalemia O O
was O O
lower O O
with O O
VAL B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
/ O O
HCTZ B B_LOCATION
combinations O O
( O O
1 O O
. O O
8 O O
% O O
- O O
6 O O
. O O
1 O O
% O O
) O O
than O O
with O O
HCTZ B B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
monotherapies O O
( O O
7 O O
. O O
1 O O
% O O
- O O
13 O O
. O O
3 O O
% O O
) O O
. O O

The O O
efficacy O O
and O O
tolerability O O
of O O
VAL B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
/ O O
HCTZ B B_LOCATION
combinations O O
were O O
maintained O O
during O O
the O O
extension O O
( O O
797 O O
patients O O
) O O
. O O

These O O
findings O O
suggest O O
that O O
it O O
may O O
be O O
possible O O
to O O
identify O O
a O O
succimer B B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
treatment O O
protocol O O
that O O
improves O O
cognitive O O
outcomes O O
in O O
Pb B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
exposed O O
children O O
. O O

BACKGROUND O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
AND O O
AIM O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
OF O O
THE O O
STUDY O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
: O O
Undersized O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
mitral O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
annuloplasty O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
( O O
MAP O B_LOCATION/B_ORGANIZATION
) O O
is O O
effective O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
in O O
patients O B_PERSON
with O O
dilated O B_DISEASE_ADJECTIVE[DISEASE]
cardiomyopathy O I_DISEASE_ADJECTIVE[DISEASE]
and O O
functional O B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
mitral O I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
regurgitation O I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
( O O
MR O B_LOCATION
) O O
since O O
, O O
as O O
well O O
as O O
addressing O O
the O O
MR O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
, O O
the O O
MAP O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
may O O
also O O
reshape O O
the O O
dilated O O
left O O
ventricular O B_BODY_PART_OR_ORGAN_COMPONENT
( O O
LV O B_LOCATION
) O O
base O B_BODY_PART_OR_ORGAN_COMPONENT/B_LOCATION
. O O

METHODS O B_MEASURE
: O O
Six O B_ENT/B_PERSON
dogs O B_ENT/I_PERSON
underwent O O
MAP O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
with O O
a O O
prosthetic O B_MEDICAL_DEVICE[OBJECT]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
band O I_MEDICAL_DEVICE[OBJECT]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
on O O
the O O
posterior O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
mitral O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
annulus O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
, O O
using O O
four O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
mattress O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
sutures O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

RESULTS O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O O
MAP O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
decreased O O
mitral O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
annular O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
dimensions O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
in O O
both O O
commissure O B_BODY_PART_OR_ORGAN_COMPONENT/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
commissure O B_BODY_PART_OR_ORGAN_COMPONENT/B_LOCATION
and O O
septal O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
- O O
lateral O B_LOCATION/B_BODY_PART_OR_ORGAN_COMPONENT
directions O I_LOCATION/I_BODY_PART_OR_ORGAN_COMPONENT
. O O

CONCLUSION O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
: O O
The O O
data O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
acquired O O
suggest O O
that O O
isolated O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
MAP O B_LOCATION/B_BIO
may O O
have O O
certain O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
benefits O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
on O O
LV O B_MEASURE
dimension O I_MEASURE
/ O O
function O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
in O O
acute O B_DISEASE
heart O I_DISEASE
failure O I_DISEASE
, O O
even O O
in O O
the O O
absence O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
MR O B_DISEASE/B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Initiation O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
high O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
- O O
flux O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
hemodialysis O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
rapidly O O
reversed O O
the O O
neurologic O B_DISEASE
symptoms O I_DISEASE
within O O
4 O B_TIME[MEASURE]
hours O I_TIME[MEASURE]
. O O

Frequency O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
transient O B_DISEASE
ipsilateral O I_DISEASE
vocal O I_DISEASE
cord O I_DISEASE
paralysis O I_DISEASE
in O O
patients O B_PERSON/B_BIO
undergoing O O
carotid O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
endarterectomy O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
under O O
local O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
anesthesia O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

METHODS O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
: O O
This O O
prospective O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
study O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
included O O
28 O B_PERSON
patients O I_PERSON
undergoing O O
carotid O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_GENE
endarterectomy O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_GENE
under O O
local O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
anesthesia O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Because O O
pre O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
existing O O
paralysis O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
is O O
of O O
a O O
relevant O B_MEASURE
frequency O I_MEASURE
( O O
up O O
to O O
3 O B_MEASURE
% O I_MEASURE
) O O
, O O
a O O
preoperative O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
evaluation O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
vocal O B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cord O I_DISEASE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
function O I_DISEASE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
before O O
carotid O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
endarterectomy O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
under O O
local O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
anesthesia O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
is O O
recommended O O
to O O
avoid O O
intraoperative O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
bilateral O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
paralysis O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O O

In O O
patients O B_PERSON
with O O
preoperative O B_DISEASE
contralateral O I_DISEASE
vocal O I_DISEASE
cord O I_DISEASE
paralysis O I_DISEASE
, O O
surgery O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
under O O
general O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
anesthesia O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
should O O
be O O
considered O O
. O O

An O O
emotional O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
facial O B_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
expression O B_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
EFE O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
) O O
task O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
consisting O O
of O O
a O O
male O B_PERSON/B_COLOR
and O O
female O B_PERSON
face O I_PERSON
expressing O O
six O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
basic O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
emotions O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
( O O
happiness O B_DISEASE/B_PERSON
, O O
surprise O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
sadness O B_DISEASE/B_PERSON
, O O
anger O B_DISEASE/B_PERSON
, O O
fear O B_DISEASE/B_PERSON
, O O
and O O
disgust O B_DISEASE/B_PERSON
) O O
was O O
administered O O
. O O

Participants O B_PERSON/B_BIO
were O O
also O O
assessed O O
with O O
the O O
" O O
Eyes O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
task O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
" O O
to O O
investigate O O
their O O
ability O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
to O O
recognize O O
more O O
complex O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
emotional O I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
states O I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
the O O
Symptom O B_MEASURE/B_PROTEIN[GENE]
CheckList O B_MEASURE/I_PROTEIN[GENE]
- O O
90 O B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
Revised O O
to O O
measure O O
psychopathology O B_DISEASE
. O O

The O O
substantia O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
nigra O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
has O O
a O O
gating O O
function O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
controlling O O
the O O
spread O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
of O O
epileptic O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
seizure O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
activity O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
. O O

The O O
neuropathology O B_DISEASE_ADJECTIVE[DISEASE]
of O O
SNR O B_DISEASE
was O O
investigated O O
using O O
immunohistochemical O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
techniques O I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
with O O
the O O
major O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
emphasis O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
on O O
the O O
time O B_TIME[MEASURE]/B_LOCATION
- O O
course O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
changes O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
in O O
neurons O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
and O O
astrocytes O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
. O O

Animals O B_BIO/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
surviving O O
20 O B_MEASURE
, O O
30 O B_MEASURE
, O O
40 O B_MEASURE
, O O
60 O B_TIME[MEASURE]
min O I_TIME[MEASURE]
, O O
2 O B_MEASURE
, O O
3 O B_NUMBER[MEASURE]
, O O
6 O B_NUMBER[MEASURE]/B_SPORT[ENT]
hours O I_NUMBER[MEASURE]/I_SPORT[ENT]
, O O
1 O B_SEQUENCE[MEASURE]
, O O
2 O B_NUMBER[MEASURE]
, O O
and O O
3 O B_NUMBER[MEASURE]/B_ENT
days O I_NUMBER[MEASURE]/I_ENT
after O O
induction O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
status O B_DISEASE
epilepticus O I_DISEASE
were O O
perfusion O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
- O O
fixed O O
, O O
and O O
brains O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
processed O O
for O O
immunohistochemical O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
staining O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O O
SNR O B_GENE/B_DISEASE
. O O

This O O
study O O
was O O
designed O O
to O O
evaluate O O
the O O
alterations O O
in O O
offspring O O
rat O O
cerebellum O O
induced O O
by O O
maternal O O
exposure O O
to O O
carmustine B B_DISEASE_ADJECTIVE[DISEASE]/B_PROTEIN[GENE]
- O O
[ O O
1 B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
3 I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
bis I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
2 I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
chloroethyl I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
1 I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
nitrosoure I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
] O O
( O O
BCNU B B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
and O O
to O O
investigate O O
the O O
effects O O
of O O
exogenous O O
melatonin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
upon O O
cerebellar O O
BCNU B B_DISEASE
- O O
induced O O
cortical O O
dysplasia O O
, O O
using O O
histological O O
and O O
biochemical O O
analyses O O
. O O

The O O
infections O B_DISEASE/B_PERSON
responded O O
to O O
antibiotic O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
treatment O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Myo B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
inositol I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
1 I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
phosphate I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
( O O
MIP B B_GENE
) O O
synthase O O
inhibition O O
: O O
in O O
- O O
vivo O O
study O O
in O O
rats O O
. O O

Non O B_DISEASE/B_MEASURE
- O O
steroidal O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
anti O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
- O O
inflammatory O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
drugs O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
- O O
associated O O
acute O B_DISEASE
interstitial O I_DISEASE
nephritis O I_DISEASE
with O O
granular O B_DISEASE
tubular O I_DISEASE
basement O I_DISEASE
membrane O I_DISEASE
deposits O I_DISEASE
. O O

Acute O B_DISEASE_ADJECTIVE[DISEASE]
tubulo O I_DISEASE_ADJECTIVE[DISEASE]
- O O
interstitial O B_DISEASE
nephritis O I_DISEASE
( O O
ATIN O B_LOCATION/B_ORGANIZATION
) O O
is O O
an O O
important O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cause O I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
acute O B_DISEASE
renal O I_DISEASE
failure O I_DISEASE
resulting O O
from O O
a O O
variety O B_ENT/B_MEASURE
of O O
insults O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
, O O
including O O
immune O B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
complex O B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
mediated O O
tubulo O B_DISEASE
- O O
interstitial O B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
injury O I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
, O O
but O O
drugs O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
such O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
as O O
non O B_DISEASE/B_PROTEIN[GENE]
- O O
steroidal O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
anti O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
- O O
inflammatory O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
drugs O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
( O O
NSAIDs O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
) O O
are O O
a O O
far O O
more O O
frequent O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
cause O B_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O O

Overall O O
, O O
as O O
an O O
entity O B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
ATIN O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
remains O O
under O O
- O O
diagnosed O O
, O O
as O O
symptoms O B_DISEASE
resolve O O
spontaneously O O
if O O
the O O
medication O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
is O O
stopped O O
. O O

He O O
then O O
presented O O
to O O
the O O
emergency O O
department O O
feeling O O
quite O O
ill O O
and O O
was O O
found O O
to O O
have O O
a O O
blood B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
urea I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
nitrogen I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
( O O
BUN B B_PROTEIN[GENE]/B_BODY_PART_OR_ORGAN_COMPONENT
) O O
concentration O O
of O O
of O O
147 O O
mg O O
/ O O
dl O O
, O O
creatinine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
of O O
15 O O
. O O
3 O O
mg O O
/ O O
dl O O
and O O
serum O O
potassium B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
8 O O
. O O
7 O O
mEq O O
/ O O
l O O
. O O

In O O
conclusion O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
, O O
this O O
is O O
a O O
first O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
report O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
of O O
NSAIDs O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
associated O O
ATIN O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
showing O O
deposits O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
granular O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
immune O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
complex O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
present O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
only O O
in O O
the O O
TBM O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
and O O
not O O
in O O
the O O
glomeruli O B_DISEASE/B_LOCATION
. O O

All O O
patients O O
were O O
also O O
tested O O
for O O
liver O O
enzymes O O
, O O
anti O O
- O O
HCV O O
, O O
HBeAg B B_DISEASE/B_GENE
, O O
and O O
anti O O
- O O
HBe O O
. O O

HBeAg B B_DISEASE/B_GENE
was O O
positive O O
in O O
40 O O
% O O
and O O
anti O O
- O O
HBe O O
in O O
60 O O
% O O
of O O
the O O
patients O O
. O O

Anti O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
HCV O B_DISEASE
was O O
negative O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
all O O
of O O
them O O
. O O

YMDD O O
motif O O
mutants O O
were O O
not O O
detected O O
in O O
any O O
of O O
the O O
patients O O
despite O O
the O O
liver O O
enzyme O O
levels O O
and O O
the O O
presence O O
of O O
HBeAg B B_DISEASE/B_GENE
or O O
anti O O
- O O
HBe O O
. O O

BACKGROUND O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
: O O
In O O
addition O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
to O O
blocking O O
nociceptive O B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
input O B_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
from O O
surgical O B_DISEASE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
sites O B_DISEASE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
, O O
long O O
- O O
acting O O
local O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
anesthetics O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
might O O
directly O O
modulate O O
inflammation O B_DISEASE/B_BACTERIUM[BIO]
. O O

In O O
the O O
present O O
study O O
, O O
we O O
describe O O
the O O
proinflammatory O O
effects O O
of O O
bupivacaine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O O
local O O
prostaglandin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
E2 I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
( O O
PGE2 B B_GENE
) O O
production O O
and O O
cyclooxygenase O O
( O O
COX O O
) O O
gene O O
expression O O
that O O
increases O O
postoperative O O
pain O O
in O O
human O O
subjects O O
. O O

After O O
extraction O O
, O O
a O O
microdialysis O O
probe O O
was O O
placed O O
at O O
the O O
surgical O O
site O O
for O O
PGE2 B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
and O O
thromboxane B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
B2 I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
( O O
TXB2 B B_GENE
) O O
measurements O O
. O O

The O O
present O O
studies O O
examine O O
the O O
expression O O
and O O
regulation O O
of O O
another O O
receptor O O
known O O
to O O
bind O O
NGF O O
, O O
p75 O O
( O O
NTR O O
) O O
, O O
after O O
various O O
durations O O
of O O
bladder O O
inflammation O O
induced O O
by O O
cyclophosphamide B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
CYP B B_LOCATION/B_ORGANIZATION
) O O
. O O

CYP B B_DISEASE/B_BIO
- O O
induced O O
cystitis O O
increased O O
( O O
P O O
< O O
or O O
= O O
0 O O
. O O
001 O O
) O O
p75 O O
( O O
NTR O O
) O O
expression O O
in O O
the O O
superficial O O
lateral O O
and O O
medial O O
dorsal O O
horn O O
in O O
L1 O O
- O O
L2 O O
and O O
L6 O O
- O O
S1 O O
spinal O O
segments O O
. O O

Retrograde O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
dye O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
- O O
tracing O O
techniques O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O O
Fastblue O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
were O O
used O O
to O O
identify O O
presumptive O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
bladder O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
afferent O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
cells O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
in O O
the O O
lumbosacral O B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
DRG O B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
. O O

These O O
studies O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
demonstrate O O
that O O
p75 O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
NTR O B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
expression O B_GENE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
micturition O B_DISEASE_ADJECTIVE[DISEASE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
reflexes O B_DISEASE_ADJECTIVE[DISEASE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
is O O
present O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
constitutively O O
and O O
modified O O
by O O
bladder O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
inflammation O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Alternatively O O
, O O
anemia O O
could O O
result O O
from O O
accelerated O O
suicidal O O
erythrocyte O O
death O O
or O O
eryptosis O O
, O O
which O O
is O O
characterized O O
by O O
exposure O O
of O O
phosphatidylserine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
PS B B_PROTEIN[GENE]/B_LOCATION
) O O
at O O
the O O
erythrocyte O O
surface O O
and O O
by O O
cell O O
shrinkage O O
. O O

Antidepressants O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
have O O
previously O O
been O O
associated O O
with O O
paranoid O B_DISEASE
reactions O I_DISEASE
in O O
psychiatric O B_PERSON/B_BIO
patients O I_PERSON/I_BIO
. O O

BACKGROUND O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
: O O
Spinal O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
anaesthesia O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
is O O
widely O O
employed O O
in O O
clinical O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_PERSON
practice O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_PERSON
but O O
has O O
the O O
main O B_DISEASE_ADJECTIVE[DISEASE]
drawback O I_DISEASE_ADJECTIVE[DISEASE]
of O O
post O B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
- O O
spinal O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
block O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
hypotension O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

RESULTS O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
: O O
Three O B_TIME[MEASURE]
patients O I_TIME[MEASURE]
( O O
8 O B_MEASURE
. O O
1 O B_MEASURE
% O I_MEASURE
) O O
in O O
the O O
unilateral O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
group O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
and O O
5 O B_NUMBER[MEASURE]/B_PERSON
( O O
13 O B_MEASURE
. O O
5 O B_MEASURE
% O I_MEASURE
) O O
in O O
the O O
conventional O B_PERSON/B_ORGANIZATION
group O I_PERSON/I_ORGANIZATION
developed O O
hypotension O B_DISEASE
, O O
P O B_OTHER/B_PROTEIN[GENE]
= O O
0 O B_MEASURE
. O O
71 O B_MEASURE
. O O

CONCLUSION O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
: O O
Compared O O
to O O
conventional O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
spinal O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
anaesthesia O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
, O O
unilateral O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
spinal O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
anaesthesia O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
was O O
associated O O
with O O
fewer O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cardiovascular O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
perturbations O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

To O O
determine O O
the O O
incidence O B_MEASURE
of O O
clinically O O
significant O B_DISEASE_ADJECTIVE[DISEASE]
adverse O I_DISEASE_ADJECTIVE[DISEASE]
events O I_DISEASE_ADJECTIVE[DISEASE]
after O O
long O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
- O O
term O B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
fixed O O
- O O
dose O B_MEASURE/B_LOCATION
, O O
generic O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
highly O O
active O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
antiretroviral O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
therapy O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
HAART O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
) O O
use O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
among O O
HIV O B_DISEASE
- O O
infected O O
individuals O B_PERSON/B_LOCATION
in O O
South O B_LOCATION/B_MEASURE
India O I_LOCATION/I_MEASURE
, O O
we O O
examined O O
the O O
experiences O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
of O O
3154 O B_DISEASE
HIV O I_DISEASE
- O O
infected O O
individuals O B_PERSON
who O O
received O O
a O O
minimum O B_MEASURE
of O O
3 O B_TIME[MEASURE]
months O I_TIME[MEASURE]
of O O
generic O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
HAART O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
between O O
February O B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
1996 O I_TIME[MEASURE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
December O B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
2006 O I_TIME[MEASURE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
at O O
a O O
tertiary O B_LOCATION
HIV O I_LOCATION
care O I_LOCATION
referral O I_LOCATION
center O I_LOCATION
in O O
South O B_LOCATION
India O I_LOCATION
. O O

The O O
most O O
common O O
regimens O O
were O O
3TC B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
+ O O
d4T B B_PROTEIN[GENE]
+ O O
nevirapine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
NVP B B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
) O O
( O O
54 O O
. O O
8 O O
% O O
) O O
, O O
zidovudine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
( O O
AZT B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
+ O O
3TC B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
+ O O
NVP B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
( O O
14 O O
. O O
5 O O
% O O
) O O
, O O
3TC B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
+ O O
d4T B B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
+ O O
efavirenz B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
( O O
EFV B B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
( O O
20 O O
. O O
1 O O
% O O
) O O
, O O
and O O
AZT B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
+ O O
3TC B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
+ O O
EFV B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
5 O O
. O O
4 O O
% O O
) O O
. O O

Anemia O B_DISEASE
and O O
hepatitis O B_DISEASE
often O O
occur O O
within O O
12 O B_TIME[MEASURE]/B_ENT
weeks O I_TIME[MEASURE]/I_ENT
of O O
initiating O O
generic O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
HAART O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
. O O

Frequent O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
early O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
monitoring O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O O
these O O
toxicities O B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O O
warranted O O
in O O
developing O O
countries O B_LOCATION/B_ORGANIZATION
where O O
generic O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
HAART O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O O
increasingly O O
available O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
. O O

Sural O B_MEASURE/B_PERSON
nerve O I_MEASURE/I_PERSON
SAP O I_MEASURE/I_PERSON
amplitude O I_MEASURE/I_PERSON
reduction O I_MEASURE/I_PERSON
> O I_MEASURE/I_PERSON
or O O
= O O
40 O B_MEASURE/B_PERSON
% O I_MEASURE/I_PERSON
was O O
the O O
criteria O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
for O O
discontinuing O O
therapy O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
. O O

CONCLUSIONS O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
: O O
Sural O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
nerve O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
SAP O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
amplitude O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
reduction O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
is O O
a O O
reliable O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
sensitive O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
marker O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O O
degeneration O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
and O O
recovery O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
sensory O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
fibres O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE
. O O

This O O
type O B_MEASURE/B_DISEASE
of O O
drug O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
induced O O
complication O B_DISEASE
may O O
not O O
be O O
that O O
uncommon O B_DISEASE_ADJECTIVE[DISEASE]
in O O
highly O O
endemic O B_PERSON/B_NUMBER[MEASURE]
regions O I_PERSON/I_NUMBER[MEASURE]
. O O

The O O
20 O B_NUMBER[MEASURE]
- O O
year O B_TIME[MEASURE]/B_LOCATION
risk O I_TIME[MEASURE]/I_LOCATION
of O O
CAD O B_DISEASE
at O O
diagnosis O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
diabetes O B_DISEASE/B_LOCATION
, O O
using O O
the O O
UKPDS O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
risk O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
engine O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
, O O
was O O
used O O
to O O
match O O
cases O B_PERSON/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O O
controls O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
. O O

Groups O O
ADR B B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
6 O O
) O O
, O O
ADR B B_LOCATION
+ O O
LOS B B_DISEASE/B_PERSON
( O O
6 O O
) O O
and O O
ADR B B_LOCATION
( O O
12 O O
) O O
, O O
and O O
ADR B B_LOCATION
+ O O
LOS B B_PERSON/B_LOCATION
( O O
12 O O
) O O
received O O
ADR B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
2 O O
mg O O
/ O O
kg O O
/ O O
b O O
. O O
w O O
. O O
i O O
. O O
v O O
. O O
) O O
twice O O
in O O
a O O
3 O O
- O O
week O O
interval O O
. O O

Group O O
ADR B B_LOCATION
+ O O
LOS B B_PERSON/B_LOCATION
( O O
6 O O
) O O
received O O
losartan B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
( O O
10 O O
mg O O
/ O O
kg O O
/ O O
b O O
. O O
w O O
. O O
/ O O
day O O
by O O
gavages O O
) O O
for O O
6 O O
weeks O O
and O O
group O O
ADR B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
+ O O
LOS B B_PERSON/B_DISEASE
( O O
12 O O
) O O
for O O
12 O O
weeks O O
after O O
second O O
injection O O
of O O
ADR B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
. O O

Except O O
for O O
antifibrinolytic O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
therapy O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
, O O
the O O
anesthetic O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
surgical O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
protocols O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
remained O O
unchanged O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
. O O

The O O
racemic O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
compound O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
significantly O O
less O O
potent O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
than O O
either O O
isomer O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_NUMBER[MEASURE]
. O O
6 O B_MEASURE/B_LOCATION
. O O

Improving O O
glioblastoma O B_DISEASE
multiforme O I_DISEASE
( O O
GBM O B_LOCATION/B_ORGANIZATION
) O O
treatment O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
with O O
radio O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
chemotherapy O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
remains O O
a O O
challenge O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
. O O

However O O
, O O
while O O
response O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
and O O
stabilization O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
concerned O O
one O B_NUMBER[MEASURE]
- O O
third O B_SEQUENCE[MEASURE]
of O O
the O O
patients O B_PERSON
, O O
the O O
study O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
did O O
not O O
show O O
increased O O
benefits O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
in O O
terms O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
of O O
survival O B_DISEASE
in O O
patients O B_PERSON/B_BIO
with O O
unresectable O B_DISEASE/B_LOCATION
GBM O I_DISEASE/I_LOCATION
. O O

Comparison O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
laryngeal O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
mask O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
with O O
endotracheal O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
tube O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
for O O
anesthesia O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_PERSON
in O O
endoscopic O B_PERSON/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
sinus O I_PERSON/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
surgery O I_PERSON/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O O

The O O
FDA O B_ORGANIZATION/B_TIME[MEASURE]
- O O
recommended O O
dose O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
during O O
PCI O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
is O O
25 O B_MEASURE
microg O I_MEASURE
/ O O
kg O B_MEASURE
/ O O
min O B_PERSON/B_TIME[MEASURE]
( O O
350 O B_MEASURE
microg O I_MEASURE
/ O O
kg O B_MEASURE
initial O I_MEASURE
bolus O I_MEASURE
) O O
, O O
adjusted O O
to O O
achieve O O
activated O O
clotting O B_TIME[MEASURE]/B_LOCATION
times O B_TIME[MEASURE]/I_LOCATION
( O O
ACTs O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
) O O
of O O
300 O B_MEASURE
- O O
450 O B_MEASURE
sec O I_MEASURE
. O O

Improved O O
familiarity O O
of O O
healthcare O O
professionals O O
with O O
argatroban B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
therapy O O
in O O
HIT O O
, O O
including O O
in O O
special O O
populations O O
and O O
during O O
PCI O O
, O O
may O O
facilitate O O
reduction O O
of O O
harm O O
associated O O
with O O
HIT O O
( O O
e O O
. O O
g O O
. O O
fewer O O
thromboses O O
) O O
or O O
its O O
treatment O O
( O O
e O O
. O O
g O O
. O O
fewer O O
argatroban B B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
medication O O
errors O O
) O O
. O O

Motor O O
impairment O O
, O O
dopamine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
( O O
DA B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
) O O
neuronal O O
activity O O
and O O
proenkephalin B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
( O O
PENK B B_LOCATION/B_PERSON
) O O
gene O O
expression O O
in O O
the O O
caudate O O
- O O
putamen O O
( O O
CPu O O
) O O
were O O
measured O O
in O O
6 B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
OHDA I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
- O O
lesioned O O
and O O
treated O O
( O O
L B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
- I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
DOPA I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
+ I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
benserazide I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
) O O
CB1 O O
KO O O
and O O
WT O O
mice O O
. O O

A O O
lesion O O
induced O O
by O O
6 B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
OHDA I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
produced O O
more O O
severe O O
motor O O
deterioration O O
in O O
CB1 O O
KO O O
mice O O
accompanied O O
by O O
more O O
loss O O
of O O
DA B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
neurons O O
and O O
increased O O
PENK B B_GENE
gene O O
expression O O
in O O
the O O
CPu O O
. O O

Oxidative O B_DISEASE_ADJECTIVE[DISEASE]
/ O O
nitrosative O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BACTERIUM[BIO]
and O O
neuroinflammatory O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
parameters O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
were O O
estimated O O
in O O
the O O
CPu O B_BODY_PART_OR_ORGAN_COMPONENT/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
cingulate O B_PERSON/B_LOCATION
cortex O I_PERSON/I_LOCATION
( O O
Cg O B_DISEASE/B_LOCATION
) O O
. O O

This O O
study O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
undertaken O O
to O O
determine O O
whether O O
oxidants O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
are O O
associated O O
with O O
the O O
hepatic O B_DISEASE_ADJECTIVE[DISEASE]
injury O I_DISEASE_ADJECTIVE[DISEASE]
and O O
to O O
determine O O
the O O
relative O B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
value O B_MEASURE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
several O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
indirect O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
methods O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O O
assessing O O
oxidant O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
exposure O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
vivo O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

The O O
lack O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
of O O
a O O
significant O B_DISEASE_ADJECTIVE[DISEASE]
increase O I_DISEASE_ADJECTIVE[DISEASE]
in O O
products O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
lipid O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
peroxidation O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
suggests O O
that O O
the O O
oxidant O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
stress O B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
is O O
of O O
insufficient O B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
magnitude O I_MEASURE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
result O O
in O O
irreversible O B_DISEASE
injury O I_DISEASE
to O O
hepatocyte O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
cell O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
membranes O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

The O O
derangements O B_DISEASE_ADJECTIVE[DISEASE]
in O O
the O O
procoagulant O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
and O O
anticoagulant O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
pathways O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
during O O
fulminant O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
liver O B_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
failure O B_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
can O O
lead O O
to O O
difficulties O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
with O O
anticoagulation O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
during O O
dialysis O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O O
especially O O
when O O
continued O O
in O O
the O O
operating O B_PERSON/B_TIME[MEASURE]
room O B_PERSON/I_TIME[MEASURE]
. O O

A O O
variety O B_ENT/B_MEASURE
of O O
factors O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
have O O
been O O
identified O O
that O O
increase O O
the O O
risk O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
of O O
posttransplant O B_DISEASE
anemia O I_DISEASE
, O O
of O O
which O O
the O O
level O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
renal O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
function O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
is O O
most O O
important O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

METHODS O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
: O O
We O O
prospectively O O
evaluated O O
the O O
safety O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
coronary O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
CTA O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
for O O
low O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
- O O
risk O B_MEASURE/B_PERSON
patients O I_MEASURE/I_PERSON
who O O
presented O O
to O O
the O O
ED O B_PERSON/B_LOCATION
with O O
cocaineassociated O B_DISEASE
chest O I_DISEASE
pain O I_DISEASE
( O O
self O B_PERSON/B_LOCATION
- O O
reported O O
or O O
positive O B_DISEASE_ADJECTIVE[DISEASE]
urine O I_DISEASE_ADJECTIVE[DISEASE]
test O I_DISEASE_ADJECTIVE[DISEASE]
) O O
. O O

Consecutive O B_PERSON
patients O I_PERSON
received O O
either O O
immediate O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
coronary O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
CTA O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
in O O
the O O
ED O B_DISEASE/B_TIME[MEASURE]
( O O
without O O
serial O B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
markers O B_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
or O O
underwent O O
coronary O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
CTA O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
after O O
a O O
brief O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
observation O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
period O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
with O O
serial O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
cardiac O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
marker O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
measurements O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
. O O

Twenty O B_NUMBER[MEASURE]/B_PERSON
patients O I_NUMBER[MEASURE]/I_PERSON
received O O
coronary O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
CTA O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
immediately O O
in O O
the O O
ED O B_PERSON/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O O
18 O B_NUMBER[MEASURE]
of O O
whom O O
were O O
discharged O O
following O O
CTA O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_LOCATION
( O O
90 O B_NUMBER[MEASURE]/B_LOCATION
% O I_NUMBER[MEASURE]/I_LOCATION
) O O
. O O

OBJECTIVES O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
: O O
Posterior O B_DISEASE
leukoencephalopathy O I_DISEASE
due O O
to O O
calcineurin O B_GENE
- O O
inhibitor O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
related O O
neurotoxicity O B_DISEASE
is O O
a O O
rare O B_DISEASE_ADJECTIVE[DISEASE]
but O O
severe O B_DISEASE_ADJECTIVE[DISEASE]
complication O I_DISEASE_ADJECTIVE[DISEASE]
that O O
results O O
from O O
treatment O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
with O O
immunosuppressive O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
agents O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
primarily O O
those O O
administered O O
after O O
a O O
liver O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
or O O
kidney O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_BODY_PART_OR_ORGAN_COMPONENT
transplant O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_BODY_PART_OR_ORGAN_COMPONENT
) O O
. O O

CASE O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O O
We O O
report O O
the O O
case O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
a O O
46 O B_MEASURE
- O O
year O B_TIME[MEASURE]
- O O
old O B_PERSON
woman O I_PERSON
who O O
received O O
a O O
liver O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
transplant O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
in O O
our O O
center O B_LOCATION
as O O
treatment O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
for O O
alcoholic O B_DISEASE/B_GENE
cirrhosis O I_DISEASE/I_GENE
and O O
in O O
whom O O
either O O
a O O
fulminant O B_DISEASE
course O I_DISEASE
of O O
posterior O B_DISEASE
leukoencephalopathy O I_DISEASE
or O O
posterior O B_DISEASE
reversible O I_DISEASE
encephalopathy O I_DISEASE
syndrome O I_DISEASE
developed O O
110 O B_TIME[MEASURE]/B_ENT
days O I_TIME[MEASURE]/I_ENT
after O O
transplant O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
. O O

The O O
termination O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
of O O
treatment O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
with O O
any O O
calcineurin O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
inhibitor O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
resulted O O
in O O
a O O
complete O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
resolution O B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
that O O
complication O B_DISEASE
. O O

We O O
recommend O O
a O O
complete O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
cessation O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O O
any O O
calcineurin O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
inhibitor O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
rather O O
than O O
a O O
dose O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
reduction O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
. O O

BACKGROUND O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
: O O
To O O
review O O
evidence O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
based O O
treatment O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_LOCATION
options O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_LOCATION
in O O
patients O B_PERSON/B_LOCATION
with O O
cerebral O B_DISEASE/B_GENE
edema O I_DISEASE/I_GENE
complicating O O
fulminant O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
hepatic O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
failure O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
( O O
FHF O B_LOCATION/B_PROTEIN[GENE]
) O O
and O O
discuss O O
the O O
potential O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
applications O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
hypothermia O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
. O O

The O O
patient O B_PERSON/B_DISEASE
was O O
treated O O
with O O
hyperosmolar O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
therapy O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
hyperventilation O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
, O O
sedation O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
, O O
and O O
chemical O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
paralysis O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

We O O
then O O
initiated O O
therapeutic O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
hypothermia O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
which O O
was O O
continued O O
for O O
5 O B_TIME[MEASURE]/B_ENT
days O I_TIME[MEASURE]/I_ENT
. O O

A O O
clinical O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
trial O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
hypothermia O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
patients O B_PERSON/B_BIO
with O O
this O O
condition O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O O
warranted O O
. O O

All O O
patients O B_PERSON
underwent O O
objective O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
assessment O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
electrophysiological O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
function O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
wide O B_NUMBER[MEASURE]/B_LOCATION
- O O
field O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
multifocal O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
electroretinography O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
) O O
and O O
conventional O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
visual O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
field O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
testing O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
( O O
static O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
perimetry O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
) O O
. O O

METHODS O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
: O O
We O O
included O O
data O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
from O O
people O B_PERSON
participating O O
in O O
the O O
Vancouver O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
Injection O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
Drug O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
Users O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
Study O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
who O O
reported O O
injecting O O
illicit O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
drugs O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
at O O
least O O
once O O
in O O
the O O
month O B_TIME[MEASURE]/B_LOCATION
before O O
enrolment O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
, O O
lived O O
in O O
the O O
greater O B_LOCATION
Vancouver O I_LOCATION
area O I_LOCATION
, O O
were O O
HIV O B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
negative O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
at O O
enrolment O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
completed O O
at O O
least O O
1 O B_NUMBER[MEASURE]/B_PERSON
follow O O
- O O
up O O
study O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
visit O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Cancer O B_PERSON
patients O I_PERSON
who O O
have O O
been O O
treated O O
with O O
systemic O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
adjuvant O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
chemotherapy O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
have O O
described O O
experiencing O O
deteriorations O B_DISEASE_ADJECTIVE[DISEASE]
in O O
cognition O B_DISEASE
. O O

We O O
have O O
recently O O
demonstrated O O
that O O
disruption O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
extracellular O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
matrix O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
( O O
ECM O B_PROTEIN[GENE]/B_LOCATION
) O O
/ O O
integrin O B_GENE
signaling O O
via O O
elimination O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
integrin O B_GENE
- O O
linked O O
kinase O B_ENZYME[GENE]/B_LOCATION
( O O
ILK O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
) O O
in O O
hepatocytes O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE
interferes O O
with O O
signals O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
leading O O
to O O
termination O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
of O O
liver O B_DISEASE/B_ORGANISM_FUNCTION
regeneration O B_DISEASE/I_ORGANISM_FUNCTION
. O O

Urine O B_MEASURE/B_PERSON
volume O I_MEASURE/I_PERSON
was O O
increased O O
, O O
while O O
urine O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
osmolality O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
and O O
free O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
water O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
reabsorption O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
were O O
decreased O O
. O O

When O O
participants O O
were O O
stratified O O
by O O
antiretroviral O O
therapy O O
( O O
ART O O
) O O
use O O
, O O
the O O
association O O
between O O
alcohol B B_DISEASE
and O O
CD4 O O
+ O O
T O O
- O O
cell O O
did O O
not O O
reach O O
statistical O O
significance O O
. O O

Our O O
findings O O
suggest O O
that O O
alcohol B B_BIO/B_DISEASE
consumption O O
has O O
a O O
direct O O
association O O
with O O
depression O O
. O O

Metallothionein B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
induction O O
reduces O O
caspase O O
- O O
3 O O
activity O O
and O O
TNFalpha O O
levels O O
with O O
preservation O O
of O O
cognitive O O
function O O
and O O
intact O O
hippocampal O O
neurons O O
in O O
carmustine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
- O O
treated O O
rats O O
. O O

Hippocampal O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
integrity O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
is O O
essential O B_DRUG_ADJECTIVE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
for O O
cognitive O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
functions O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O O

On O O
the O O
other O O
hand O O
, O O
induction O O
of O O
metallothionein B B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
( O O
MT B B_LOCATION/B_PROTEIN[GENE]
) O O
by O O
ZnSO B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
( I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
4 I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
) I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
and O O
its O O
role O O
in O O
neuroprotection O O
has O O
been O O
documented O O
. O O

The O O
present O O
study O O
aimed O O
to O O
explore O O
the O O
effect O O
of O O
MT B B_GENE/B_DISEASE
induction O O
on O O
carmustine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
( O O
BCNU B B_LOCATION/B_ORGANIZATION
) O O
- O O
induced O O
hippocampal O O
cognitive O O
dysfunction O O
in O O
rats O O
. O O

Also O O
, O O
BCNU B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
administration O O
increased O O
serum O O
tumor O O
necrosis O O
factor O O
- O O
alpha O O
( O O
TNFalpha O O
) O O
, O O
hippocampal O O
MT B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
and O O
malondialdehyde B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
( O O
MDA B B_LOCATION
) O O
contents O O
as O O
well O O
as O O
caspase O O
- O O
3 O O
activity O O
in O O
addition O O
to O O
histological O O
alterations O O
. O O

ZnSO B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
( I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
4 I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
) I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
pretreatment O O
counteracted O O
BCNU B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
- O O
induced O O
inhibition O O
of O O
GR O O
and O O
depletion O O
of O O
GSH B B_GENE/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
resulted O O
in O O
significant O O
reduction O O
in O O
the O O
levels O O
of O O
MDA B B_GENE/B_BIO
and O O
TNFalpha O O
as O O
well O O
as O O
the O O
activity O O
of O O
caspase O O
- O O
3 O O
. O O

The O O
histological O O
features O O
were O O
improved O O
in O O
hippocampus O O
of O O
rats O O
treated O O
with O O
ZnSO B B_LOCATION
( I I_LOCATION
4 I I_LOCATION
) I I_LOCATION
+ O O
BCNU B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
compared O O
to O O
only O O
BCNU B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
- O O
treated O O
animals O O
. O O

In O O
conclusion O O
, O O
MT B B_GENE/B_DISEASE
induction O O
halts O O
BCNU B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
- O O
induced O O
hippocampal O O
toxicity O O
as O O
it O O
prevented O O
GR O O
inhibition O O
and O O
GSH B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
depletion O O
and O O
counteracted O O
the O O
increased O O
levels O O
of O O
TNFalpha O O
, O O
MDA B B_GENE/B_BIO
and O O
caspase O O
- O O
3 O O
activity O O
with O O
subsequent O O
preservation O O
of O O
cognition O O
. O O

BACKGROUND O O
: O O
Renal O O
dysfunction O O
induced O O
by O O
iodinated O O
contrast B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
medium I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
( O O
CM B B_TIME[MEASURE]/B_DISEASE
) O O
administration O O
can O O
minimize O O
the O O
benefit O O
of O O
the O O
interventional O O
procedure O O
in O O
patients O O
undergoing O O
renal O O
angioplasty O O
( O O
PTRA O O
) O O
. O O

MATERIAL O O
AND O O
METHODS O O
: O O
A O O
total O O
of O O
33 O O
patients O O
successfully O O
treated O O
with O O
PTRA O O
( O O
PTRA O O
group O O
, O O
mean O O
age O O
70 O O
+ O O
/ O O
- O O
12 O O
years O O
, O O
23 O O
female O O
, O O
basal O O
creatinine B B_MEASURE/B_LOCATION
1 O O
. O O
46 O O
+ O O
/ O O
- O O
0 O O
. O O
79 O O
, O O
range O O
0 O O
. O O
7 O O
- O O
4 O O
. O O
9 O O
mg O O
/ O O
dl O O
) O O
were O O
compared O O
with O O
33 O O
patients O O
undergoing O O
successful O O
PCI O O
( O O
PCI O O
group O O
) O O
, O O
matched O O
for O O
basal O O
creatinine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
( O O
1 O O
. O O
44 O O
+ O O
/ O O
- O O
0 O O
. O O
6 O O
, O O
range O O
0 O O
. O O
7 O O
- O O
3 O O
. O O
4 O O
mg O O
/ O O
dl O O
) O O
, O O
gender O O
, O O
and O O
age O O
. O O

Patients O B_PERSON
often O O
consume O O
the O O
drug O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O O
suicidal O B_DISEASE
intent O I_DISEASE
or O O
with O O
a O O
background O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
substance O B_DISEASE
dependence O I_DISEASE
. O O

BACKGROUND O B_TIME[MEASURE]/B_LOCATION
AND O O
PURPOSE O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
: O O
Cerebral O B_DISEASE
microbleeds O I_DISEASE
( O O
MB O B_LOCATION/B_PERSON
) O O
are O O
potential O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
risk O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
factors O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
for O O
intracerebral O B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
hemorrhage O I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
( O O
ICH O B_DISEASE/B_LOCATION
) O O
, O O
but O O
it O O
is O O
unclear O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
if O O
they O O
are O O
a O O
contraindication O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
to O O
using O O
antithrombotic O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
drugs O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

METHODS O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
: O O
We O O
performed O O
a O O
systematic O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
review O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O O
published O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
unpublished O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
data O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
from O O
cohorts O B_PERSON/B_LOCATION
with O O
stroke O B_DISEASE/B_LOCATION
or O O
TIA O B_DISEASE/B_LOCATION
to O O
compare O O
the O O
presence O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
of O O
MB O B_DISEASE/B_GENE
in O O
: O O
( O O
1 O O
) O O
antithrombotic O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
users O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
vs O O
nonantithrombotic O B_PERSON/B_ORGANIZATION
users O I_PERSON/I_ORGANIZATION
with O O
ICH O B_DISEASE/B_LOCATION
; O O
( O O
2 O O
) O O
antithrombotic O B_PERSON/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
users O I_PERSON/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
vs O O
nonusers O B_PERSON/B_DISEASE
with O O
IS O B_DISEASE/B_LOCATION
/ O O
TIA O B_LOCATION/B_ORGANIZATION
; O O
and O O
( O O
3 O B_NUMBER[MEASURE]
) O O
ICH O B_PERSON/B_LOCATION
vs O I_PERSON/I_LOCATION
ischemic O I_PERSON/I_LOCATION
events O I_PERSON/I_LOCATION
stratified O O
by O O
antithrombotic O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
use O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
. O O

The O O
doses O O
calculated O O
to O O
cause O O
50 O O
% O O
reversal O O
of O O
hyperalgesia O O
( O O
ED50 O O
) O O
were O O
7 O O
. O O
54 O O
( O O
1 O O
. O O
81 O O
) O O
and O O
4 O O
. O O
83 O O
( O O
1 O O
. O O
54 O O
) O O
in O O
the O O
carrageenan B B_DISEASE
model O O
and O O
44 O O
. O O
18 O O
( O O
1 O O
. O O
37 O O
) O O
and O O
9 O O
. O O
14 O O
( O O
1 O O
. O O
24 O O
) O O
in O O
the O O
STZ B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
induced O O
neuropathy O O
model O O
for O O
CNSB002 B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
morphine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
respectively O O
( O O
mg O O
/ O O
kg O O
; O O
mean O O
, O O
SEM O O
) O O
. O O

The O O
ED50 O O
values O O
for O O
morphine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
when O O
given O O
in O O
combination O O
with O O
CNSB002 B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
5 O O
mg O O
/ O O
kg O O
) O O
were O O
less O O
than O O
the O O
maximum O O
nonsedating O O
dose O O
: O O
0 O O
. O O
56 O O
( O O
1 O O
. O O
55 O O
) O O
in O O
the O O
carrageenan B B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
model O O
and O O
1 O O
. O O
37 O O
( O O
1 O O
. O O
23 O O
) O O
in O O
the O O
neuropathy O O
model O O
( O O
mg O O
/ O O
kg O O
; O O
mean O O
, O O
SEM O O
) O O
. O O

Early O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
recognition O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
that O O
incorporates O O
the O O
clinical O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
serologic O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
clues O I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
is O O
paramount O B_DRUG_ADJECTIVE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
to O O
timely O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_LOCATION
institution O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_LOCATION
of O O
treatment O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
as O O
its O O
delay O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
may O O
result O O
in O O
catastrophic O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
outcomes O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Direct B B_NUMBER[MEASURE]/B_PERSON
thrombin I B_NUMBER[MEASURE]/I_PERSON
inhibitors I B_NUMBER[MEASURE]/I_PERSON
are O O
appropriate O O
, O O
evidence O O
- O O
based O O
alternatives O O
to O O
heparin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
in O O
patients O O
with O O
a O O
history O O
of O O
HIT O O
, O O
who O O
need O O
to O O
undergo O O
percutaneous O O
coronary O O
intervention O O
. O O

Drug O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O O
induced O O
immune O B_DISEASE
hemolytic O I_DISEASE
anemia O I_DISEASE
was O O
suspected O O
because O O
of O O
positive O B_DISEASE
direct O I_DISEASE
antiglobulin O I_DISEASE
test O I_DISEASE
, O O
negative O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
eluate O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
, O O
and O O
microspherocytes O B_BACTERIUM[BIO]/B_DISEASE_ADJECTIVE[DISEASE]
on O O
smear O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
pre O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
and O O
post O B_DISEASE/B_MEASURE
- O O
transfusion O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
. O O

The O O
patient O B_PERSON/B_DISEASE
recovered O O
after O O
discontinuing O O
the O O
drug O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
with O O
no O O
recurrence O B_DISEASE
in O O
2 O B_TIME[MEASURE]/B_ENT
years O I_TIME[MEASURE]/I_ENT
. O O

RESEARCH O B_NUMBER[MEASURE]/B_ORGANIZATION
DESIGN O I_NUMBER[MEASURE]/I_ORGANIZATION
AND O O
METHODS O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O O
EndoMT O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
induced O O
in O O
a O O
mouse O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
pancreatic O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
microvascular O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
endothelial O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
cell O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
line O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
( O O
MMEC O B_DISEASE/B_TIME[MEASURE]
) O O
in O O
the O O
presence O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
of O O
advanced O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
glycation O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
end O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
products O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
( O O
AGEs O B_DISEASE/B_BACTERIUM[BIO]
) O O
and O O
in O O
the O O
endothelial O B_DISEASE/B_GENE
lineage O I_DISEASE/I_GENE
- O O
traceble O B_GENE/B_DISEASE
mouse O I_GENE/I_DISEASE
line O I_GENE/I_DISEASE
Tie2 O I_GENE/I_DISEASE
- O O
Cre O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
; O O
Loxp O B_GENE/B_MEASURE
- O O
EGFP O B_GENE/B_MEASURE
by O O
administration O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
AGEs O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BACTERIUM[BIO]
, O O
with O O
nonglycated O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
mouse O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
albumin O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
serving O O
as O O
a O O
control O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
. O O

RESULTS O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
: O O
Confocal O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
microscopy O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
and O O
real O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
time O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
PCR O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
demonstrated O O
that O O
AGEs O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BACTERIUM[BIO]
induced O O
EndoMT O O
in O O
MMECs O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
and O O
in O O
Tie2 O B_GENE
- O O
Cre O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
; O O
Loxp O B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
EGFP O B_GENE
mice O I_GENE
. O O

Confocal O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
microscopy O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
real O B_PERSON/B_MEASURE
- O O
time O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
PCR O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
further O O
demonstrated O O
that O O
SIS3 O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
abrogated O O
EndoMT O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
reduced O O
renal O B_DISEASE/B_GENE
fibrosis O I_DISEASE/I_GENE
, O O
and O O
retarded O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
progression O I_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
nephropathy O B_DISEASE
. O O

Blockade O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
EndoMT O B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
by O O
SIS3 O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
may O O
provide O O
a O O
new O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
strategy O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
to O O
retard O O
the O O
progression O B_DISEASE_ADJECTIVE[DISEASE]/B_ORGANISM_FUNCTION
of O O
diabetic O B_DISEASE
nephropathy O I_DISEASE
and O O
other O B_DISEASE/B_GENE
diabetes O I_DISEASE/I_GENE
complications O I_DISEASE/I_GENE
. O O

Patients O B_PERSON/B_DISEASE
become O O
progressively O O
refractory O B_DISEASE_ADJECTIVE[DISEASE]
to O O
conventional O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
chemotherapy O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
and O O
their O O
prognosis O B_DISEASE
is O O
poor O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

A O O
23 O B_MEASURE
- O O
year O B_TIME[MEASURE]
- O O
old O B_PERSON
male O I_PERSON
patient O I_PERSON
with O O
bacteriologically O O
proven O O
pulmonary O B_DISEASE
tuberculosis O I_DISEASE
was O O
treated O O
with O O
the O O
various O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
regimens O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
of O O
antituberculosis O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
drugs O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
for O O
nearly O O
15 O B_TIME[MEASURE]/B_PERSON
months O I_TIME[MEASURE]/I_PERSON
. O O

Rifampicin B B_PERSON
was O O
administered O O
thrice O O
as O O
one O O
of O O
the O O
3 O O
- O O
4 O O
drug O O
regimen O O
and O O
each O O
time O O
he O O
developed O O
untoward O O
side O O
effects O O
like O O
nausea O O
, O O
vomiting O O
and O O
fever O O
with O O
chills O O
and O O
rigors O O
. O O

Syncope O O
caused O O
by O O
hyperkalemia O O
during O O
use O O
of O O
a O O
combined O O
therapy O O
with O O
the O O
angiotensin B B_GENE
- O O
converting O O
enzyme O O
inhibitor O O
and O O
spironolactone B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Daptomycin B B_MEASURE/B_BACTERIUM[BIO]
serum O O
and O O
CSF O O
trough O O
concentrations O O
were O O
11 O O
. O O
21 O O
ug O O
/ O O
mL O O
and O O
0 O O
. O O
52 O O
ug O O
/ O O
mL O O
, O O
respectively O O
, O O
prior O O
to O O
the O O
third O O
dose O O
. O O

At O O
a O O
dose O B_MEASURE/B_LOCATION
of O O
9 O B_MEASURE
mg O I_MEASURE
/ O O
kg O B_MEASURE
, O O
resultant O B_DISEASE_ADJECTIVE[DISEASE]
penetration O I_DISEASE_ADJECTIVE[DISEASE]
of O O
5 O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
% O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
higher O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
than O O
in O O
previous O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
reports O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
, O O
more O O
consistent O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
with O O
inflamed O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
meninges O B_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

These O O
results O O
support O O
the O O
conclusion O O
that O O
NO B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
plays O O
a O O
role O O
of O O
endogenous O O
convulsant O O
in O O
rat O O
model O O
of O O
lindane B B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
seizures O O
. O O

Two O O
cases O O
of O O
severe O O
delayed O O
neurologic O O
toxicity O O
related O O
to O O
the O O
administration O O
of O O
intrathecal O O
( O O
IT O O
) O O
combination O O
chemotherapy O O
including O O
thiotepa B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BACTERIUM[BIO]
( O O
TSPA B B_LOCATION/B_ORGANIZATION
) O O
are O O
presented O O
. O O

To O O
our O O
knowledge O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
however O O
, O O
axonal O B_DISEASE
neuropathy O I_DISEASE
following O O
administration O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_ORGANISM_FUNCTION
of O O
these O O
three O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
agents O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
has O O
not O O
been O O
previously O O
described O O
. O O

This O O
unexpected O O
complication O O
indicates O O
the O O
need O O
for O O
further O O
toxicology O O
research O O
on O O
IT O O
- O O
TSPA B B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
. O O

A O O
brief O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
review O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
of O O
autoimmune O B_DISEASE_ADJECTIVE[DISEASE]
and O O
drug O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
induced O O
hemolytic O B_DISEASE
anemias O I_DISEASE
is O O
provided O O
. O O

The O O
information O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O O
sociodemographic O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
background O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
and O O
drug O B_DISEASE_ADJECTIVE[DISEASE]
use O I_DISEASE_ADJECTIVE[DISEASE]
history O I_DISEASE_ADJECTIVE[DISEASE]
was O O
obtained O O
from O O
interview O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
or O O
medical O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
records O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

We O O
recently O O
reported O O
in O O
young O B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
healthy O I_SPECIES[BIO]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
subjects O I_SPECIES[BIO]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
that O O
inhibitory O O
cerebellar O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
stimulation O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
enhanced O O
the O O
sensorimotor O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
plasticity O B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
M1 O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
that O O
was O O
induced O O
by O O
paired O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
associative O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
stimulation O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
( O O
PAS O B_DISEASE/B_LOCATION
) O O
. O O

This O O
was O O
evident O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
only O O
when O O
a O O
sensory O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
component O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
was O O
involved O O
in O O
the O O
induction O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
plasticity O B_DISEASE
, O O
indicating O O
that O O
cerebellar O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
sensory O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
processing O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
function O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O O
involved O O
in O O
the O O
resurgence O B_DISEASE_ADJECTIVE[DISEASE]/B_TIME[MEASURE]
of O O
M1 O B_DISEASE/B_ORGANISM_FUNCTION
plasticity O I_DISEASE/I_ORGANISM_FUNCTION
. O O

To O O
explore O O
whether O O
this O O
benefit O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O O
linked O O
to O O
the O O
restoration O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
sensorimotor O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
plasticity O B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
M1 O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
we O O
conducted O O
an O O
additional O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
study O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
looking O O
at O O
changes O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
in O O
LIDs O B_DISEASE_ADJECTIVE[DISEASE]
and O O
PAS O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
induced O O
plasticity O B_DISEASE
after O O
10 O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
sessions O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
of O O
either O O
bilateral O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
, O O
real O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
inhibitory O I_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
cerebellar O I_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
stimulation O I_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
or O O
sham O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
stimulation O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
. O O

Only O O
real O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
not O O
sham O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
stimulation O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
had O O
an O O
antidyskinetic O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
effect O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
it O O
was O O
paralleled O O
by O O
a O O
resurgence O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O O
the O O
sensorimotor O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
plasticity O B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
of O O
M1 O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
. O O

PURPOSE O O
: O O
The O O
purpose O O
of O O
the O O
study O O
is O O
to O O
explore O O
the O O
function O O
of O O
P2X3 O O
and O O
NK1 O O
receptors O O
antagonists O O
on O O
cyclophosphamide B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
CYP B B_LOCATION/B_PROTEIN[GENE]
) O O
- O O
induced O O
cystitis O O
in O O
rats O O
. O O

Perfusion O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_BODY_PART_OR_ORGAN_COMPONENT
of O O
bladder O B_BODY_PART_OR_ORGAN_COMPONENT/B_BIO
with O O
P2X3 O B_GENE
and O O
NK1 O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
receptors O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
antagonists O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
ameliorated O O
the O O
bladder O B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
function O I_DISEASE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Chlorhexidine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
phosphanilate I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
( O O
CHP B B_DISEASE/B_MEASURE
) O O
, O O
a O O
new O O
broad O O
- O O
spectrum O O
antimicrobial O O
agent O O
, O O
has O O
been O O
evaluated O O
as O O
a O O
topical O O
burn O O
wound O O
dressing O O
in O O
cream O O
form O O
, O O
but O O
preliminary O O
clinical O O
trials O O
reported O O
that O O
it O O
was O O
painful O O
upon O O
application O O
. O O

Twenty O B_NUMBER[MEASURE]
- O O
nine O B_NUMBER[MEASURE]/B_PERSON
burn O I_NUMBER[MEASURE]/I_PERSON
patients O I_NUMBER[MEASURE]/I_PERSON
, O O
each O O
with O O
two O B_NUMBER[MEASURE]/B_DISEASE
similar O I_NUMBER[MEASURE]/I_DISEASE
burns O I_NUMBER[MEASURE]/I_DISEASE
which O O
could O O
be O O
separately O O
treated O O
, O O
were O O
given O O
pairs O B_PERSON/B_MEASURE
of O O
treatments O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
at O O
successive O B_MEASURE
12 O I_MEASURE
- O O
h O O
intervals O B_TIME[MEASURE]/B_LOCATION
over O O
a O O
3 O B_NUMBER[MEASURE]
- O O
day O B_TIME[MEASURE]
period O I_TIME[MEASURE]
. O O

One O O
burn O O
site O O
was O O
treated O O
with O O
each O O
of O O
four O O
different O O
CHP B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
concentrations O O
, O O
from O O
0 O O
. O O
25 O O
per O O
cent O O
to O O
2 O O
per O O
cent O O
, O O
their O O
vehicle O O
, O O
and O O
1 O O
per O O
cent O O
silver B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
sulphadiazine I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
AgSD B B_LOCATION/B_DISEASE
) O O
cream O O
, O O
an O O
antimicrobial O O
agent O O
frequently O O
used O O
for O O
topical O O
treatment O O
of O O
burn O O
wounds O O
. O O

The O O
0 O O
. O O
25 O O
per O O
cent O O
CHP B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
cream O O
was O O
closest O O
to O O
AgSD B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
in O O
pain O O
tolerance O O
; O O
however O O
, O O
none O O
of O O
the O O
treatments O O
differed O O
statistically O O
from O O
AgSD B B_DISEASE/B_MEASURE
or O O
from O O
each O O
other O O
. O O

Drug O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
induced O O
hepatotoxicity O B_DISEASE
is O O
a O O
common O B_DISEASE_ADJECTIVE[DISEASE]
cause O I_DISEASE_ADJECTIVE[DISEASE]
of O O
acute O B_DISEASE
hepatitis O I_DISEASE
, O O
and O O
the O O
recognition O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
the O O
responsible O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
drug O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
may O O
be O O
difficult O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Bortezomib B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
bort B B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
) O O
- O O
dexamethasone B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
dex B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
) O O
is O O
an O O
effective O O
therapy O O
for O O
relapsed O O
/ O O
refractory O O
( O O
R O O
/ O O
R O O
) O O
multiple O O
myeloma O O
( O O
MM O O
) O O
. O O

On O O
PND71 O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_TIME[MEASURE]
, O O
a O O
behavioral O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
assay O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
performed O O
using O O
the O O
elevated O O
plus O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
maze O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
( O O
EPM O B_DISEASE/B_PROTEIN[GENE]
) O O
and O O
the O O
light O B_COLOR
/ O O
dark O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ENT
test O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ENT
. O O

In O O
addition O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
, O O
AChE O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
activity O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
was O O
measured O O
in O O
the O O
prefrontal O B_BODY_PART_OR_ORGAN_COMPONENT
cortex O I_BODY_PART_OR_ORGAN_COMPONENT
, O O
hypothalamus O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
, O O
cerebellum O B_BODY_PART_OR_ORGAN_COMPONENT
and O O
hippocampus O B_BODY_PART_OR_ORGAN_COMPONENT
. O O

Further O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
studies O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
are O O
necessary O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
investigate O O
the O O
cholinergic O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
signaling O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
of O O
the O O
hippocampus O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
in O O
PBE O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
induced O O
anxiety O B_DISEASE
- O O
like O B_DISEASE_ADJECTIVE[DISEASE]
behaviors O I_DISEASE_ADJECTIVE[DISEASE]
. O O

Captopril B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
50 O O
mg O O
/ O O
kg O O
/ O O
day O O
, O O
given O O
orally O O
) O O
, O O
an O O
inhibitor O O
of O O
angiotensin B B_GENE
- O O
converting O O
enzyme O O
used O O
as O O
a O O
standard O O
cardioprotective O O
drug O O
, O O
was O O
used O O
as O O
a O O
positive O O
control O O
in O O
this O O
study O O
. O O

The O O
study O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
emphasizes O O
the O O
beneficial O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
action O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
S O B_OTHER/B_LOCATION
. O O
virgaurea O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BACTERIUM[BIO]
extract O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BACTERIUM[BIO]
as O O
a O O
cardioprotective O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
agent O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Lenalidomide B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
and O O
dexamethasone B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
( O O
RD B B_DISEASE/B_PROTEIN[GENE]
) O O
is O O
a O O
standard O O
of O O
care O O
for O O
relapsed O O
/ O O
refractory O O
multiple O O
myeloma O O
( O O
RRMM O O
) O O
, O O
but O O
there O O
is O O
limited O O
published O O
data O O
on O O
its O O
efficacy O O
and O O
safety O O
in O O
the O O
" O O
real O O
world O O
" O O
( O O
RW O O
) O O
, O O
according O O
to O O
the O O
International O O
Society O O
of O O
Pharmacoeconomics O O
and O O
Outcomes O O
Research O O
definition O O
. O O

Ifosfamide B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
( O O
IFO B B_LOCATION/B_DISEASE
) O O
is O O
an O O
alkylating O O
nitrogen B B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mustard O O
, O O
administrated O O
as O O
an O O
antineoplasmic O O
agent O O
. O O

This O O
side O O
effect O O
of O O
IFO B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
raises O O
the O O
requirement O O
for O O
the O O
co O O
- O O
administration O O
with O O
sodium B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
2 I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
sulfanylethanesulfonate I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
( O O
Mesna B B_DISEASE
) O O
aiming O O
to O O
avoid O O
or O O
minimize O O
this O O
effect O O
. O O

IFO B B_PERSON/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
Mesna B B_LOCATION/B_PERSON
were O O
administrated O O
separately O O
on O O
rabbit O O
' O O
s O O
lymphocytes O O
in O O
vivo O O
, O O
which O O
were O O
later O O
developed O O
in O O
vitro O O
. O O

Mesna B B_PERSON/B_COLOR
' O O
s O O
action O O
, O O
in O O
conjunction O O
with O O
IFO B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
reduces O O
the O O
frequency O O
of O O
SCEs O O
, O O
in O O
comparison O O
with O O
the O O
SCEs O O
recordings O O
obtained O O
when O O
IFO B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
is O O
administered O O
alone O O
. O O

Twenty O O
- O O
seven O O
patients O O
were O O
given O O
a O O
600 O O
- O O
mg O O
/ O O
m2 O O
busulfan B B_TIME[MEASURE]/B_PERSON
total O O
dose O O
with O O
continuous O O
i O O
. O O
v O O
. O O
infusion O O
of O O
clonazepam B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
; O O
none O O
had O O
any O O
neurological O O
symptoms O O
. O O

Busulfan B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
levels O O
were O O
measured O O
by O O
a O O
gas O O
chromatographic O O
- O O
mass O O
spectrometry O O
assay O O
in O O
the O O
plasma O O
and O O
cerebrospinal O O
fluid O O
of O O
9 O O
children O O
without O O
central O O
nervous O O
system O O
disease O O
under O O
600 O O
mg O O
/ O O
m2 O O
busulfan B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
with O O
clonazepam B B_BODY_SUBSTANCE[BODY_PART_OR_ORGAN_COMPONENT]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O O
busulfan B B_PERSON/B_MEASURE
cerebrospinal O O
fluid O O
: O O
plasma O O
ratio O O
was O O
1 O O
. O O
39 O O
. O O

A O O
busulfan B B_MEASURE/B_BIO
dose O O
calculated O O
on O O
the O O
basis O O
of O O
body O O
surface O O
area O O
, O O
resulting O O
in O O
higher O O
doses O O
in O O
young O O
children O O
, O O
was O O
followed O O
by O O
increased O O
neurotoxicity O O
, O O
close O O
to O O
neurotoxicity O O
incidence O O
observed O O
in O O
adults O O
. O O

Since O O
plasma O O
pharmacokinetic O O
studies O O
showed O O
a O O
faster O O
busulfan B B_BODY_PART_OR_ORGAN_COMPONENT/B_BIO
clearance O O
in O O
children O O
than O O
in O O
adults O O
, O O
this O O
new O O
dose O O
may O O
approximate O O
more O O
closely O O
the O O
adult O O
systemic O O
exposure O O
obtained O O
after O O
the O O
usual O O
16 O O
- O O
mg O O
/ O O
kg O O
total O O
dose O O
, O O
with O O
potential O O
inferences O O
in O O
terms O O
of O O
anticancer O O
or O O
myeloablative O O
effects O O
. O O

One O O
month O O
of O O
oral O O
galactose B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
treatment O O
initiated O O
immediately O O
after O O
the O O
STZ B B_LOCATION/B_DISEASE
- O O
icv O O
administration O O
, O O
successfully O O
prevented O O
development O O
of O O
the O O
STZ B B_LOCATION
- O O
icv O O
- O O
induced O O
cognitive O O
deficits O O
. O O

The O O
secondary O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
outcome O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
investigated O O
is O O
to O O
identify O O
eventual O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
independent O I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
risk O I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
factors O I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
among O O
demographic O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
data O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
anesthetic O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
drugs O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
used O O
. O O

Thiopentone B B_DISEASE/B_PERSON
was O O
independently O O
associated O O
with O O
an O O
increase O O
in O O
its O O
relative O O
risk O O
. O O

This O O
is O O
especially O O
relevant O B_DISEASE_ADJECTIVE[DISEASE]
in O O
multidrug O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
therapy O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
where O O
more O B_MEASURE/B_PERSON
than O O
one O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
drug O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
can O O
cause O O
a O O
similar O B_DISEASE
ocular O I_DISEASE
adverse O I_DISEASE
effect O I_DISEASE
. O O

Mortality O B_DISEASE
was O O
not O O
significantly O O
different O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
between O O
the O O
three O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
treatment O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
groups O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
, O O
but O O
was O O
significantly O O
lower O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
in O O
all O O
the O O
treatment O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
groups O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
compared O O
with O O
control O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
. O O

BACKGROUND O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
: O O
Thrombocytopenia O B_DISEASE
in O O
patients O B_PERSON/B_BIO
with O O
end O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
stage O B_DISEASE
liver O I_DISEASE
disease O I_DISEASE
is O O
a O O
common O B_DISEASE_ADJECTIVE[DISEASE]
disorder O I_DISEASE_ADJECTIVE[DISEASE]
caused O O
mainly O O
by O O
portal O B_DISEASE
hypertension O I_DISEASE
, O O
low O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
levels O I_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
thrombopoetin O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
, O O
and O O
endotoxemia O B_DISEASE
. O O

Extensive O O
literature O O
search O O
revealed O O
multiple O O
cases O O
of O O
coronary O O
artery O O
vasospasm O O
secondary O O
to O O
zolmitriptan B B_DISEASE/B_LOCATION
, O O
but O O
none O O
of O O
the O O
cases O O
were O O
associated O O
with O O
TS O O
. O O

METHODS O O
: O O
A O O
sample O O
of O O
997 O O
participants O O
( O O
52 O O
% O O
male O O
) O O
was O O
recruited O O
to O O
four O O
control O O
groups O O
( O O
non O O
- O O
drug O O
( O O
ND O O
) O O
, O O
alcohol B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
/ O O
nicotine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
AN B B_LOCATION
) O O
, O O
cannabis B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
/ O O
alcohol B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
/ O O
nicotine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
CAN B B_LOCATION/B_EDU[ORGANIZATION]
) O O
, O O
non O O
- O O
ecstasy B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
polydrug O O
( O O
PD O O
) O O
) O O
, O O
and O O
two O O
ecstasy B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
polydrug O O
groups O O
( O O
present O O
( O O
MDMA B B_LOCATION
) O O
and O O
past O O
users O O
( O O
EX O O
- O O
MDMA B B_LOCATION/B_PERSON
) O O
. O O

Participants O B_PERSON
completed O O
a O O
drug O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
history O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
questionnaire O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
, O O
Beck O B_DISEASE
Depression O I_DISEASE
Inventory O I_DISEASE
, O O
Barratt O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
Impulsiveness O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
Scale O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
, O O
Pittsburgh O B_TIME[MEASURE]/B_DISEASE
Sleep O I_TIME[MEASURE]/I_DISEASE
Quality O I_TIME[MEASURE]/I_DISEASE
Index O I_TIME[MEASURE]/I_DISEASE
, O O
and O O
Wechsler O B_DISEASE/B_MEASURE
Memory O I_DISEASE/I_MEASURE
Scale O I_DISEASE/I_MEASURE
- O O
Revised O O
which O O
, O O
in O O
total O B_MEASURE
, O O
provided O O
13 O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
psychometric O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
measures O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
. O O

RESULTS O O
: O O
While O O
the O O
CAN B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
and O O
PD O O
groups O O
tended O O
to O O
record O O
greater O O
deficits O O
than O O
the O O
non O O
- O O
drug O O
controls O O
, O O
the O O
MDMA B B_LOCATION
and O O
EX O O
- O O
MDMA B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
groups O O
recorded O O
greater O O
deficits O O
than O O
all O O
the O O
control O O
groups O O
on O O
ten O O
of O O
the O O
13 O O
psychometric O O
measures O O
. O O

Crocin B B_BIO/B_GENE
improves O O
lipid O O
dysregulation O O
in O O
subacute O O
diazinon B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
exposure O O
through O O
ERK1 O O
/ O O
2 O O
pathway O O
in O O
rat O O
liver O O
. O O

The O O
aim O O
of O O
this O O
study O O
was O O
to O O
evaluate O O
changes O O
in O O
the O O
regulation O O
of O O
lipid O O
metabolism O O
, O O
ERK O O
and O O
LDLr O O
expression O O
in O O
the O O
liver O O
of O O
rats O O
exposed O O
to O O
subacute O O
diazinon B B_DISEASE/B_BIO
. O O

Furthermore O O
ameliorating O O
effect O O
of O O
crocin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
on O O
diazinon B B_DISEASE/B_BIO
induced O O
disturbed O O
cholesterol B B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
homeostasis O O
was O O
studied O O
. O O

Crocin B B_PERSON/B_LOCATION
reduced O O
inhibition O O
of O O
ERK O O
activation O O
and O O
diazinon B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
- O O
induced O O
hyperlipemia O O
and O O
increased O O
levels O O
of O O
LDLr O O
transcript O O
. O O

However O O
, O O
for O O
those O O
who O O
relapse O O
, O O
high O B_MEASURE
- O O
dose O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
chemotherapy O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
with O O
autologous O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
stem O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cell O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
transplant O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O O
the O O
treatment O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
of O O
choice O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_PERSON
which O O
relies O O
on O O
adequate O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
disease O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
control O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
with O O
salvage O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
chemotherapy O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O O

Regimens O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
commonly O O
used O O
often O O
require O O
inpatient O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
administration O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
and O O
can O O
be O O
difficult O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
deliver O O
due O O
to O O
toxicity O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

One O O
hundred O O
and O O
twenty O O
- O O
two O O
cycles O O
of O O
GEM B B_LOCATION/B_ORGANIZATION
- O O
P O O
were O O
administered O O
in O O
total O O
( O O
median O O
3 O O
cycles O O
; O O
range O O
1 O O
- O O
6 O O
) O O
. O O

Twenty O O
of O O
41 O O
( O O
48 O O
% O O
) O O
patients O O
received O O
GEM B B_LOCATION/B_ORGANIZATION
- O O
P O O
as O O
second O O
- O O
line O O
treatment O O
and O O
11 O O
/ O O
41 O O
( O O
27 O O
% O O
) O O
as O O
third O O
- O O
line O O
therapy O O
. O O

Overall O O
response O O
rate O O
( O O
ORR O O
) O O
to O O
GEM B B_LOCATION/B_ORGANIZATION
- O O
P O O
in O O
the O O
entire O O
cohort O O
was O O
80 O O
% O O
( O O
complete O O
response O O
( O O
CR O O
) O O
37 O O
% O O
, O O
partial O O
response O O
44 O O
% O O
) O O
with O O
14 O O
/ O O
15 O O
CR O O
confirmed O O
as O O
a O O
metabolic O O
CR O O
on O O
PET O O
and O O
ORR O O
of O O
85 O O
% O O
in O O
the O O
20 O O
second O O
- O O
line O O
patients O O
. O O

Following O O
GEM B B_LOCATION/B_ORGANIZATION
- O O
P O O
, O O
5 O O
- O O
year O O
progression O O
- O O
free O O
survival O O
was O O
46 O O
% O O
( O O
95 O O
% O O
confidence O O
interval O O
( O O
CI O O
) O O
, O O
30 O O
- O O
62 O O
% O O
) O O
and O O
5 O O
- O O
year O O
overall O O
survival O O
was O O
59 O O
% O O
( O O
95 O O
% O O
CI O O
, O O
43 O O
- O O
74 O O
% O O
) O O
. O O

CIN O O
was O O
defined O O
as O O
an O O
increase O O
in O O
serum O O
creatinine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
( O O
Cr B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
) O O
of O O
0 O O
. O O
5 O O
mg O O
/ O O
dl O O
or O O
more O O
, O O
or O O
elevation O O
of O O
Cr B B_LOCATION/B_MEASURE
to O O
25 O O
% O O
over O O
baseline O O
. O O

CONCLUSIONS O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
: O O
Clinicians O B_PERSON
should O O
be O O
aware O B_PERSON
of O O
the O O
potential O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
for O O
antidepressants O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
to O O
cause O O
hyponatremia O B_DISEASE
, O O
and O O
take O O
appropriate O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
corrective O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
action O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
where O O
necessary O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
. O O

Cardiac O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
total O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
antioxidant O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
performance O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
( O O
TAP O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
) O O
, O O
DNA O B_DISEASE_ADJECTIVE[DISEASE]/B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
damage O B_DISEASE_ADJECTIVE[DISEASE]/I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
and O O
morphology O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
analyses O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
were O O
carried O O
out O O
at O O
each O O
time O B_MEASURE/B_LOCATION
point O B_MEASURE/I_LOCATION
. O O

All O O
exhibited O O
generalized O O
tonic O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
clonic O B_DISEASE_ADJECTIVE[DISEASE]
seizures O I_DISEASE_ADJECTIVE[DISEASE]
within O O
the O O
first O B_TIME[MEASURE]/B_ORGANIZATION
two O I_TIME[MEASURE]/I_ORGANIZATION
wk O I_TIME[MEASURE]/I_ORGANIZATION
after O O
LT O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
. O O

All O O
children O B_PERSON/B_BIO
who O O
experienced O O
seizures O B_DISEASE
survived O O
with O O
good O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
graft O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
function O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
and O O
remained O O
seizure O B_DISEASE
- O O
free O B_DISEASE_ADJECTIVE[DISEASE]/B_TIME[MEASURE]
without O O
anti O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
epileptic O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
drugs O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
over O O
a O O
mean O B_MEASURE
follow O O
- O O
up O O
period O B_TIME[MEASURE]/B_LOCATION
of O O
33 O B_MEASURE
. O O
7 O B_MEASURE
+ O I_MEASURE
14 O I_MEASURE
. O O
6 O B_TIME[MEASURE]
months O I_TIME[MEASURE]
. O O

In O O
the O O
saline O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
treated O O
group O B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
the O O
first O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
significant O I_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
decline O I_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O O
passive O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
avoidance O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
response O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
was O O
observed O O
at O O
four O B_TIME[MEASURE]/B_ENT
weeks O I_TIME[MEASURE]/I_ENT
, O O
and O O
complete O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
memory O I_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
loss O I_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
was O O
found O O
five O B_TIME[MEASURE]/B_ENT
weeks O I_TIME[MEASURE]/I_ENT
after O O
the O O
acquisition O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_PERSON
of O O
the O O
passive O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
avoidance O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
task O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
. O O

Prior O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
dosing O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
with O O
antagonists O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
partially O O
prevented O O
the O O
fall O B_DISEASE_ADJECTIVE[DISEASE]
in O O
systemic O B_DISEASE/B_GENE
vascular O B_DISEASE/I_GENE
resistance O B_DISEASE/I_GENE
. O O

Thus O O
prior O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
dosing O O
with O O
H1 O B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
and O O
H2 O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
- O O
antagonists O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
provides O O
only O O
partial O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
protection O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
. O O

Cholecystokinin B B_PERSON/B_LOCATION
- I I_PERSON/I_LOCATION
octapeptide I I_PERSON/I_LOCATION
restored O O
morphine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O O
induced O O
hippocampal O O
long O O
- O O
term O O
potentiation O O
impairment O O
in O O
rats O O
. O O

Cholecystokinin B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
octapeptide I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O O
CCK B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
8 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
) O O
, O O
which O O
is O O
a O O
typical O O
brain O O
- O O
gut O O
peptide O O
, O O
exerts O O
a O O
wide O O
range O O
of O O
biological O O
activities O O
on O O
the O O
central O O
nervous O O
system O O
. O O

The O O
present O O
results O O
demonstrate O O
that O O
CCK B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
8 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
attenuates O O
the O O
effect O O
of O O
morphine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
on O O
hippocampal O O
LTP O O
through O O
CCK2 O O
receptors O O
and O O
suggest O O
an O O
ameliorative O O
function O O
of O O
CCK B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
8 I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
on O O
morphine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
induced O O
memory O O
impairment O O
. O O

In O O
the O O
present O O
study O O
the O O
role O O
of O O
glial O O
activation O O
and O O
post O O
synaptic O O
toxicity O O
in O O
ICV O O
Streptozotocin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
( O O
STZ B B_DISEASE/B_LOCATION
) O O
induced O O
memory O O
impaired O O
rats O O
was O O
explored O O
. O O

All O O
of O O
the O O
patients O O
' O O
plasma O O
blood B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
urea I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
nitrogen I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
( O O
BUN B B_PROTEIN[GENE]/B_BODY_PART_OR_ORGAN_COMPONENT
) O O
and O O
creatinine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
levels O O
were O O
measured O O
on O O
the O O
second O O
and O O
seventh O O
day O O
after O O
the O O
administration O O
of O O
intravenous O O
contrast B B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
material O O
. O O

In O O
this O O
study O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
, O O
neurocognitive O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
outcomes O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
neuroradiologic O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
evidence O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O O
leukoencephalopathy O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
were O O
compared O O
in O O
children O B_PERSON/B_BIO
treated O O
with O O
intense O B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
central O B_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
nervous O B_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
system O B_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
( O O
CNS O B_LOCATION/B_ORGANIZATION
) O O
- O O
directed O O
therapy O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
( O O
P9605 O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
) O O
versus O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
those O O
receiving O O
fewer O B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
CNS O B_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
- O O
directed O O
treatment O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
days O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
during O O
intensive O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
consolidation O B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
( O O
P9201 O B_MEASURE/B_PROTEIN[GENE]
) O O
. O O

A O O
total O B_MEASURE
of O O
66 O B_MEASURE/B_PERSON
children O I_MEASURE/I_PERSON
from O O
16 O B_PERSON/B_ORGANIZATION
Pediatric O I_PERSON/I_ORGANIZATION
Oncology O I_PERSON/I_ORGANIZATION
Group O I_PERSON/I_ORGANIZATION
institutions O I_PERSON/I_ORGANIZATION
with O O
" O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
standard O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
- O O
risk O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
" O O
acute O B_DISEASE
lymphoblastic O I_DISEASE
leukemia O I_DISEASE
, O O
1 O B_MEASURE
. O O
00 O B_MEASURE
to O O
9 O B_MEASURE
. O O
99 O B_MEASURE/B_ENT
years O I_MEASURE/I_ENT
at O O
diagnosis O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O O
without O O
evidence O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
CNS O B_DISEASE
leukemia O I_DISEASE
at O O
diagnosis O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
were O O
enrolled O O
on O O
ACCL0131 O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O O
28 O B_MEASURE
from O O
P9201 O B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
38 O B_MEASURE
from O O
P9605 O B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Children O B_PERSON
on O O
both O O
studies O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
had O O
significant O B_DISEASE
attention O I_DISEASE
problems O I_DISEASE
, O O
but O O
P9605 O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
children O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
scored O O
below O O
average O B_MEASURE/B_SOCIAL_CIRCUMSTANCES
on O O
more O O
neurocognitive O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
measures O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
than O O
those O O
treated O O
on O O
P9201 O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
82 O B_MEASURE
% O I_MEASURE
, O O
14 O B_NUMBER[MEASURE]
/ O O
17 O B_MEASURE
measures O I_MEASURE
vs O I_MEASURE
. O O
24 O B_MEASURE/B_PERSON
% O I_MEASURE/I_PERSON
, O O
4 O B_MEASURE
/ O O
17 O B_MEASURE
measures O I_MEASURE
) O O
. O O

RESULTS O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
: O O
The O O
time O B_TIME[MEASURE]/B_DISEASE
to O O
first O O
dysrhythmia O B_DISEASE_ADJECTIVE[DISEASE]
occurrence O I_DISEASE_ADJECTIVE[DISEASE]
, O O
time O B_MEASURE/B_LOCATION
to O O
25 O B_SEQUENCE[MEASURE]/B_LOCATION
% O I_SEQUENCE[MEASURE]/I_LOCATION
and O O
50 O B_MEASURE
% O I_MEASURE
reductions O I_MEASURE
in O O
HR O B_MEASURE/B_DISEASE
, O O
and O O
time O B_TIME[MEASURE]/B_DISEASE
to O O
asystole O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
were O O
longer O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
in O O
Group O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
P O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
than O O
the O O
other O B_TIME[MEASURE]/B_PERSON
groups O I_TIME[MEASURE]/I_PERSON
. O O

Therefore O O
, O O
when O O
prescribing O O
statins O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
the O O
possibility O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
of O O
hepatic O B_DISEASE
damage O I_DISEASE
should O O
be O O
taken O O
into O O
account O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
. O O

This O O
case O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
highlights O O
that O O
drug O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
induced O O
blood O B_DISEASE
dyscrasias O I_DISEASE
can O O
occur O O
unexpectedly O O
as O O
a O O
result O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
of O O
treatment O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
with O O
a O O
commonly O O
used O O
drug O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
thought O O
to O O
be O O
" O O
safe O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
" O O
. O O

A O O
> O B_MEASURE
15 O I_MEASURE
. O O
9 O B_MEASURE
% O I_MEASURE
decrease O I_MEASURE
in O O
GLS O B_MEASURE
[ O I_MEASURE
sensitivity O I_MEASURE
, O O
86 O B_MEASURE/B_PERSON
% O I_MEASURE/I_PERSON
; O O
specificity O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
, O O
75 O B_MEASURE/B_LOCATION
% O I_MEASURE/I_LOCATION
; O O
area O B_LOCATION/B_MEASURE
under O O
the O O
curve O B_MEASURE
( O O
AUC O B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
= O O
0 O B_MEASURE
. O O
815 O B_MEASURE
; O O
P O B_OTHER/B_LOCATION
= O O
0 O B_MEASURE
. O O
001 O B_MEASURE
] O I_MEASURE
and O O
a O O
> O O
0 O B_MEASURE
. O O
004 O B_MEASURE/B_PERSON
ng O I_MEASURE/I_PERSON
/ O O
mL O B_MEASURE/B_LOCATION
elevation O I_MEASURE/I_LOCATION
in O O
cTnT O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
( O O
sensitivity O B_MEASURE
, O O
79 O B_MEASURE/B_PERSON
% O I_MEASURE/I_PERSON
; O O
specificity O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
64 O B_MEASURE/B_PERSON
% O I_MEASURE/I_PERSON
; O O
AUC O B_LOCATION/B_MEASURE
= O O
0 O B_MEASURE
. O O
757 O B_MEASURE
; O O
P O B_OTHER/B_LOCATION
= O O
0 O B_MEASURE
. O O
005 O B_MEASURE
) O O
from O O
baseline O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
to O O
the O O
third O B_MEASURE/B_LOCATION
cycle O I_MEASURE/I_LOCATION
of O O
chemotherapy O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
predicted O O
later O B_DISEASE_ADJECTIVE[DISEASE]
cardiotoxicity O I_DISEASE_ADJECTIVE[DISEASE]
. O O

Lindane B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
( O O
gamma B B_PROTEIN[GENE]/B_LOCATION
- I I_PROTEIN[GENE]/I_LOCATION
hexachlorocyclohexane I I_PROTEIN[GENE]/I_LOCATION
) O O
is O O
an O O
organochlorine O O
insecticide O O
with O O
known O O
neurotoxic O O
effects O O
. O O

Unanticipated O B_DISEASE_ADJECTIVE[DISEASE]/B_TIME[MEASURE]
and O O
previously O O
unreported O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
outcomes O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
may O O
be O O
witnessed O O
as O O
we O O
expand O O
the O O
use O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_LOCATION
of O O
certain O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
sedatives O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
alternative O B_NUMBER[MEASURE]/B_LOCATION
routes O B_NUMBER[MEASURE]/I_LOCATION
of O O
administration O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O O

Oral O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
bovine O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
LF O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
( O O
30 O B_MEASURE
, O O
100 O B_MEASURE
, O O
300 O B_MEASURE
mg O I_MEASURE
/ O O
kg O B_TIME[MEASURE]
) O O
was O O
given O O
from O O
day O B_TIME[MEASURE]
8 O I_TIME[MEASURE]
to O O
14 O B_MEASURE
in O O
a O O
reversal O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
study O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
. O O

Thymus O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
weight O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
was O O
used O O
as O O
a O O
marker O B_MEASURE/B_DISEASE
of O O
glucocorticoid O B_MEASURE/B_ORGANISM_FUNCTION
activity O B_MEASURE/I_ORGANISM_FUNCTION
. O O

Because O O
of O O
a O O
lack O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
of O O
contemporary O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
data O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
regarding O O
seizures O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
after O O
cardiac O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
surgery O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
, O O
we O O
undertook O O
a O O
retrospective O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
analysis O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
prospectively O O
collected O O
data O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
from O O
11 O B_PERSON/B_LOCATION
529 O I_PERSON/I_LOCATION
patients O I_PERSON/I_LOCATION
in O O
whom O O
cardiopulmonary O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
bypass O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
was O O
used O O
from O O
January O B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
2004 O I_TIME[MEASURE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
December O B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
2010 O I_TIME[MEASURE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

When O O
tested O O
in O O
a O O
multivariate O O
regression O O
analysis O O
, O O
tranexamic B B_DISEASE/B_BIO
acid I I_DISEASE/I_BIO
was O O
a O O
strong O O
independent O O
predictor O O
of O O
seizures O O
( O O
OR O O
14 O O
. O O
3 O O
, O O
95 O O
% O O
CI O O
5 O O
. O O
5 O O
- O O
36 O O
. O O
7 O O
; O O
p O O
< O O
0 O O
. O O
001 O O
) O O
. O O

However O O
, O O
rapid O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
pain O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
relief O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
sometimes O O
brings O O
about O O
unfavourable O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
side O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
effects O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
that O O
largely O O
limit O O
its O O
clinical O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
utility O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O O

In O O
this O O
case O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
report O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
, O O
we O O
highlight O O
opioid O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
' O O
s O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
inhibitory O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
side O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
effects O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
on O O
the O O
cerebellar O B_BODY_PART_OR_ORGAN_COMPONENT/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
structure O I_BODY_PART_OR_ORGAN_COMPONENT/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
that O O
causes O O
dysmetria O B_DISEASE
, O O
dysarthria O B_DISEASE/B_LOCATION
, O O
reduced O O
smooth O B_DISEASE/B_MEASURE
pursuit O I_DISEASE/I_MEASURE
gain O I_DISEASE/I_MEASURE
and O O
decreased O O
saccadic O B_DISEASE
velocity O I_DISEASE
. O O

Baboon O B_DISEASE/B_PROTEIN[GENE]
syndrome O B_DISEASE/I_PROTEIN[GENE]
is O O
a O O
drug O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
- O O
or O O
contact O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
allergen O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
- O O
related O O
maculopapular O B_DISEASE
eruption O I_DISEASE
that O O
typically O O
involves O O
the O O
flexural O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
and O O
gluteal O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
areas O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
. O O

This O O
drug O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O O
rapidly O O
absorbed O O
from O O
the O O
gastrointestinal O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
tract O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
, O O
and O O
most O B_DISEASE/B_MEASURE
of O O
it O O
is O O
excreted O O
from O O
the O O
kidney O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
. O O

All B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
trans I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
retinoic I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
acid I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
( O O
ATRA B B_LOCATION/B_ORGANIZATION
) O O
, O O
a O O
component O O
of O O
standard O O
therapy O O
for O O
acute O O
promyelocytic O O
leukemia O O
( O O
APL O O
) O O
, O O
is O O
associated O O
with O O
potentially O O
serious O O
but O O
treatable O O
adverse O O
effects O O
involving O O
numerous O O
organ O O
systems O O
, O O
including O O
rare O O
skeletal O O
muscle O O
involvement O O
. O O

This O O
retrospective O O
study O O
describes O O
toxicity O O
associated O O
with O O
a O O
protocol O O
of O O
lomustine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
CCNU B B_LOCATION
) O O
and O O
cyclophosphamide B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
CTX B B_LOCATION/B_ORGANIZATION
) O O
in O O
dogs O O
with O O
lymphoma O O
. O O

CCNU B B_LOCATION
was O O
administered O O
per O O
os O O
( O O
PO O O
) O O
at O O
a O O
targeted O O
dosage O O
of O O
60 O O
mg O O
/ O O
m O O
( O O
2 O O
) O O
body O O
surface O O
area O O
on O O
day O O
0 O O
, O O
CTX B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
administered O O
PO O O
at O O
a O O
targeted O O
dosage O O
of O O
250 O O
mg O O
/ O O
m O O
( O O
2 O O
) O O
divided O O
over O O
days O O
0 O O
through O O
4 O O
, O O
and O O
all O O
dogs O O
received O O
prophylactic O O
antibiotics O O
. O O

Neutropenia O O
was O O
the O O
principal O O
toxic O O
effect O O
, O O
and O O
the O O
overall O O
frequency O O
of O O
grade O O
4 O O
neutropenia O O
after O O
the O O
first O O
treatment O O
of O O
CCNU B B_LOCATION
/ O O
CTX B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
was O O
30 O O
% O O
( O O
95 O O
% O O
confidence O O
interval O O
, O O
19 O O
- O O
43 O O
% O O
) O O
. O O

Nelarabine B B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
neurotoxicity O O
with O O
concurrent O O
intrathecal O O
chemotherapy O O
: O O
Case O O
report O O
and O O
review O O
of O O
literature O O
. O O

Severe O O
nelarabine B B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
neurotoxicity O O
in O O
a O O
patient O O
who O O
received O O
concurrent O O
intrathecal O O
( O O
IT O O
) O O
chemotherapy O O
is O O
reported O O
. O O

She O O
was O O
originally O O
treated O O
with O O
induction O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
chemotherapy O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
followed O O
by O O
an O O
autologous O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
transplant O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O O

At O O
the O O
time O B_TIME[MEASURE]/B_LOCATION
of O O
treatment O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
, O O
she O O
was O O
on O O
continuous O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
renal O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
replacement O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
therapy O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
due O O
to O O
sequelae O B_DISEASE_ADJECTIVE[DISEASE]
of O O
tumor O B_DISEASE
lysis O I_DISEASE
syndrome O I_DISEASE
( O O
TLS O B_DISEASE/B_GENE
) O O
. O O

She O O
tolerated O O
therapy O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
well O O
, O O
entered O O
a O O
complete O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
remission O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
and O O
recovered O O
her O O
renal O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
function O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Predominantly O O
sensory O B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
, O O
though O O
also O O
motor O B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
and O O
autonomic O B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
, O O
peripheral O B_DISEASE_ADJECTIVE[DISEASE]
neuropathy O I_DISEASE_ADJECTIVE[DISEASE]
started O O
in O O
her O O
feet O B_BODY_PART_OR_ORGAN_COMPONENT
, O O
ascended O O
proximally O O
to O O
the O O
mid O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
thoracic O B_BODY_PART_OR_ORGAN_COMPONENT
region O I_BODY_PART_OR_ORGAN_COMPONENT
, O O
and O O
eventually O O
included O O
her O O
distal O B_BODY_PART_OR_ORGAN_COMPONENT
upper O I_BODY_PART_OR_ORGAN_COMPONENT
extremities O I_BODY_PART_OR_ORGAN_COMPONENT
. O O

Nelarabine B B_DISEASE/B_PERSON
was O O
felt O O
to O O
be O O
the O O
cause O O
of O O
her O O
symptoms O O
. O O

Her O O
neuropathy O B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
stabilized O O
and O O
showed O O
slight O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
improvement O I_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
and O O
ultimately O O
received O O
an O O
unrelated O B_DISEASE_ADJECTIVE[DISEASE]
, O O
reduced O O
- O O
intensity O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
allogeneic O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
transplant O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
while O O
in O O
complete O B_DISEASE_ADJECTIVE[DISEASE]
remission O I_DISEASE_ADJECTIVE[DISEASE]
, O O
but O O
relapsed O O
disease O B_TIME[MEASURE]/B_ENT
10 O I_TIME[MEASURE]/I_ENT
weeks O I_TIME[MEASURE]/I_ENT
later O O
. O O

She O O
is O O
currently O O
being O O
treated O O
with O O
best O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
supportive O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
care O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

However O O
, O O
information O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
is O O
limited O O
concerning O O
the O O
safety O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
of O O
the O O
regimen O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
elderly O B_PERSON/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
patients O I_PERSON/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Functional O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
indices O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
assessed O O
by O O
cardiac O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
MRI O I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
( O O
including O O
left O O
ventricular O B_MEASURE/B_BODY_PART_OR_ORGAN_COMPONENT
ejection O I_MEASURE/I_BODY_PART_OR_ORGAN_COMPONENT
fraction O I_MEASURE/I_BODY_PART_OR_ORGAN_COMPONENT
( O O
LVEF O B_LOCATION/B_MEASURE
) O O
, O O
cardiac O B_MEASURE/B_LOCATION
output O B_MEASURE/I_LOCATION
, O O
and O O
E O B_OTHER/B_PROTEIN[GENE]
/ O O
A O B_LOCATION/B_MEASURE
ratio O I_LOCATION/I_MEASURE
) O O
declined O O
progressively O O
, O O
reaching O O
statistical O B_MEASURE/B_DISEASE
significance O I_MEASURE/I_DISEASE
after O O
two O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_ORGANISM_FUNCTION
doses O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_ORGANISM_FUNCTION
and O O
culminating O O
in O O
" O O
clinical O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
" O O
LV O B_DISEASE_ADJECTIVE[DISEASE]
dysfunction O I_DISEASE_ADJECTIVE[DISEASE]
by O O
12 O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
weeks O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Magnitudes O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
of O O
secondary O B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
pinprick O I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
hyperalgesia O I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
and O O
brush O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
- O O
evoked O O
allodynia O B_DISEASE
were O O
investigated O O
using O O
von O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
Frey O B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
filaments O B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
( O O
gauges O B_MEASURE
10 O I_MEASURE
, O O
15 O B_MEASURE
, O O
60 O B_MEASURE
and O O
100 O B_MEASURE
g O I_MEASURE
) O O
and O O
brush O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
strokes O I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Reproducibility O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
across O O
and O O
within O O
volunteers O B_PERSON/B_LOCATION
( O O
inter O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
and O O
intra O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
individual O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
variation O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
, O O
respectively O O
) O O
was O O
assessed O O
using O O
intraclass O B_MEASURE/B_ORGANIZATION
correlation O I_MEASURE/I_ORGANIZATION
coefficient O I_MEASURE/I_ORGANIZATION
( O O
ICC O B_ORGANIZATION/B_DISEASE
) O O
and O O
coefficient O B_MEASURE
of O O
variation O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
( O O
CV O B_LOCATION/B_ORGANIZATION
) O O
. O O

Glutamate B B_PERSON/B_LOCATION
evoked O O
reproducible O O
VAS O O
response O O
to O O
all O O
von O O
Frey O O
gauges O O
( O O
ICC O O
> O O
0 O O
. O O
60 O O
) O O
and O O
brush O O
strokes O O
( O O
ICC O O
> O O
0 O O
. O O
83 O O
) O O
. O O

Intra O B_DISEASE/B_MEASURE
- O O
individual O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
variability O I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
generally O O
lower O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
for O O
the O O
VAS O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
response O B_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
von O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
Frey O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
and O O
brush O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
compared O O
with O O
areas O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
secondary O B_DISEASE
hyperalgesia O I_DISEASE
and O O
allodynia O B_DISEASE
. O O

Ocular O B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
- O O
specific O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
ER O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
stress O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
reduction O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
rescues O O
glaucoma O O
in O O
murine O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
glucocorticoid O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
- O O
induced O O
glaucoma O B_DISEASE
. O O

Administration O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
of O O
glucocorticoids O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
induces O O
ocular O B_DISEASE
hypertension O I_DISEASE
in O O
some O O
patients O B_PERSON/B_BIO
. O O

The O O
underlying O B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
pathology O I_DISEASE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
glucocorticoid O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
induced O O
glaucoma O B_DISEASE
is O O
not O O
fully O O
understood O O
, O O
due O B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
in O O
part O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
lack O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
an O O
appropriate O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
animal O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
model O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Here O O
, O O
we O O
developed O O
a O O
murine O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
model O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
of O O
glucocorticoid O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
induced O O
glaucoma O B_DISEASE
that O O
exhibits O O
glaucoma O B_DISEASE_ADJECTIVE[DISEASE]
features O I_DISEASE_ADJECTIVE[DISEASE]
that O O
are O O
observed O O
in O O
patients O B_PERSON/B_BIO
. O O

Our O O
data O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
indicate O O
that O O
ER O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
stress O B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
contributes O O
to O O
glucocorticoid O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
induced O O
ocular O B_DISEASE/B_GENE
hypertension O I_DISEASE/I_GENE
and O O
suggest O O
that O O
reducing O O
ER O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
stress O B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
has O O
potential O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
as O O
a O O
therapeutic O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_LOCATION
strategy O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_LOCATION
for O O
treating O O
glucocorticoid O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O O
induced O O
glaucoma O B_DISEASE
. O O

Opioid O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
induced O O
hyperalgesia O B_DISEASE
( O O
OIH O B_DISEASE/B_LOCATION
) O O
is O O
characterized O O
by O O
nociceptive O B_DISEASE
sensitization O I_DISEASE
caused O O
by O O
the O O
cessation O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
chronic O B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
opioid O B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
use O B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

OIH O B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
can O O
limit O O
the O O
clinical O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
use O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
opioid O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
analgesics O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
complicate O O
withdrawal O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
from O O
opioid O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
addiction O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Our O O
data O O
suggested O O
that O O
the O O
ginsenoside B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
Re I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
but O O
not O O
Rg1 B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
or O O
Rb1 B B_PROTEIN[GENE]/B_LOCATION
, O O
may O O
contribute O O
toward O O
reversal O O
of O O
OIH O O
. O O

However O O
, O O
both O O
agents O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
are O O
associated O O
with O O
significant O B_DISEASE
hemodynamic O I_DISEASE
side O I_DISEASE
effects O I_DISEASE
. O O

Providers O B_PERSON
should O O
similarly O O
consider O O
the O O
likelihood O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
hypotension O B_DISEASE
or O O
bradycardia O B_DISEASE
before O O
starting O O
either O O
sedative O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Twelve O B_TIME[MEASURE]/B_LOCATION
hours O I_TIME[MEASURE]/I_LOCATION
after O O
the O O
initiation O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
therapy O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
, O O
FT4 O B_GENE
was O O
0 O B_MEASURE
. O O
96 O B_MEASURE/B_PERSON
ng O I_MEASURE/I_PERSON
/ O O
dL O B_PROTEIN[GENE]/B_MEASURE
. O O

A O O
percutaneous O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
mechanical O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
thrombectomy O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
and O O
CDT O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
with O O
alteplase O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O O
attempted O O
, O O
but O O
the O O
procedure O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
was O O
aborted O O
due O O
to O O
epistaxis O O
. O O

METHODS O O
: O O
Seventy O O
Swiss O O
albino O O
female O O
mice O O
( O O
25 O O
- O O
35 O O
g O O
) O O
were O O
divided O O
into O O
4 O O
groups O O
: O O
amphetamine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
- O O
free O O
( O O
control O O
) O O
, O O
amphetamine B B_MEASURE
, O O
50 O O
, O O
and O O
100 O O
mg O O
/ O O
kg O O
DHEA B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Field O O
potential O O
duration O O
( O O
FPD O O
) O O
in O O
human O O
- O O
induced O O
pluripotent O O
stem O O
cell O O
- O O
derived O O
cardiomyocytes O O
( O O
hiPS O O
- O O
CMs O O
) O O
, O O
which O O
can O O
express O O
QT O O
interval O O
in O O
an O O
electrocardiogram O O
, O O
is O O
reported O O
to O O
be O O
a O O
useful O O
tool O O
to O O
predict O O
K B B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
+ O O
) O O
channel O O
and O O
Ca B B_LOCATION/B_PERSON
( O O
2 O O
+ O O
) O O
channel O O
blocker O O
effects O O
on O O
QT O O
interval O O
. O O

The O O
aim O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
of O O
this O O
study O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
is O O
to O O
show O O
that O O
FPD O B_DISEASE_ADJECTIVE[DISEASE]/B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
from O O
MEA O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
( O O
Multielectrode O B_MEASURE/B_LOCATION
array O B_MEASURE/I_LOCATION
) O O
of O O
hiPS O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
- O O
CMs O B_DISEASE/B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
can O O
detect O O
QT O B_DISEASE
prolongation O I_DISEASE
induced O O
by O O
multichannel O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
blockers O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

hiPS O B_LOCATION/B_DISEASE
- O O
CMs O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE
were O O
seeded O O
onto O O
MEA O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
and O O
FPD O B_DISEASE_ADJECTIVE[DISEASE]
was O O
measured O O
for O O
2min O B_MEASURE/B_LOCATION
every O O
10min O B_TIME[MEASURE]
for O O
30min O B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
after O O
drug O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
exposure O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
for O O
the O O
vehicle O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
and O O
each O O
drug O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
concentration O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
. O O

hiPS O B_DISEASE/B_PROTEIN[GENE]
- O O
CMs O B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
using O O
MEA O B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
system O I_LOCATION/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
FPDc O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
can O O
predict O O
the O O
effects O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
drug O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
candidates O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
on O O
QT O B_DISEASE/B_GENE
interval O I_DISEASE/I_GENE
. O O

This O O
study O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
also O O
shows O O
that O O
this O O
assay O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
can O O
help O O
detect O O
EAD O B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O O
drugs O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
with O O
TdP O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
potential O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Dermal O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
developmental O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
toxicity O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
of O O
N O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O O
phenylimide O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
herbicides O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
rats O B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Our O O
objective O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
in O O
this O O
study O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
to O O
investigate O O
whether O O
the O O
compounds O B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
induce O O
developmental O B_DISEASE/B_LOCATION
toxicity O I_DISEASE/I_LOCATION
via O O
the O O
dermal O B_BODY_PART_OR_ORGAN_COMPONENT/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
route O I_BODY_PART_OR_ORGAN_COMPONENT/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
which O O
is O O
more O O
relevant O B_DISEASE_ADJECTIVE[DISEASE]
to O O
occupational O B_DISEASE_ADJECTIVE[DISEASE]/B_SPECIES[BIO]
exposure O B_DISEASE_ADJECTIVE[DISEASE]/I_SPECIES[BIO]
, O O
hence O O
better O O
addressing O O
human O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
health O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
risks O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Patients O B_PERSON
who O O
received O O
the O O
100 O B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mg O I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
/ O O
m O B_OTHER/B_MEASURE
( O O
2 O B_TIME[MEASURE]/B_LOCATION
) O O
dosing O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
and O O
patients O B_PERSON/B_LOCATION
who O O
had O O
a O O
history O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
hypertension O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
also O O
had O O
a O O
higher O B_MEASURE
likelihood O I_MEASURE
of O O
developing O O
nephrotoxicity O B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O O
OR O O
= O O
11 O B_MEASURE
. O O
494 O B_MEASURE
( O O
95 O B_LOCATION/B_MEASURE
% O I_LOCATION/I_MEASURE
CI O I_LOCATION/I_MEASURE
= O O
4 O B_MEASURE
. O O
149 O B_MEASURE
, O O
32 O B_MEASURE
. O O
258 O B_MEASURE
; O O
P O B_MEASURE
< O I_MEASURE
0 O I_MEASURE
. O O
0001 O B_MEASURE
) O O
and O O
OR O O
= O O
3 O B_MEASURE
. O O
219 O B_MEASURE
( O O
95 O B_LOCATION/B_MEASURE
% O I_LOCATION/I_MEASURE
CI O I_LOCATION/I_MEASURE
= O O
1 O B_MEASURE
. O O
228 O B_MEASURE
, O O
8 O B_MEASURE
. O O
439 O B_MEASURE
; O O
P O B_OTHER/B_LOCATION
= O O
0 O B_MEASURE
. O O
017 O B_MEASURE
) O O
, O O
respectively O O
. O O

Thus O O
, O O
there O O
is O O
an O O
urgent O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
need O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
for O O
new O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
kinds O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O O
agents O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
targeting O O
both O O
seizures O B_DISEASE
and O O
cognition O B_DISEASE
deficits O I_DISEASE
. O O

Oxidative O B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
stress O B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O O
considered O O
to O O
play O O
an O O
important O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
role O I_PERSON/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
epileptogenesis O B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
and O O
cognitive O B_DISEASE/B_ORGANISM_FUNCTION
deficits O I_DISEASE/I_ORGANISM_FUNCTION
, O O
and O O
antioxidants O B_LOCATION/B_PERSON
have O O
a O O
putative O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
antiepileptic O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
potential O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Furthermore O O
, O O
these O O
data O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
suggest O O
an O O
explanation O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
as O O
to O O
how O O
p53 O B_DISEASE
inhibition O I_DISEASE
can O O
result O O
in O O
cardioprotection O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
during O O
drug O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
treatment O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
and O O
, O O
paradoxically O O
, O O
enhanced O O
cardiotoxicity O B_DISEASE
long O O
after O O
the O O
cessation O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_LOCATION
of O O
drug O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
treatment O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
. O O

We O O
found O O
that O O
Ca B B_LOCATION/B_MEASURE
( O O
2 O O
+ O O
) O O
overload O O
lead O O
to O O
accelerated O O
beating O O
rhythm O O
in O O
adult O O
rat O O
ventricular O O
myocytes O O
and O O
caused O O
arrhythmia O O
in O O
conscious O O
freely O O
moving O O
rats O O
. O O

The O O
expression O O
analysis O O
of O O
Ca B B_LOCATION/B_PERSON
( O O
2 O O
+ O O
) O O
handling O O
proteins O O
demonstrated O O
that O O
aconitine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
promoted O O
Ca B B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
( O O
2 O O
+ O O
) O O
overload O O
through O O
the O O
expression O O
regulation O O
of O O
Ca B B_LOCATION/B_PERSON
( O O
2 O O
+ O O
) O O
handling O O
proteins O O
. O O

The O O
expression O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
analysis O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
apoptosis O B_DISEASE/B_GENE
- O O
related O O
proteins O B_GENE/B_DISEASE
revealed O O
that O O
pro O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
apoptotic O B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
protein O I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
expression O I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
upregulated O O
, O O
and O O
anti O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
apoptotic O B_GENE/B_DISEASE
protein O I_GENE/I_DISEASE
BCL O I_GENE/I_DISEASE
- O O
2 O B_MEASURE/B_PROTEIN[GENE]
expression O I_MEASURE/I_PROTEIN[GENE]
was O O
downregulated O O
. O O

The O O
literature O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
related O O
to O O
antithyroid O B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
drug O I_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
side O I_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
effects O I_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
the O O
mechanisms O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O O
their O O
occurrence O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
are O O
reviewed O O
and O O
the O O
efficacy O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
complications O B_DISEASE
of O O
thyroidectomy O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
and O O
radioiodine O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
compared O O
to O O
those O O
of O O
antithyroid O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
drugs O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O O

AIM O O
: O O
To O O
study O O
the O O
effects O O
of O O
testosterone B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O O
streptozotocin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
( O O
STZ B B_DISEASE/B_LOCATION
) O O
- O O
induced O O
memory O O
impairment O O
in O O
male O O
rats O O
. O O

Garcinielliptone B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_NUMBER[MEASURE]
FC I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_NUMBER[MEASURE]
( O O
GFC B B_MEASURE
) O O
isolated O O
from O O
hexanic O O
fraction O O
seed O O
extract O O
of O O
species O O
Platonia O O
insignis O O
Mart O O
. O O

It O O
is O O
widely O O
used O O
in O O
folk O B_LOCATION/B_PERSON
medicine O I_LOCATION/I_PERSON
to O O
treat O O
skin O B_DISEASE
diseases O I_DISEASE
in O O
both O O
humans O B_PERSON/B_BIO
and O O
animals O B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
as O O
well O O
as O O
the O O
seed O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
decoction O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
has O O
been O O
used O O
to O O
treat O O
diarrheas O B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
and O O
inflammatory O B_DISEASE
diseases O I_DISEASE
. O O

Hippocampus O B_BIO/B_PERSON
mice O I_BIO/I_PERSON
treated O O
with O O
GFC75 O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
plus O O
P400 O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
showed O O
an O O
increase O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O O
AChE O B_DISEASE/B_MEASURE
activity O I_DISEASE/I_MEASURE
( O O
63 O B_MEASURE
. O O
30 O B_MEASURE/B_LOCATION
% O I_MEASURE/I_LOCATION
) O O
when O O
compared O O
with O O
seized O O
mice O B_BIO/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

This O O
compound O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
may O O
be O O
useful O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
to O O
produce O O
neuronal O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
protection O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
it O O
can O O
be O O
considered O O
as O O
an O O
anticonvulsant O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
agent O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Patients O B_PERSON
with O O
an O O
adherence O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
to O O
SOP O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
> O O
70 O B_MEASURE/B_LOCATION
% O I_MEASURE/I_LOCATION
were O O
classified O O
into O O
the O O
high O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
adherence O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
group O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
( O O
HAG O B_LOCATION/B_ORGANIZATION
) O O
and O O
patients O B_PERSON
with O O
an O O
adherence O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
of O O
< O O
70 O B_MEASURE/B_LOCATION
% O I_MEASURE/I_LOCATION
into O O
the O O
low O B_MEASURE/B_LOCATION
adherence O I_MEASURE/I_LOCATION
group O I_MEASURE/I_LOCATION
( O O
LAG O B_LOCATION/B_ORGANIZATION
) O O
. O O

Multivariate O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
analysis O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
revealed O O
an O O
odds O B_MEASURE
ratio O I_MEASURE
of O O
2 O B_MEASURE
. O O
5 O B_MEASURE
- O O
fold O B_MEASURE
for O O
LAG O B_PROTEIN[GENE]/B_DISEASE
to O O
develop O O
AKI O B_DISEASE
compared O O
with O O
HAG O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
( O O
95 O B_MEASURE
% O I_MEASURE
confidence O I_MEASURE
interval O I_MEASURE
1 O I_MEASURE
. O O
195 O B_MEASURE
to O O
5 O B_MEASURE
. O O
124 O B_MEASURE
, O O
P O B_OTHER/B_MEASURE
= O O
0 O B_MEASURE
. O O
039 O B_MEASURE
) O O
. O O

One O B_TIME[MEASURE]/B_LOCATION
month O I_TIME[MEASURE]/I_LOCATION
after O O
starting O O
the O O
antiviral O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
therapy O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
the O O
patient O B_PERSON
was O O
admitted O O
to O O
the O O
hospital O B_LOCATION/B_ORGANIZATION
because O O
he O O
developed O O
rhabdomyolysis O B_DISEASE
. O O

The O O
VTD O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
regimen O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
may O O
be O O
safe O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
and O O
effective O B_DRUG_ADJECTIVE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
as O O
a O O
consolidation O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
therapy O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_MEASURE
in O O
the O O
treatment O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
MM O B_DISEASE/B_LOCATION
in O O
Japanese O B_PERSON/B_LOCATION
population O I_PERSON/I_LOCATION
. O O

Protocols O O
of O O
conversion O O
from O O
cyclosporin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
A I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
CsA B B_LOCATION/B_ORGANIZATION
) O O
to O O
sirolimus B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
SRL B B_LOCATION/B_ORGANIZATION
) O O
have O O
been O O
widely O O
used O O
in O O
immunotherapy O O
after O O
transplantation O O
to O O
prevent O O
CsA B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
induced O O
nephropathy O O
, O O
but O O
the O O
molecular O O
mechanisms O O
underlying O O
these O O
protocols O O
remain O O
nuclear O O
. O O

This O O
study O O
aimed O O
to O O
identify O O
the O O
molecular O O
pathways O O
and O O
putative O O
biomarkers O O
of O O
CsA B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
to O O
- O O
SRL B B_DISEASE
conversion O O
in O O
a O O
rat O O
model O O
. O O

Conversion O O
to O O
SRL B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
prevented O O
CsA B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
induced O O
renal O O
damage O O
evolution O O
( O O
absent O O
/ O O
mild O O
grade O O
lesions O O
) O O
, O O
while O O
NGAL O O
( O O
serum O O
versus O O
urine O O
) O O
seems O O
to O O
be O O
a O O
feasible O O
biomarker O O
of O O
CsA B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
replacement O O
to O O
SRL B B_DISEASE
. O O

At O O
baseline O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
54 O B_MEASURE
. O O
5 O B_MEASURE
% O I_MEASURE
patients O I_MEASURE
were O O
on O O
immunomodulatory O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
agents O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

WT O B_BIO/B_PERSON
mice O I_BIO/I_PERSON
had O O
increased O O
urine O B_MEASURE/B_DISEASE
output O I_MEASURE/I_DISEASE
and O O
lowered O O
urine O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
osmolality O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
after O O
3 O B_NUMBER[MEASURE]
and O O
5 O B_TIME[MEASURE]/B_ENT
days O I_TIME[MEASURE]/I_ENT
of O O
treatment O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
whereas O O
PKCa O B_BIO/B_GENE
KO O I_BIO/I_GENE
mice O I_BIO/I_GENE
had O O
no O O
change O B_MEASURE
in O O
urine O B_MEASURE
output O I_MEASURE
or O O
concentration O B_MEASURE
. O O

Condition O B_PERSON
moderately O O
improved O O
on O O
stoppage O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
of O O
the O O
drug O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
for O O
25 O B_TIME[MEASURE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
days O I_TIME[MEASURE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O O

Clinicians O B_PERSON
need O O
to O O
be O O
aware O B_PERSON
of O O
prescribing O O
concomitant O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
medications O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
that O O
increase O O
the O O
risk O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
of O O
myopathy O B_DISEASE/B_GENE
or O O
inhibit O O
the O O
CYP3A4 O B_GENE/B_DISEASE
enzyme O B_GENE/I_DISEASE
. O O

Characterization O O
of O O
a O O
novel O O
BCHE O O
" O O
silent O O
" O O
allele O O
: O O
point O O
mutation O O
( O O
p O O
. O O
Val204Asp O O
) O O
causes O O
loss O O
of O O
activity O O
and O O
prolonged O O
apnea O O
with O O
suxamethonium B B_DISEASE
. O O

Electrophoretic O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
analysis O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
plasma O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
BChE O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
of O O
the O O
proband O B_PERSON
and O O
his O O
mother O B_PERSON
showed O O
that O O
patient O B_PERSON/B_BIO
has O O
a O O
reduced O O
amount O B_MEASURE/B_LOCATION
of O O
tetrameric O B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
enzyme O I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
in O O
plasma O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
and O O
that O O
minor O B_PERSON/B_NUMBER[MEASURE]
fast O O
- O O
moving O O
BChE O B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
components O I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
: O O
monomer O B_GENE/B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
dimer O B_GENE/B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
and O O
monomer O B_GENE
- O O
albumin O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
conjugate O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
are O O
missing O O
. O O

Both O O
catalytic O O
parameters O O
Km O O
= O O
265 O O
uM O O
for O O
BTC B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
, O O
two O O
times O O
higher O O
than O O
that O O
of O O
the O O
atypical O O
enzyme O O
, O O
and O O
a O O
low O O
Vmax O O
are O O
consistent O O
with O O
the O O
absence O O
of O O
activity O O
against O O
suxamethonium B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
. O O

Maleate B B_DISEASE
- O O
induced O O
renal O O
injury O O
included O O
increase O O
in O O
renal O O
vascular O O
resistance O O
and O O
in O O
the O O
urinary O O
excretion O O
of O O
total O O
protein O O
, O O
glucose B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
, O O
sodium B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
, O O
neutrophil O O
gelatinase O O
- O O
associated O O
lipocalin O O
( O O
NGAL O O
) O O
and O O
N O O
- O O
acetyl O O
b O O
- O O
D O O
- O O
glucosaminidase O O
( O O
NAG O O
) O O
, O O
upregulation O O
of O O
kidney O O
injury O O
molecule O O
( O O
KIM O O
) O O
- O O
1 O O
, O O
decrease O O
in O O
renal O O
blood O O
flow O O
and O O
claudin O O
- O O
2 O O
expression O O
besides O O
of O O
necrosis O O
and O O
apoptosis O O
of O O
tubular O O
cells O O
on O O
24 O O
h O O
. O O

Oxidative O B_DISEASE
stress O I_DISEASE
was O O
determined O O
by O O
measuring O O
the O O
oxidation O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
lipids O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
and O O
proteins O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
and O O
diminution O B_DISEASE_ADJECTIVE[DISEASE]
in O O
renal O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
Nrf2 O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
levels O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

In O O
particular O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
patients O B_PERSON/B_BIO
with O O
severe O B_DISEASE_ADJECTIVE[DISEASE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
neutropenia O B_DISEASE_ADJECTIVE[DISEASE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
( O O
less O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
than O O
100 O B_MEASURE
/ O O
mm3 O B_MEASURE
) O O
have O O
shown O O
a O O
poor O B_DISEASE_ADJECTIVE[DISEASE]
response O I_DISEASE_ADJECTIVE[DISEASE]
to O O
antibiotics O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

There O O
were O O
125 O B_DISEASE
infectious O I_DISEASE
episodes O I_DISEASE
in O O
116 O B_PERSON/B_BIO
cancer O I_PERSON/I_BIO
patients O I_PERSON/I_BIO
receiving O O
myelosuppressive O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
chemotherapy O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Among O O
applicators O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
with O O
usage O B_DISEASE
information O I_DISEASE
sufficient O I_DISEASE
to O O
evaluate O O
exposure O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
- O O
response O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
patterns O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
we O O
used O O
Poisson O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
regression O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
to O O
estimate O O
adjusted O B_MEASURE/B_DISEASE
rate O I_MEASURE/I_DISEASE
ratios O I_MEASURE/I_DISEASE
( O O
RRs O B_LOCATION/B_ORGANIZATION
) O O
and O O
95 O B_MEASURE
% O I_MEASURE
CI O I_MEASURE
for O O
cancer O B_LOCATION/B_ORGANIZATION
sites O I_LOCATION/I_ORGANIZATION
with O O
> O B_MEASURE
10 O I_MEASURE
exposed O O
cases O B_PERSON/B_LOCATION
for O O
both O O
lifetime O B_TIME[MEASURE]
( O O
LT O B_PERSON/B_LOCATION
) O O
exposure O B_TIME[MEASURE]/B_ENT
days O I_TIME[MEASURE]/I_ENT
and O O
intensity O B_MEASURE/B_DISEASE
- O O
weighted O O
( O O
IW O B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
lifetime O B_TIME[MEASURE]/B_ENT
exposure O I_TIME[MEASURE]/I_ENT
days O I_TIME[MEASURE]/I_ENT
( O O
accounting O O
for O O
factors O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
impacting O O
exposure O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
) O O
. O O

CONCLUSIONS O O
: O O
Our O O
updated O O
evaluation O O
of O O
diazinon B B_DISEASE/B_BIO
provides O O
additional O O
evidence O O
of O O
an O O
association O O
with O O
lung O O
cancer O O
risk O O
. O O

CONCLUSIONS O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
: O O
The O O
plausibility O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
of O O
an O O
effect O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
of O O
ambient O B_NUMBER[MEASURE]/B_LOCATION
concentrations O I_NUMBER[MEASURE]/I_LOCATION
of O O
these O O
pollutants O B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
on O O
Parkinson O B_DISEASE_ADJECTIVE[DISEASE]
' O I_DISEASE_ADJECTIVE[DISEASE]
s O I_DISEASE_ADJECTIVE[DISEASE]
disease O I_DISEASE_ADJECTIVE[DISEASE]
risk O I_DISEASE_ADJECTIVE[DISEASE]
is O O
supported O O
by O O
experimental O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
data O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
demonstrating O O
damage O B_DISEASE
to O O
dopaminergic O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
neurons O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
at O O
relevant O B_MEASURE/B_LOCATION
concentrations O I_MEASURE/I_LOCATION
. O O

However O O
, O O
whether O O
PCE O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
could O O
induce O O
glomerulosclerosis O B_DISEASE/B_GENE
and O O
its O O
underlying O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
mechanisms O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
remain O O
unknown O B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
. O O

This O O
study O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
aimed O O
to O O
demonstrate O O
the O O
induction O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
to O O
glomerulosclerosis O O
in O O
adult O B_PERSON
offspring O O
by O O
PCE O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
and O O
its O O
intrauterine O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
programming O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
mechanisms O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

The O O
results O O
revealed O O
that O O
the O O
adult O O
offspring O O
kidneys O O
in O O
the O O
PCE O O
group O O
exhibited O O
glomerulosclerosis O O
as O O
well O O
as O O
interstitial O O
fibrosis O O
, O O
accompanied O O
by O O
elevated O O
levels O O
of O O
serum O O
creatinine B B_MEASURE/B_GENE
and O O
urine O O
protein O O
. O O

Renal O O
angiotensin B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
II I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
receptor O O
type O O
2 O O
( O O
AT2R O O
) O O
gene O O
expression O O
in O O
adult O O
offspring O O
was O O
reduced O O
by O O
PCE O O
, O O
whereas O O
the O O
renal O O
angiotensin B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
II I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
receptor O O
type O O
1a O O
( O O
AT1aR O O
) O O
/ O O
AT2R O O
expression O O
ratio O O
was O O
increased O O
. O O

1 B B_DISEASE
, I I_DISEASE
3 I I_DISEASE
- I I_DISEASE
Butadiene I I_DISEASE
, O O
CML O O
and O O
the O O
t O O
( O O
9 O O
: O O
22 O O
) O O
translocation O O
: O O
A O O
reality O O
check O O
. O O

UNASSIGNED O O
: O O
Epidemiological O O
studies O O
of O O
1 B B_SPECIES[BIO]/B_DISEASE_ADJECTIVE[DISEASE]
, I I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
3 I I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
- I I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
butadiene I I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
have O O
suggest O O
that O O
exposures O O
to O O
humans O O
are O O
associated O O
with O O
chronic O O
myeloid O O
leukemia O O
( O O
CML O O
) O O
. O O

We O O
have O O
proposed O O
that O O
1 B B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
, I I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
3 I I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
- I I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
butadiene I I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
metabolites O O
be O O
so O O
tested O O
as O O
a O O
reality O O
check O O
on O O
the O O
epidemiological O O
reports O O
. O O

Results O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
described O O
here O O
demonstrate O O
that O O
this O O
agent O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
does O O
in O O
fact O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
induce O O
pathogenic O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
t O O
( O O
9 O B_MEASURE
: O O
22 O B_MEASURE
) O O
translocations O B_DISEASE/B_GENE
in O O
a O O
human O B_DISEASE_ADJECTIVE[DISEASE]/B_BIO
myeloid O I_DISEASE_ADJECTIVE[DISEASE]/I_BIO
cell O I_DISEASE_ADJECTIVE[DISEASE]/I_BIO
line O I_DISEASE_ADJECTIVE[DISEASE]/I_BIO
in O O
vitro O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
, O O
but O O
does O O
so O O
at O O
low O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
frequencies O B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
. O O

For O O
liver O B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
cancer O B_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
, O O
in O O
analyses O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
restricted O O
to O O
exposed O B_PERSON/B_ORGANIZATION
workers O I_PERSON/I_ORGANIZATION
, O O
elevations O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
observed O O
at O O
higher O B_MEASURE/B_LOCATION
categories O B_MEASURE/I_LOCATION
of O O
use O B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
were O O
not O O
statistically O O
significant O B_DISEASE_ADJECTIVE[DISEASE]
. O O

However O O
, O O
in O O
hearts O B_PERSON/B_BIO
deprived O O
of O O
compensatory O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
sympathetic O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
drive O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
, O O
it O O
may O O
lead O O
to O O
bradycardia O B_DISEASE
. O O

The O O
mean O O
arterial O O
pressure O O
was O O
decreased O O
from O O
86 O O
+ O O
/ O O
- O O
5 O O
( O O
s O O
. O O
e O O
. O O
mean O O
) O O
mmHg O O
to O O
52 O O
+ O O
/ O O
- O O
1 O O
mmHg O O
( O O
11 O O
. O O
5 O O
+ O O
/ O O
- O O
0 O O
. O O
7 O O
to O O
6 O O
. O O
9 O O
+ O O
/ O O
- O O
0 O O
. O O
1 O O
kPa O O
) O O
for O O
98 O O
+ O O
/ O O
- O O
10 O O
min O O
in O O
the O O
halothane B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
H B B_OTHER/B_PROTEIN[GENE]
) O O
group O O
, O O
from O O
79 O O
+ O O
/ O O
- O O
5 O O
to O O
53 O O
+ O O
/ O O
- O O
1 O O
mmHg O O
( O O
10 O O
. O O
5 O O
+ O O
/ O O
- O O
0 O O
. O O
7 O O
to O O
7 O O
. O O
1 O O
+ O O
/ O O
- O O
0 O O
. O O
1 O O
kPa O O
) O O
for O O
129 O O
+ O O
/ O O
- O O
11 O O
min O O
in O O
the O O
enflurane B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
E B B_OTHER/B_PROTEIN[GENE]
) O O
group O O
, O O
and O O
from O O
80 O O
+ O O
/ O O
- O O
4 O O
to O O
49 O O
+ O O
/ O O
- O O
1 O O
mmHg O O
( O O
10 O O
. O O
7 O O
+ O O
/ O O
- O O
0 O O
. O O
5 O O
to O O
6 O O
. O O
5 O O
+ O O
/ O O
- O O
0 O O
. O O
1 O O
kPa O O
) O O
for O O
135 O O
+ O O
/ O O
- O O
15 O O
min O O
in O O
the O O
isoflurane B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
( O O
I B B_OTHER/B_MEASURE
) O O
group O O
. O O

The O O
systemic O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
toxic O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
signs O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
both O O
agents O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
were O O
similar O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
occurred O O
at O O
approximately O O
equivalent O B_MEASURE/B_LOCATION
doses O I_MEASURE/I_LOCATION
. O O

At O O
the O O
end O O
of O O
each O O
14 O O
- O O
day O O
treatment O O
, O O
a O O
dose O O
- O O
response O O
curve O O
( O O
DRC O O
) O O
was O O
performed O O
, O O
and O O
airway O O
( O O
FEV1 O O
, O O
FEF25 O O
- O O
75 O O
) O O
chronotropic O O
( O O
HR O O
) O O
, O O
tremor O O
, O O
and O O
metabolic O O
( O O
K B B_OTHER/B_LOCATION
, O O
Glu B B_LOCATION/B_PERSON
) O O
responses O O
were O O
measured O O
at O O
each O O
step O O
( O O
from O O
100 O O
to O O
4 O O
, O O
000 O O
micrograms O O
) O O
. O O

There O O
were O O
dose O B_MEASURE
- O O
dependent O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
increases O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
FEV1 O B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
FEF25 O B_LOCATION
- O O
75 O B_MEASURE
( O O
p O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
less O B_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
than O O
0 O B_MEASURE/B_LOCATION
. O O
001 O B_MEASURE
) O O
, O O
and O O
pretreatment O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_PERSON
with O O
HDS O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
did O O
not O O
displace O O
the O O
DRC O B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
to O O
the O O
right O B_BODY_PART_OR_ORGAN_COMPONENT/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

DRC O O
for O O
HR O O
( O O
p O O
less O O
than O O
0 O O
. O O
001 O O
) O O
, O O
K B B_OTHER/B_LOCATION
( O O
p O O
less O O
than O O
0 O O
. O O
001 O O
) O O
, O O
and O O
Glu B B_LOCATION/B_PERSON
( O O
p O O
less O O
than O O
0 O O
. O O
005 O O
) O O
were O O
attenuated O O
after O O
treatment O O
with O O
HDS O O
compared O O
with O O
PI O O
. O O

There O O
were O O
also O O
differences O O
between O O
HDS O O
and O O
LDS O O
for O O
HR O O
( O O
p O O
less O O
than O O
0 O O
. O O
001 O O
) O O
and O O
Glu B B_LOCATION/B_PROTEIN[GENE]
( O O
p O O
less O O
than O O
0 O O
. O O
05 O O
) O O
responses O O
. O O

Frequency O B_MEASURE
and O O
severity O B_MEASURE
of O O
subjective O B_DISEASE
adverse O I_DISEASE
effects O I_DISEASE
were O O
also O O
reduced O O
after O O
HDS O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
: O O
tremor O B_DISEASE
( O O
p O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
less O B_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
than O O
0 O B_MEASURE
. O O
001 O B_MEASURE
) O O
, O O
palpitations O B_DISEASE
( O O
p O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
less O B_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
than O O
0 O B_MEASURE
. O O
001 O B_MEASURE
) O O
. O O
( O O
ABSTRACT O B_PERSON/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
TRUNCATED O O
AT O O
250 O B_LOCATION/B_ENT
WORDS O I_LOCATION/I_ENT
) O O

Without O O
treatment O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
, O O
73 O B_MEASURE
of O O
92 O B_PERSON
animals O I_PERSON
( O O
80 O B_MEASURE/B_LOCATION
% O I_MEASURE/I_LOCATION
) O O
died O O
after O O
injection O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
of O O
bovine O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
serum O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
albumin O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
( O O
BSA O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
) O O
on O O
day O B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
+ O B_TIME[MEASURE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
7 O B_TIME[MEASURE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
pertussis O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
immunization O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
. O O

By O O
means O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
intra O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
arterial O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_BODY_PART_OR_ORGAN_COMPONENT
ambulatory O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_BODY_PART_OR_ORGAN_COMPONENT
monitoring O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_BODY_PART_OR_ORGAN_COMPONENT
the O O
haemodynamic O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
effects O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
were O O
followed O O
for O O
18 O B_MEASURE
h O O
after O O
the O O
infusions O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O O
stopped O O
. O O

More O O
serious O B_DISEASE_ADJECTIVE[DISEASE]
ocular O I_DISEASE_ADJECTIVE[DISEASE]
adverse O I_DISEASE_ADJECTIVE[DISEASE]
reactions O I_DISEASE_ADJECTIVE[DISEASE]
include O O
papilledema O B_DISEASE
, O O
pseudotumor O B_DISEASE
cerebri O I_DISEASE
, O O
and O O
white O B_COLOR
or O O
gray O B_DISEASE
subepithelial O I_DISEASE
corneal O I_DISEASE
opacities O I_DISEASE
; O O
all O O
of O O
these O O
are O O
reversible O B_DISEASE_ADJECTIVE[DISEASE]
if O O
the O O
drug O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O O
discontinued O O
. O O

A O O
correlation O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
the O O
blood O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
pressure O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
was O O
neither O O
found O O
in O O
the O O
development O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
nor O O
in O O
the O O
attempt O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
to O O
suppress O O
the O O
development O B_DISEASE_ADJECTIVE[DISEASE]
of O O
heart O B_DISEASE/B_GENE
hypertrophy O I_DISEASE/I_GENE
with O O
the O O
two O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
beta O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
- O O
receptor O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
blockers O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Both O O
beta O B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
blockers O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
influenced O O
the O O
development O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
of O O
hypertrophy O B_DISEASE
to O O
a O O
different O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
but O O
not O O
reproducible O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
extent O I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Morning O B_DISEASE
dipping O I_DISEASE
, O O
assessed O O
by O O
the O O
fall O B_DISEASE/B_MEASURE
in O O
peak O B_MEASURE/B_PROTEIN[GENE]
flow O B_MEASURE/I_PROTEIN[GENE]
overnight O O
, O O
was O O
significantly O O
reduced O O
in O O
the O O
periods O B_TIME[MEASURE]/B_LOCATION
when O O
either O O
active O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
drug O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
was O O
taken O O
, O O
whereas O O
no O O
difference O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
was O O
noticed O O
during O O
the O O
placebo O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
administration O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
. O O

Repeat O O
neuropsychological O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
testing O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
7 O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
weeks O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
after O O
discontinuation O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
of O O
the O O
drug O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
revealed O O
dramatic O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
improvement O I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
IQ O B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
memory O B_PERSON/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
naming O B_TIME[MEASURE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
and O O
other O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
tasks O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
commensurate O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
with O O
clinical O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
recovery O I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
his O O
intellectual O B_MEASURE/B_PERSON
capacity O I_MEASURE/I_PERSON
. O O

These O O
results O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
extend O O
previous O B_LOCATION/B_MEASURE
findings O I_LOCATION/I_MEASURE
implicating O O
a O O
cholinergic O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O O
opioid O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
interaction O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
in O O
memory O B_DISEASE
processes O I_DISEASE
. O O

The O O
initial O O
response O O
to O O
the O O
primary O O
attack O O
by O O
the O O
cyclophosphamide B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
metabolites O O
seems O O
to O O
be O O
fragmentation O O
of O O
the O O
luminal B B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE
membrane O O
. O O

The O O
morphological O B_DISEASE_ADJECTIVE[DISEASE]
changes O I_DISEASE_ADJECTIVE[DISEASE]
of O O
the O O
endothelial O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
cells O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
, O O
which O O
become O O
more O O
pronounced O O
in O O
the O O
later O B_TIME[MEASURE]/B_LOCATION
stages O I_TIME[MEASURE]/I_LOCATION
of O O
the O O
experiment O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
the O O
involvement O B_DISEASE/B_MEASURE
of O O
blood O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
vessels O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
regardless O O
of O O
their O O
diameter O B_MEASURE/B_LOCATION
and O O
the O O
location O B_MEASURE
- O O
dependent O B_MEASURE/B_LOCATION
extent O I_MEASURE/I_LOCATION
of O O
the O O
damage O B_DISEASE
indicate O O
a O O
direct O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
type O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O O
damage O B_DISEASE
which O O
is O O
preceded O O
by O O
a O O
mediator O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
induced O O
increase O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O O
permeability O B_DISEASE/B_MEASURE
, O O
the O O
morphological O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
correlate O I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
of O O
which O O
is O O
the O O
formation O B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
of O O
gaps O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
the O O
interendothelial O B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
cell O B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
connections O B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
on O O
the O O
venules O B_BODY_PART_OR_ORGAN_COMPONENT/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

It O O
is O O
concluded O O
that O O
intragastric O O
pressure O O
increases O O
significantly O O
during O O
muscle O O
fasciculations O O
caused O O
by O O
suxamethonium B B_DISEASE
in O O
healthy O O
children O O
. O O

Thirty O O
to O O
135 O O
min O O
after O O
the O O
injection O O
of O O
crystalline O O
insulin O O
, O O
ISO B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
was O O
given O O
subcutaneously O O
and O O
when O O
ISO B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
induced O O
fibrosis O O
in O O
the O O
myocardium O O
was O O
morphometrically O O
analyzed O O
7 O O
days O O
later O O
, O O
a O O
highly O O
significant O O
correlation O O
( O O
r O O
= O O
0 O O
. O O
83 O O
, O O
2 O O
p O O
= O O
0 O O
. O O
006 O O
) O O
to O O
the O O
slope O O
of O O
the O O
fall O O
in O O
blood O O
glucose B B_MEASURE/B_BODY_PART_OR_ORGAN_COMPONENT
after O O
insulin O O
treatment O O
appeared O O
. O O

Etoposide B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
VP B B_LOCATION/B_PROTEIN[GENE]
- I I_LOCATION/I_PROTEIN[GENE]
16 I I_LOCATION/I_PROTEIN[GENE]
- I I_LOCATION/I_PROTEIN[GENE]
213 I I_LOCATION/I_PROTEIN[GENE]
) O O
has O O
been O O
used O O
in O O
the O O
treatment O O
of O O
many O O
solid O O
tumors O O
and O O
hematologic O O
malignancies O O
. O O

When O O
used O O
in O O
high O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
doses O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
and O O
in O O
conjunction O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O O
autologous O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
bone O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
marrow O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
transplantation O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
this O O
agent O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
has O O
activity O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
against O O
several O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
treatment O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
resistant O B_DISEASE_ADJECTIVE[DISEASE]
cancers O I_DISEASE_ADJECTIVE[DISEASE]
including O O
malignant O B_DISEASE
glioma O I_DISEASE
. O O

This O O
case O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
represents O O
an O O
example O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
of O O
" O B_PERSON/B_LOCATION
idiosyncratic O I_PERSON/I_LOCATION
" O O
drug O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
induced O O
liver O B_DISEASE
damage O I_DISEASE
in O O
which O O
the O O
primary O B_LOCATION/B_PERSON
target O I_LOCATION/I_PERSON
of O O
injury O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
is O O
the O O
bile O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
duct O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
. O O

The O O
favorable O B_DRUG_ADJECTIVE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
efficacy O I_DRUG_ADJECTIVE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
and O O
tolerability O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
profiles O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
of O O
these O O
agents O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
make O O
them O O
attractive O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
therapeutic O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
modalities O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

An O O
experimental O O
model O O
of O O
focal O O
segmental O O
glomerular O O
sclerosis O O
( O O
FSGS O O
) O O
was O O
developed O O
in O O
rats O O
by O O
the O O
combined O O
administration O O
of O O
puromycin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
aminonucleoside I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
AMNS B B_LOCATION/B_ORGANIZATION
) O O
and O O
protamine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
sulfate I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
PS B B_LOCATION/B_DISEASE
) O O
. O O

The O O
time O O
- O O
course O O
curve O O
of O O
creatinine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
clearance O O
dropped O O
and O O
showed O O
significant O O
difference O O
( O O
P O O
less O O
than O O
0 O O
. O O
01 O O
) O O
from O O
that O O
of O O
each O O
control O O
group O O
, O O
such O O
as O O
, O O
AMNS B B_LOCATION/B_ORGANIZATION
alone O O
, O O
PS B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
alone O O
or O O
saline O O
injected O O
. O O

From O O
this O O
experience O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
, O O
we O O
urge O O
extreme O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
caution O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
the O O
use O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
tricyclic O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
antidepressants O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
children O B_PERSON/B_BIO
with O O
active O B_DISEASE
neuroblastoma O I_DISEASE
. O O

Patients O O
who O O
undergo O O
bone O O
marrow O O
transplantation O O
are O O
generally O O
immunosuppressed O O
with O O
a O O
dose O O
of O O
cyclophosphamide B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
CYA B B_LOCATION/B_ORGANIZATION
) O O
which O O
is O O
usually O O
calculated O O
based O O
on O O
the O O
patient O O
' O O
s O O
weight O O
. O O

We O O
conclude O O
that O O
the O O
CYA B B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cardiotoxicity O O
correlates O O
with O O
CYA B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
dosage O O
as O O
calculated O O
by O O
body O O
surface O O
area O O
, O O
and O O
that O O
patients O O
with O O
aplastic O O
anemia O O
and O O
immunodeficiencies O O
can O O
be O O
effectively O O
prepared O O
for O O
bone O O
marrow O O
grafting O O
at O O
a O O
CYA B B_MEASURE
dose O O
of O O
1 O O
. O O
55 O O
g O O
/ O O
m2 O O
/ O O
d O O
for O O
four O O
days O O
with O O
a O O
lower O O
incidence O O
of O O
cardiotoxicity O O
than O O
patients O O
whose O O
CYA B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
dosage O O
is O O
calculated O O
based O O
on O O
weight O O
. O O

Further O O
analysis O O
of O O
these O O
data O O
suggests O O
that O O
the O O
duration O O
of O O
therapy O O
, O O
plasma O O
aminoglycoside B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
levels O O
, O O
liver O O
disease O O
, O O
advanced O O
age O O
, O O
high O O
initial O O
estimated O O
creatinine B B_BODY_PART_OR_ORGAN_COMPONENT
clearance O O
and O O
, O O
possibly O O
, O O
female O O
gender O O
all O O
increase O O
the O O
risk O O
for O O
nephrotoxicity O O
. O O

Central O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
action O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
of O O
narcotic O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
analgesics O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Noradrenergic O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
influences O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
on O O
the O O
activity O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
analgesics O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
in O O
rats O B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Codeine B B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
catalepsy O O
was O O
increased O O
by O O
clonidine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
decreased O O
by O O
naphazoline B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
and O O
xylometazoline B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

It O O
is O O
suggested O O
that O O
in O O
rats O O
the O O
brain O O
NA B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
plays O O
a O O
less O O
important O O
function O O
than O O
the O O
other O O
monoamines B B_LOCATION/B_DISEASE_ADJECTIVE[DISEASE]
in O O
the O O
behavioural O O
activity O O
of O O
potent O O
analgesics O O
. O O

A O O
flurothyl B B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
ether B I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
seizure O O
screening O O
technique O O
was O O
used O O
to O O
evaluate O O
seizure O O
susceptibility O O
in O O
adult O O
mice O O
that O O
received O O
neonatal O O
injections O O
of O O
MSG B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
( O O
4 O O
mg O O
/ O O
g O O
and O O
1 O O
mg O O
/ O O
g O O
) O O
. O O

Vasoactive O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
intestinal O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
polypeptide O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
( O O
VIP O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
is O O
a O O
systemic O B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
and O O
coronary O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
vasodilator O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
that O O
may O O
have O O
positive O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
inotropic O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
properties O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Myocardial O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
levels O I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O O
VIP O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
were O O
assayed O O
before O O
and O O
after O O
the O O
development O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
of O O
heart O B_DISEASE
failure O I_DISEASE
in O O
two O B_SPECIES[BIO]/B_PERSON
canine O I_SPECIES[BIO]/I_PERSON
models O I_SPECIES[BIO]/I_PERSON
. O O

The O O
hearts O B_PERSON/B_BODY_PART_OR_ORGAN_COMPONENT
without O O
coronary O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
artery O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
disease O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
( O O
average O B_MEASURE/B_PERSON
ejection O B_MEASURE/I_PERSON
fraction O B_MEASURE/I_PERSON
of O O
this O O
group O B_MEASURE/B_ORGANIZATION
62 O I_MEASURE/I_ORGANIZATION
% O I_MEASURE/I_ORGANIZATION
+ O I_MEASURE/I_ORGANIZATION
/ O O
- O O
10 O B_MEASURE
% O I_MEASURE
) O O
had O O
a O O
VIP O B_MEASURE
concentration O I_MEASURE
of O O
14 O B_MEASURE
. O O
1 O B_MEASURE/B_LOCATION
+ O I_MEASURE/I_LOCATION
/ O O
- O O
7 O B_MEASURE
. O O
9 O B_MEASURE
pg O I_MEASURE
/ O O
mg O B_MEASURE
protein O I_MEASURE
, O O
and O O
this O O
was O O
greater O B_MEASURE
than O O
in O O
hearts O B_PERSON/B_BODY_PART_OR_ORGAN_COMPONENT
of O O
the O O
patients O B_PERSON/B_BODY_PART_OR_ORGAN_COMPONENT
with O O
coronary O B_DISEASE
disease O I_DISEASE
and O O
the O O
hearts O B_PERSON/B_BODY_PART_OR_ORGAN_COMPONENT
of O O
patients O B_PERSON
receiving O O
a O O
transplant O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
P O B_MEASURE/B_PERSON
less O I_MEASURE/I_PERSON
than O O
0 O B_MEASURE
. O O
05 O B_MEASURE
) O O
. O O

Myocardial O O
catecholamines B B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
were O O
also O O
determined O O
in O O
14 O O
subjects O O
; O O
a O O
weak O O
correlation O O
( O O
r O O
= O O
0 O O
. O O
57 O O
, O O
P O O
less O O
than O O
0 O O
. O O
05 O O
) O O
between O O
the O O
tissue O O
concentrations O O
of O O
VIP O O
and O O
norepinephrine B B_LOCATION/B_ORGANIZATION
was O O
noted O O
. O O
( O O
ABSTRACT O O
TRUNCATED O O
AT O O
250 O O
WORDS O O
) O O

Patients O B_PERSON
were O O
divided O O
into O O
three O B_MEASURE/B_ORGANIZATION
groups O B_MEASURE/I_ORGANIZATION
; O O
19 O B_NUMBER[MEASURE]
patients O I_NUMBER[MEASURE]
without O O
myocardial O B_DISEASE/B_LOCATION
infarction O I_DISEASE/I_LOCATION
( O O
non O B_LOCATION
- O O
MI O B_LOCATION/B_ORGANIZATION
group O I_LOCATION/I_ORGANIZATION
) O O
, O O
14 O B_NUMBER[MEASURE]
with O O
anterior O B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
infarction O I_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
( O O
ANT O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
MI O B_LOCATION/B_DISEASE
) O O
and O O
eight O B_NUMBER[MEASURE]
with O O
inferior O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
infarction O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
( O O
INF O B_DISEASE/B_PROTEIN[GENE]
- O O
MI O B_LOCATION/B_DISEASE
) O O
. O O

Exercise O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
induced O O
ST O B_DISEASE
depression O I_DISEASE
was O O
observed O O
in O O
84 O B_PERSON/B_MEASURE
% O I_PERSON/I_MEASURE
of O O
the O O
non O B_LOCATION
- O O
MI O B_PERSON/B_ORGANIZATION
group O I_PERSON/I_ORGANIZATION
, O O
43 O B_MEASURE/B_PERSON
% O I_MEASURE/I_PERSON
of O O
the O O
ANT O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
MI O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
group O I_PERSON/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
38 O B_MEASURE/B_PERSON
% O I_MEASURE/I_PERSON
of O O
the O O
INF O B_DISEASE/B_LOCATION
- O O
MI O B_ORGANIZATION/B_LOCATION
group O B_ORGANIZATION/I_LOCATION
and O O
61 O B_MEASURE/B_PERSON
% O I_MEASURE/I_PERSON
of O O
the O O
total O B_MEASURE/B_PERSON
. O O

No O O
significant O B_DISEASE_ADJECTIVE[DISEASE]
changes O I_DISEASE_ADJECTIVE[DISEASE]
in O O
plasma O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
concentrations O I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
electrolytes O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
were O O
found O O
. O O

In O O
patients O B_PERSON/B_LOCATION
with O O
downbeat O B_DISEASE/B_LOCATION
nystagmus O I_DISEASE/I_LOCATION
who O O
are O O
taking O O
anticonvulsant O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
medications O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
consideration O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
should O O
be O O
given O O
to O O
reduction O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
dose O B_MEASURE/B_DISEASE
before O O
further O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
investigation O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O O
undertaken O O
. O O

The O O
antihypertensive O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
effect O I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
of O O
the O O
drug O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
greater O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
in O O
patients O B_PERSON/B_BIO
with O O
more O O
severe O B_DISEASE
hypertension O I_DISEASE
. O O

These O O
rats O B_BIO/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
are O O
also O O
highly O O
susceptible O B_TIME[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
to O O
develop O O
papillary O B_DISEASE
necrosis O I_DISEASE
with O O
analgesic O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
administration O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
. O O

PGE2 B B_GENE
synthesis O O
was O O
significantly O O
higher O O
in O O
outer O O
medulla O O
, O O
but O O
not O O
cortex O O
or O O
inner O O
medulla O O
, O O
of O O
jj O O
( O O
38 O O
+ O O
/ O O
- O O
6 O O
ng O O
/ O O
mg O O
prot O O
) O O
than O O
jJ O O
rats O O
( O O
15 O O
+ O O
/ O O
- O O
3 O O
) O O
( O O
p O O
less O O
than O O
0 O O
. O O
01 O O
) O O
. O O

During O O
the O O
1 O B_TIME[MEASURE]/B_ENT
hour O I_TIME[MEASURE]/I_ENT
after O O
administration O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
of O O
the O O
drug O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
the O O
incidence O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
of O O
ventricular O B_DISEASE_ADJECTIVE[DISEASE]
fibrillation O I_DISEASE_ADJECTIVE[DISEASE]
or O O
sustained O O
ventricular O B_DISEASE
tachycardia O I_DISEASE
among O O
the O O
204 O B_PERSON
patients O I_PERSON
with O O
acute O B_DISEASE
myocardial O I_DISEASE
infarction O I_DISEASE
was O O
low O B_MEASURE/B_COLOR
, O O
1 O B_MEASURE
. O O
5 O B_MEASURE
% O I_MEASURE
. O O

Phenylpropanolamine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
( O O
PPA B B_DISEASE
) O O
overdose O O
can O O
cause O O
severe O O
hypertension O O
, O O
intracerebral O O
hemorrhage O O
, O O
and O O
death O O
. O O

Subjects O O
received O O
propranolol B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
either O O
by O O
mouth O O
for O O
48 O O
hours O O
before O O
PPA B B_DISEASE
or O O
as O O
a O O
rapid O O
intravenous O O
infusion O O
after O O
PPA B B_DISEASE
. O O

PPA B B_MEASURE/B_DISEASE
, O O
75 O O
mg O O
alone O O
, O O
increased O O
blood O O
pressure O O
( O O
31 O O
+ O O
/ O O
- O O
14 O O
mm O O
Hg O O
systolic O O
, O O
20 O O
+ O O
/ O O
- O O
5 O O
mm O O
Hg O O
diastolic O O
) O O
, O O
and O O
propranolol B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
pretreatment O O
antagonized O O
this O O
increase O O
( O O
12 O O
+ O O
/ O O
- O O
10 O O
mm O O
Hg O O
systolic O O
, O O
10 O O
+ O O
/ O O
- O O
7 O O
mm O O
Hg O O
diastolic O O
) O O
. O O

We O O
conclude O O
that O O
PPA B B_DISEASE/B_GENE
increases O O
blood O O
pressure O O
by O O
increasing O O
systemic O O
vascular O O
resistance O O
and O O
cardiac O O
output O O
, O O
and O O
that O O
propranolol B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
antagonizes O O
this O O
increase O O
by O O
reversing O O
the O O
effect O O
of O O
PPA B B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O O
cardiac O O
output O O
. O O

The O O
possible O O
relationship O O
between O O
mesangial O O
dysfunction O O
and O O
development O O
of O O
glomerular O O
sclerosis O O
was O O
studied O O
in O O
the O O
puromycin B B_DISEASE
aminonucleoside I I_DISEASE
( O O
PAN B B_DISEASE
) O O
model O O
. O O

Glomeruli O O
of O O
PAN B B_DISEASE
rats O O
contained O O
significantly O O
more O O
CC O O
than O O
glomeruli O O
of O O
controls O O
. O O

Cluster O O
analysis O O
showed O O
a O O
random O O
distribution O O
of O O
lesions O O
in O O
the O O
PAN B B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
glomeruli O O
in O O
concordance O O
with O O
the O O
random O O
localization O O
of O O
mesangial O O
areas O O
with O O
dysfunction O O
in O O
this O O
model O O
. O O

Similar O O
to O O
the O O
remnant O O
kidney O O
model O O
in O O
PAN B B_DISEASE_ADJECTIVE[DISEASE]
nephrosis O O
the O O
development O O
of O O
glomerular O O
sclerosis O O
may O O
be O O
related O O
to O O
" O O
mesangial O O
overloading O O
. O O
" O O

A O O
controversy O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
has O O
existed O O
for O O
several O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
years O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
concerning O O
the O O
physiological O B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
relevance O B_MEASURE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
the O O
nicotinic O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
receptor O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
measured O O
by O O
alpha O B_PROTEIN[GENE]/B_MEASURE
- O O
bungarotoxin O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
binding O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Thus O O
it O O
appears O O
that O O
the O O
difference O B_MEASURE
between O O
seizure O B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
sensitive O I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
and O O
insensitive O B_DISEASE_ADJECTIVE[DISEASE]
animals O I_DISEASE_ADJECTIVE[DISEASE]
may O O
be O O
due O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
to O O
a O O
difference O B_MEASURE
in O O
hippocampal O B_MEASURE/B_DISEASE
nicotinic O I_MEASURE/I_DISEASE
receptor O I_MEASURE/I_DISEASE
concentration O I_MEASURE/I_DISEASE
as O O
measured O O
with O O
alpha O B_PROTEIN[GENE]
- O O
bungarotoxin O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
binding O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Recently O O
, O O
p B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
aminophenol I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
( O O
PAP B B_GENE/B_DISEASE
) O O
, O O
a O O
known O O
potent O O
nephrotoxicant O O
, O O
was O O
identified O O
as O O
a O O
metabolite O O
of O O
APAP B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
in O O
F344 O O
rats O O
. O O

Therefore O O
, O O
the O O
effect O O
of O O
bis B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
( I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
p I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
nitrophenyl I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
) I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
phosphate I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
( O O
BNPP B B_DISEASE/B_GENE
) O O
, O O
an O O
acylamidase O O
inhibitor O O
, O O
on O O
APAP B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
and O O
PAP B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
nephrotoxicity O O
and O O
metabolism O O
was O O
determined O O
. O O

Pretreatment O O
of O O
animals O O
with O O
BNPP B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
prior O O
to O O
APAP B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
or O O
PAP B B_PROTEIN[GENE]/B_DISEASE
administration O O
resulted O O
in O O
marked O O
reduction O O
of O O
APAP B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
( O O
900 O O
mg O O
/ O O
kg O O
) O O
nephrotoxicity O O
but O O
not O O
PAP B B_PROTEIN[GENE]
nephrotoxicity O O
. O O

BNPP B B_DISEASE/B_GENE
did O O
not O O
alter O O
the O O
excretion O O
of O O
APAP B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
or O O
any O O
of O O
its O O
non O O
- O O
deacetylated O O
metabolites O O
nor O O
did O O
BNPP B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
alter O O
excretion O O
of O O
PAP B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
or O O
its O O
metabolites O O
after O O
PAP B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
doses O O
of O O
150 O O
and O O
300 O O
mg O O
/ O O
kg O O
. O O

On O O
the O O
antiarrhythmic O O
activity O O
of O O
one O O
N O O
- O O
substituted O O
piperazine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
derivative O O
of O O
trans B B_LOCATION
- I I_LOCATION
2 I I_LOCATION
- I I_LOCATION
amino I I_LOCATION
- I I_LOCATION
3 I I_LOCATION
- I I_LOCATION
hydroxy I I_LOCATION
- I I_LOCATION
1 I I_LOCATION
, I I_LOCATION
2 I I_LOCATION
, I I_LOCATION
3 I I_LOCATION
, I I_LOCATION
4 I I_LOCATION
- I I_LOCATION
tetrahydroanaphthalene I I_LOCATION
. O O

The O O
antiarrhythmic O O
activity O O
of O O
the O O
compound O O
N B B_TIME[MEASURE]/B_PROTEIN[GENE]
- I B_TIME[MEASURE]/I_PROTEIN[GENE]
( I B_TIME[MEASURE]/I_PROTEIN[GENE]
trans I B_TIME[MEASURE]/I_PROTEIN[GENE]
- I B_TIME[MEASURE]/I_PROTEIN[GENE]
3 I B_TIME[MEASURE]/I_PROTEIN[GENE]
- I B_TIME[MEASURE]/I_PROTEIN[GENE]
hydroxy I B_TIME[MEASURE]/I_PROTEIN[GENE]
- I B_TIME[MEASURE]/I_PROTEIN[GENE]
1 I B_TIME[MEASURE]/I_PROTEIN[GENE]
, I B_TIME[MEASURE]/I_PROTEIN[GENE]
2 I B_TIME[MEASURE]/I_PROTEIN[GENE]
, I B_TIME[MEASURE]/I_PROTEIN[GENE]
3 I B_TIME[MEASURE]/I_PROTEIN[GENE]
, I B_TIME[MEASURE]/I_PROTEIN[GENE]
4 I B_TIME[MEASURE]/I_PROTEIN[GENE]
- I B_TIME[MEASURE]/I_PROTEIN[GENE]
tetrahydro I B_TIME[MEASURE]/I_PROTEIN[GENE]
- I B_TIME[MEASURE]/I_PROTEIN[GENE]
2 I B_TIME[MEASURE]/I_PROTEIN[GENE]
- I B_TIME[MEASURE]/I_PROTEIN[GENE]
naphthyl I B_TIME[MEASURE]/I_PROTEIN[GENE]
) I B_TIME[MEASURE]/I_PROTEIN[GENE]
- I B_TIME[MEASURE]/I_PROTEIN[GENE]
N I B_TIME[MEASURE]/I_PROTEIN[GENE]
- I B_TIME[MEASURE]/I_PROTEIN[GENE]
( I B_TIME[MEASURE]/I_PROTEIN[GENE]
3 I B_TIME[MEASURE]/I_PROTEIN[GENE]
- I B_TIME[MEASURE]/I_PROTEIN[GENE]
oxo I B_TIME[MEASURE]/I_PROTEIN[GENE]
- I B_TIME[MEASURE]/I_PROTEIN[GENE]
3 I B_TIME[MEASURE]/I_PROTEIN[GENE]
- I B_TIME[MEASURE]/I_PROTEIN[GENE]
phenyl I B_TIME[MEASURE]/I_PROTEIN[GENE]
- I B_TIME[MEASURE]/I_PROTEIN[GENE]
2 I B_TIME[MEASURE]/I_PROTEIN[GENE]
- I B_TIME[MEASURE]/I_PROTEIN[GENE]
methylpropyl I B_TIME[MEASURE]/I_PROTEIN[GENE]
) I B_TIME[MEASURE]/I_PROTEIN[GENE]
- I B_TIME[MEASURE]/I_PROTEIN[GENE]
piperazine I B_TIME[MEASURE]/I_PROTEIN[GENE]
hydrochloride I B_TIME[MEASURE]/I_PROTEIN[GENE]
, O O
referred O O
to O O
as O O
P11 B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
, O O
is O O
studied O O
on O O
anaesthesized O O
cats O O
and O O
Wistar O O
albino O O
rats O O
, O O
as O O
well O O
as O O
on O O
non O O
- O O
anaesthesized O O
rabbits O O
. O O

The O O
results O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
obtained O O
are O O
associated O O
with O O
the O O
beta O B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
adrenoblocking O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
and O O
with O O
the O O
membrane O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
stabilizing O O
action O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
the O O
compound O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

These O O
studies O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
suggest O O
that O O
an O O
antimetabolite O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
induced O O
leukopenia O B_DISEASE
predisposes O O
to O O
severe O B_DISEASE
Pseudomonas O I_DISEASE
sepsis O I_DISEASE
and O O
that O O
such O B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
monkeys O I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
may O O
serve O O
as O O
a O O
biological O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
model O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
for O O
study O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
comparative O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
efficacy O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
of O O
antimicrobial O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
agents O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

The O O
cardiovascular O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
effects O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O O
hypoglycaemia O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
, O O
with O O
and O O
without O O
beta O B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
blockade O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
, O O
were O O
compared O O
in O O
fourteen O B_TIME[MEASURE]/B_PERSON
healthy O I_TIME[MEASURE]/I_PERSON
men O I_TIME[MEASURE]/I_PERSON
. O O

Hypertension O B_DISEASE/B_PERSON
in O O
diabetics O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
prone O I_PERSON/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
hypoglycaemia O B_DISEASE/B_GENE
attacks O I_DISEASE/I_GENE
should O O
not O O
be O O
treated O O
with O O
beta O B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
blockers O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
because O O
these O O
drugs O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
may O O
cause O O
a O O
sharp O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
rise O I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
blood O B_BODY_PART_OR_ORGAN_COMPONENT
- O O
pressure O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
in O O
such O B_PERSON/B_BIO
patients O I_PERSON/I_BIO
. O O

An O O
attempt O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O O
made O O
to O O
differentiate O O
drug O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_ORGANISM_FUNCTION
- O O
related O O
complications O B_DISEASE
from O O
maternal O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
disease O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
- O O
- O O
related O O
complications O B_DISEASE
. O O

Toxic O O
actions O O
of O O
flurazepam B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
FZP B B_PROTEIN[GENE]/B_DISEASE
) O O
were O O
studied O O
in O O
cats O O
, O O
mice O O
and O O
rats O O
. O O

High O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
doses O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
caused O O
an O O
apparent O B_DISEASE
central O I_DISEASE
excitation O I_DISEASE
, O O
most O O
clearly O O
seen O O
as O O
clonic O B_DISEASE_ADJECTIVE[DISEASE]
convulsions O I_DISEASE_ADJECTIVE[DISEASE]
, O O
superimposed O O
on O O
general O B_DISEASE
depression O I_DISEASE
. O O

Comparing O O
the O O
relative O B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
sensitivity O B_MEASURE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
central O B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
depression O B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
excitation O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
revealed O O
that O O
rats O B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O O
least O O
likely O B_DISEASE_ADJECTIVE[DISEASE]
to O O
have O O
convulsions O B_DISEASE
at O O
doses O B_TIME[MEASURE]/B_LOCATION
that O O
did O O
not O O
first O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cause O O
loss O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
consciousness O B_DISEASE
, O O
while O O
cats O B_SPECIES[BIO]
most O O
clearly O O
showed O O
marked O O
central O B_DISEASE
excitatory O I_DISEASE
actions O I_DISEASE
. O O

Signs O O
of O O
FZP B B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
toxocity O O
in O O
cats O O
included O O
excessive O O
salivation O O
, O O
extreme O O
apprehensive O O
behavior O O
, O O
retching O O
, O O
muscle O O
tremors O O
and O O
convulsions O O
. O O

It O O
otherwise O O
was O O
well O O
tolerated O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
no O O
important O B_DISEASE_ADJECTIVE[DISEASE]
side O I_DISEASE_ADJECTIVE[DISEASE]
effects O I_DISEASE_ADJECTIVE[DISEASE]
were O O
observed O O
. O O

Treatment O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
has O O
been O O
continued O O
in O O
3 O B_PERSON/B_BIO
individuals O I_PERSON/I_BIO
for O O
6 O B_NUMBER[MEASURE]
- O O
13 O B_TIME[MEASURE]
months O I_TIME[MEASURE]
with O O
persistence O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
the O O
pressor O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
effect O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
, O O
although O O
there O O
appears O O
to O O
have O O
been O O
some O O
decrease O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
in O O
the O O
degree O B_MEASURE
of O O
response O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
with O O
time O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Evidence O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O O
cardiac O B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
beta O I_PROTEIN[GENE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
2 O I_PROTEIN[GENE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
adrenoceptors O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
man O B_PERSON/B_BIO
. O O

While O O
there O O
appear O O
to O O
be O O
beta O B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
2 O I_PROTEIN[GENE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
receptors O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
in O O
the O O
human O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
heart O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
, O O
their O O
physiologic O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
or O O
pathologic O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
roles O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
remain O O
to O O
be O O
defined O O
. O O

Hormones O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
risk O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
breast O B_DISEASE
cancer O I_DISEASE
. O O

This O O
paper O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PRODUCT[OBJECT]
reports O O
the O O
results O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
a O O
study O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
50 O B_PERSON
menopausal O I_PERSON
women O I_PERSON
receiving O O
hormonal O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
replacement O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
therapy O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

These O O
results O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
suggest O O
that O O
hormonal O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
replacement O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
therapy O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
can O O
be O O
safely O O
prescribed O O
if O O
the O O
following O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
criteria O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
are O O
satisfied O O
: O O
1 O B_SEQUENCE[MEASURE]
) O O
preliminary O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
evaluation O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
patients O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
from O O
a O O
clinical O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
, O O
metabolic O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
, O O
cytologic O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
and O O
mammographic O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_EDU[ORGANIZATION]
perspective O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_EDU[ORGANIZATION]
; O O
2 O B_NUMBER[MEASURE]
) O O
cyclic O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
treatment O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
schedule O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O O
with O O
a O O
progestative O B_MEASURE/B_LOCATION
phase O I_MEASURE/I_LOCATION
of O O
10 O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
days O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
; O O
and O O
3 O B_NUMBER[MEASURE]
) O O
periodic O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
complete O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
follow O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
- O O
up O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
, O O
with O O
accurate O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
thermographic O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
evaluation O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
the O O
breast O B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
target O I_DISEASE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
tissues O I_DISEASE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Seventeen O O
renal O O
patients O O
received O O
azathioprine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
Aza B B_SPECIES[BIO]/B_LOCATION
) O O
and O O
prednisone B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
as O O
part O O
of O O
a O O
randomized O O
trial O O
of O O
immunosuppression O O
with O O
21 O O
cyclosporine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
and O O
- O O
prednisone B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
treated O O
renal O O
transplant O O
patients O O
. O O

Aza B B_PERSON/B_BIO
patients O O
had O O
significantly O O
more O O
staphylococcal O O
infections O O
than O O
all O O
other O O
transplant O O
groups O O
( O O
P O O
less O O
than O O
0 O O
. O O
005 O O
) O O
, O O
and O O
systemic O O
fungal O O
infections O O
occurred O O
only O O
in O O
the O O
liver O O
transplant O O
group O O
. O O

Structure O O
- O O
activity O O
and O O
dose O O
- O O
effect O O
relationships O O
of O O
the O O
antagonism O O
of O O
picrotoxin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
- O O
induced O O
seizures O O
by O O
cholecystokinin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
, O O
fragments O O
and O O
analogues O O
of O O
cholecystokinin B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
in O O
mice O O
. O O

Intraperitoneal O O
administration O O
of O O
cholecystokinin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
octapeptide I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
sulphate O O
ester O O
( O O
CCK B B_LOCATION/B_GENE
- I I_LOCATION/I_GENE
8 I I_LOCATION/I_GENE
- O O
SE O O
) O O
and O O
nonsulphated O O
cholecystokinin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
octapeptide I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
( O O
CCK B B_LOCATION
- I I_LOCATION
8 I I_LOCATION
- O O
NS O O
) O O
enhanced O O
the O O
latency O O
of O O
seizures O O
induced O O
by O O
picrotoxin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
in O O
mice O O
. O O

Experiments O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O O
N O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
and O O
C O B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
terminal O B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
fragments O B_PROTEIN[GENE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
revealed O O
that O O
the O O
C O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O O
terminal O B_PROTEIN[GENE]/B_LOCATION
tetrapeptide O B_PROTEIN[GENE]/I_LOCATION
( O O
CCK O B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
5 O B_MEASURE/B_LOCATION
- O O
8 O B_NUMBER[MEASURE]
) O O
was O O
the O O
active O B_LOCATION/B_PERSON
centre O I_LOCATION/I_PERSON
of O O
the O O
CCK O B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
octapeptide O B_PROTEIN[GENE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
molecule O B_PROTEIN[GENE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

The O O
analogues O O
CCK B B_LOCATION
- I I_LOCATION
8 I I_LOCATION
- O O
SE O O
and O O
CCK B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
8 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- O O
NS O O
( O O
dose O O
range O O
0 O O
. O O
2 O O
- O O
6 O O
. O O
4 O O
mumol O O
/ O O
kg O O
) O O
and O O
caerulein B B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
dose O O
range O O
0 O O
. O O
1 O O
- O O
0 O O
. O O
8 O O
mumol O O
/ O O
kg O O
) O O
showed O O
bell O O
- O O
shaped O O
dose O O
- O O
effect O O
curves O O
, O O
with O O
the O O
greatest O O
maximum O O
inhibition O O
for O O
CCK B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
8 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- O O
NS O O
. O O

Experiments O O
with O O
analogues O O
and O O
derivatives O O
of O O
CCK O O
- O O
5 O O
- O O
8 O O
demonstrated O O
that O O
the O O
effectiveness O O
of O O
the O O
beta O O
- O O
alanyl O O
derivatives O O
of O O
CCK O O
- O O
5 O O
- O O
8 O O
were O O
enhanced O O
and O O
that O O
they O O
were O O
equipotent O O
with O O
CCK B B_LOCATION/B_ORGANIZATION
- I I_LOCATION/I_ORGANIZATION
8 I I_LOCATION/I_ORGANIZATION
- O O
SE O O
. O O

Of O O
the O O
CCK O O
- O O
2 O O
- O O
8 O O
analogues O O
, O O
Ser O O
( O O
SO3H O O
) O O
7 O O
- O O
Ac O O
- O O
CCK O O
- O O
2 O O
- O O
8 O O
- O O
SE O O
and O O
Thr O O
( O O
SO3H O O
) O O
7 O O
- O O
Ac O O
- O O
CCK O O
- O O
2 O O
- O O
8 O O
- O O
SE O O
and O O
Hyp O O
( O O
SO3H O O
) O O
- O O
Ac O O
- O O
CCK O O
- O O
2 O O
- O O
8 O O
- O O
SE O O
were O O
slightly O O
more O O
active O O
than O O
CCK B B_LOCATION
- I I_LOCATION
8 I I_LOCATION
- O O
SE O O
. O O

An O O
unproportional O O
release O O
of O O
vasopressin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
compared O O
to O O
plasma O O
osmolality O O
may O O
be O O
induced O O
by O O
the O O
absence O O
of O O
an O O
adjusting O O
control O O
of O O
angiotensin B B_GENE/B_MEASURE
II O O
forming O O
and O O
receptor O O
binding O O
capacity O O
for O O
sodium B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
balance O O
in O O
the O O
brain O O
. O O

Pilocarpine B B_PERSON/B_LOCATION
may O O
have O O
had O O
a O O
contributory O O
effect O O
. O O

Succinylcholine B B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
apnoea O O
: O O
attempted O O
reversal O O
with O O
anticholinesterases O O
. O O

It O O
is O O
concluded O O
that O O
anticholinesterases O O
are O O
only O O
partially O O
effective O O
in O O
restoring O O
neuromuscular O O
function O O
in O O
succinylcholine B B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
apnoea O O
despite O O
muscle O O
twitch O O
activity O O
typical O O
of O O
phase O O
II O O
block O O
. O O

Coronary O O
blood O O
flow O O
, O O
cardiac O O
work O O
and O O
metabolism O O
were O O
studied O O
in O O
dogs O O
under O O
sodium B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
nitroprusside I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
SNP B B_LOCATION/B_ORGANIZATION
) O O
and O O
trimetaphan B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
TMP B B_LOCATION/B_ORGANIZATION
) O O
deliberate O O
hypotension O O
( O O
20 O O
% O O
and O O
40 O O
% O O
mean O O
pressure O O
decrease O O
from O O
baseline O O
) O O
. O O

Cardiac O O
work O O
was O O
significantly O O
reduced O O
during O O
SNP B B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
hypotension O O
. O O

Careful O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
invasive O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
monitoring O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O O
the O O
blood O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
pressure O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
, O O
blood O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
gases O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
and O O
of O O
the O O
ECG O B_DISEASE/B_PROTEIN[GENE]
ST O B_DISEASE/I_PROTEIN[GENE]
- O O
T O B_NUMBER[MEASURE]/B_LOCATION
segment O I_NUMBER[MEASURE]/I_LOCATION
is O O
mandatory O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

During O O
the O O
last O O
2 O O
1 O O
/ O O
2 O O
years O O
, O O
38 O O
patients O O
with O O
ovarian O O
cancer O O
were O O
treated O O
with O O
a O O
combination O O
of O O
cisplatinum B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
( O O
CPDD B B_LOCATION/B_ORGANIZATION
) O O
, O O
50 O O
mg O O
/ O O
m2 O O
, O O
adriamycin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
30 O O
mg O O
/ O O
m2 O O
, O O
cyclophosphamide B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
300 O O
mg O O
/ O O
m2 O O
, O O
on O O
day O O
1 O O
; O O
and O O
hexamethylmelamine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
HMM B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
) O O
, O O
6 O O
mg O O
/ O O
kg O O
daily O O
, O O
for O O
14 O O
days O O
. O O

14 O O
of O O
the O O
38 O O
patients O O
were O O
previously O O
treated O O
with O O
chemotherapy O O
, O O
1 O O
with O O
radiation O O
, O O
6 O O
with O O
both O O
chemotherapy O O
and O O
radiation O O
, O O
and O O
17 O O
did O O
not O O
have O O
any O O
treatment O O
before O O
CPDD B B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
combination O O
. O O

A O O
case O O
of O O
nontraumatic O O
dissecting O O
aneurysm O O
of O O
the O O
basilar O O
artery O O
in O O
association O O
with O O
hypertension O O
, O O
smoke O O
, O O
and O O
oral B B_DISEASE
contraceptives I I_DISEASE
is O O
reported O O
in O O
a O O
young O O
female O O
patient O O
with O O
a O O
locked O O
- O O
in O O
syndrome O O
. O O

A O O
method O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
for O O
the O O
measurement O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
tremor O B_DISEASE/B_GENE
, O O
and O O
a O O
comparison O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
the O O
effects O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
of O O
tocolytic O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
beta O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
- O O
mimetics O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

At O O
therapeutic O B_TIME[MEASURE]/B_LOCATION
doses O I_TIME[MEASURE]/I_LOCATION
both O O
substances O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
raised O O
the O O
mean O B_MEASURE/B_DISEASE
tremor O I_MEASURE/I_DISEASE
amplitude O I_MEASURE/I_DISEASE
to O O
about O O
three O B_MEASURE/B_LOCATION
times O I_MEASURE/I_LOCATION
the O O
control O B_MEASURE/B_LOCATION
level O I_MEASURE/I_LOCATION
. O O

Five O B_TIME[MEASURE]/B_ENT
hours O I_TIME[MEASURE]/I_ENT
after O O
starting O O
the O O
infusions O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
a O O
study O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
the O O
pituitary O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
responses O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
to O O
LH O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O O
releasing O O
hormone O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
LH O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
RH O B_PROTEIN[GENE]/B_DISEASE
) O O
was O O
carried O O
out O O
. O O

No O O
correlation O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
found O O
between O O
the O O
severity O B_MEASURE
of O O
clinical O B_DISEASE
manifestations O I_DISEASE
and O O
the O O
total O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
dose O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
taken O O
by O O
the O O
patients O B_PERSON
. O O

Antibodies O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
suggested O O
to O O
be O O
of O O
the O O
IgM O B_GENE/B_DISEASE
class O B_GENE/I_DISEASE
were O O
detected O O
in O O
all O O
3 O B_PERSON
patients O I_PERSON
with O O
hematological O B_DISEASE/B_GENE
disorders O I_DISEASE/I_GENE
. O O

Adenosine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
triphosphate I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
( O O
ATP B B_ORGANIZATION/B_GENE
) O O
and O O
sodium B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
nitroprusside I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
SNP B B_PROTEIN[GENE]/B_LOCATION
) O O
are O O
administered O O
to O O
patients O O
to O O
induce O O
and O O
control O O
hypotension O O
during O O
anesthesia O O
. O O

SNP B B_LOCATION/B_ORGANIZATION
is O O
authorized O O
for O O
clinical O O
use O O
in O O
USA O O
and O O
UK O O
, O O
and O O
ATP B B_GENE/B_DISEASE
is O O
clinically O O
used O O
in O O
other O O
countries O O
such O O
as O O
Japan O O
. O O

We O O
investigated O O
how O O
these O O
two O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
drugs O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
act O O
on O O
the O O
cardiovascular O B_BODY_PART_OR_ORGAN_COMPONENT/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
systems O I_BODY_PART_OR_ORGAN_COMPONENT/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
20 O B_PERSON/B_ENT
dogs O I_PERSON/I_ENT
whose O O
hearts O B_BODY_PART_OR_ORGAN_COMPONENT/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
had O O
been O O
denervated O O
by O O
a O O
procedure O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
we O O
had O O
devised O O
. O O

Both O O
ATP B B_ORGANIZATION/B_LOCATION
and O O
SNP B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
should O O
act O O
on O O
the O O
pacemaker O O
tissue O O
of O O
the O O
heart O O
. O O

Contrary O O
to O O
an O O
earlier O O
report O O
by O O
Coxon O O
, O O
scoline B B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
pain O O
occurs O O
in O O
African O O
negroes O O
. O O

About O O
62 O O
% O O
of O O
the O O
out O O
- O O
patients O O
developed O O
scoline B B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
pain O O
as O O
compared O O
with O O
about O O
26 O O
% O O
among O O
the O O
in O O
- O O
patients O O
. O O

The O O
abolition O O
of O O
muscle O O
fasciculations O O
( O O
by O O
0 O O
. O O
075mg O O
/ O O
kg O O
dose O O
of O O
Fazadinium B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
did O O
not O O
influence O O
the O O
occurrence O O
of O O
scoline B B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
pain O O
. O O

These O O
findings O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
suggest O O
that O O
smooth O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
muscle O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
cells O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
are O O
susceptible O B_TIME[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
to O O
damage O B_DISEASE
in O O
the O O
course O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O O
their O O
specific O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
function O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Abnormalities O O
of O O
the O O
pupil O O
and O O
visual O O
- O O
evoked O O
potential O O
in O O
quinine B B_DISEASE_ADJECTIVE[DISEASE]/B_BIO
amblyopia O O
. O O

A O O
transient O O
tonic O O
pupillary O O
response O O
, O O
denervation O O
supersensitivity O O
, O O
and O O
abnormal O O
visual O O
- O O
evoked O O
potentials O O
in O O
quinine B B_DISEASE/B_PROTEIN[GENE]
toxicity O O
, O O
to O O
our O O
knowledge O O
, O O
have O O
not O O
been O O
previously O O
reported O O
. O O

Etomidate B B_MEASURE
: O O
a O O
foreshortened O O
clinical O O
trial O O
. O O

Finally O O
, O O
only O O
five O B_TIME[MEASURE]/B_PERSON
cases O B_TIME[MEASURE]/I_PERSON
of O O
acute O B_DISEASE
parenchymal O I_DISEASE
renal O I_DISEASE
disease O I_DISEASE
occurred O O
, O O
none O B_DISEASE_ADJECTIVE[DISEASE]/B_TIME[MEASURE]
likely O I_DISEASE_ADJECTIVE[DISEASE]/I_TIME[MEASURE]
to O O
be O O
caused O O
by O O
a O O
study O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
drug O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
. O O

We O O
conclude O O
that O O
the O O
risk O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
of O O
the O O
serious O B_DISEASE_ADJECTIVE[DISEASE]
diseases O I_DISEASE_ADJECTIVE[DISEASE]
studied O O
is O O
small O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
for O O
the O O
three O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
agents O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
and O O
compares O O
reasonably O O
with O O
the O O
risk O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O O
many O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
other O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
antibiotics O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O O

Experimental O B_DISEASE
progressive O I_DISEASE
muscular O I_DISEASE
dystrophy O I_DISEASE
and O O
its O O
treatment O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
with O O
high O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
doses O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
anabolizing O O
agents O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

In O O
this O O
way O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
they O O
obtained O O
appreciable O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
changes O I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
body O B_MEASURE
weight O I_MEASURE
( O O
increased O O
from O O
50 O B_MEASURE
to O O
70 O B_MEASURE
g O I_MEASURE
after O O
forty O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_ORGANISM_FUNCTION
days O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_ORGANISM_FUNCTION
at O O
a O O
dose O B_MEASURE/B_DISEASE
of O O
5 O B_MEASURE
mg O I_MEASURE
per O O
day O B_TIME[MEASURE]
of O O
anabolizing O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
agent O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
) O O
, O O
but O O
most O B_SEQUENCE[MEASURE]
of O O
all O O
they O O
found O O
histological O B_DISEASE_ADJECTIVE[DISEASE]/B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
changes O I_DISEASE_ADJECTIVE[DISEASE]/I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
due O I_DISEASE_ADJECTIVE[DISEASE]/I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
" O O
regenerative O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
" O O
changes O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
in O O
the O O
muscle O B_BODY_PART_OR_ORGAN_COMPONENT
tissue O I_BODY_PART_OR_ORGAN_COMPONENT
, O O
which O O
however O O
maintained O O
its O O
myopathic O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
characteristics O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
the O O
control O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
animals O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
that O O
were O O
not O O
treated O O
with O O
the O O
anabolizing O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
agent O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

The O O
225 O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
mg O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
/ O O
m2 O B_MEASURE/B_LOCATION
level O I_MEASURE/I_LOCATION
was O O
expanded O O
for O O
the O O
phase O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
II O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
study O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
since O O
the O O
highest O B_MEASURE/B_LOCATION
level O I_MEASURE/I_LOCATION
achieved O O
( O O
250 O B_MEASURE
mg O I_MEASURE
/ O O
m2 O B_MEASURE/B_LOCATION
) O O
required O O
modification O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
because O O
of O O
nonhematologic O B_DISEASE
toxicities O I_DISEASE
( O O
arthralgia O B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
and O O
sensory O B_DISEASE
neuropathy O I_DISEASE
) O O
. O O

Adverse O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
reactions O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
drugs O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
are O O
well O O
recognized O O
as O O
a O O
cause O B_DISEASE
of O O
acute O B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
or O O
chronic O B_DISEASE_ADJECTIVE[DISEASE]
urticaria O I_DISEASE_ADJECTIVE[DISEASE]
, O O
and O O
angio O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
- O O
oedema O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O O

The O O
potential O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
neurotoxic O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
effects O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O O
the O O
drug O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
and O O
its O O
vehicle O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
) O O
in O O
this O O
population O B_PERSON/B_LOCATION
are O O
discussed O O
. O O

An O O
introducer O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
sheath O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
, O O
a O O
pacemaker O B_MEDICAL_DEVICE[OBJECT]/B_BODY_PART_OR_ORGAN_COMPONENT
, O O
and O O
sterile O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
pacing O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
wires O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O O
made O O
readily O O
available O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O O
the O O
patients O B_PERSON/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O O
should O O
the O O
need O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
arise O O
to O O
terminate O O
resistant O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
cardiac O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
dysrhythmias O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O O

Right O B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
ventricular O I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
pacemaker O I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
wires O I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
were O O
inserted O O
in O O
all O O
of O O
them O O
during O O
cardiopulmonary O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_BODY_PART_OR_ORGAN_COMPONENT
resuscitation O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_BODY_PART_OR_ORGAN_COMPONENT
( O O
CPR O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
) O O
. O O

In O O
four O B_PERSON/B_MEASURE
patients O I_PERSON/I_MEASURE
, O O
cardiac O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
pacing O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
was O O
used O O
, O O
resulting O O
in O O
a O O
temporary O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
captured O O
rhythm O B_DISEASE/B_MEASURE
and O O
restoration O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
their O O
cardiac O B_MEASURE/B_BODY_PART_OR_ORGAN_COMPONENT
output O B_MEASURE/I_BODY_PART_OR_ORGAN_COMPONENT
. O O

Patients O B_PERSON/B_DISEASE
were O O
observed O O
on O O
an O O
inpatient O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
basis O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
for O O
18 O B_NUMBER[MEASURE]
to O O
24 O B_TIME[MEASURE]/B_SPORT[ENT]
hours O I_TIME[MEASURE]/I_SPORT[ENT]
, O O
and O O
vital O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
signs O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
nausea O B_DISEASE
, O O
vomiting O B_DISEASE
, O O
retching O B_DISEASE
, O O
and O O
appetite O B_DISEASE
were O O
assessed O O
. O O

There O O
was O O
a O O
statistically O O
longer O B_TIME[MEASURE]
time O I_TIME[MEASURE]
to O O
first O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
episode O B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
nausea O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
( O O
P O B_MEASURE
= O I_MEASURE
. O O
0015 O B_MEASURE
) O O
and O O
vomiting O B_DISEASE
( O O
P O B_OTHER/B_LOCATION
= O O
. O O
0001 O B_MEASURE
) O O
, O O
and O O
fewer O B_PERSON
patients O I_PERSON
were O O
administered O O
additional O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
antiemetic O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
medication O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
the O O
10 O B_MEASURE
- O O
micrograms O B_MEASURE/B_LOCATION
/ O O
kg O B_MEASURE
dosing O I_MEASURE
groups O I_MEASURE
than O O
in O O
the O O
5 O B_MEASURE
- O O
micrograms O B_MEASURE/B_LOCATION
/ O O
kg O B_MEASURE/B_ORGANIZATION
dosing O I_MEASURE/I_ORGANIZATION
group O I_MEASURE/I_ORGANIZATION
. O O

Granisetron B B_PERSON
was O O
well O O
tolerated O O
at O O
all O O
doses O O
. O O

Clinicians O B_PERSON
should O O
be O O
acquainted O O
with O O
this O O
possibly O O
fatal O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
interaction O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
between O O
two O B_NUMBER[MEASURE]/B_PERSON
commonly O O
used O O
antihypertensive O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
drugs O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

The O O
two O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
drugs O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
may O O
act O O
synergistically O O
on O O
both O O
the O O
AV O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
node O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
and O O
the O O
peripheral O B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
circulation O B_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
. O O

Pharmacological O O
studies O O
on O O
a O O
new O O
dihydrothienopyridine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
calcium I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
antagonist O O
, O O
S B B_LOCATION
- I I_LOCATION
312 I I_LOCATION
- I I_LOCATION
d I I_LOCATION
. O O

5th O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
communication O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
: O O
anticonvulsant O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
effects O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
mice O B_SPECIES[BIO]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

S B B_MEASURE/B_LOCATION
- I I_MEASURE/I_LOCATION
312 I I_MEASURE/I_LOCATION
, O O
S B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
- I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
312 I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
- I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
d I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
, O O
but O O
not O O
S B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
312 I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
l I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
, O O
L O O
- O O
type O O
calcium B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
channel O O
antagonists O O
, O O
showed O O
anticonvulsant O O
effects O O
on O O
the O O
audiogenic O O
tonic O O
convulsions O O
in O O
DBA O O
/ O O
2 O O
mice O O
; O O
and O O
their O O
ED50 O O
values O O
were O O
18 O O
. O O
4 O O
( O O
12 O O
. O O
8 O O
- O O
27 O O
. O O
1 O O
) O O
mg O O
/ O O
kg O O
, O O
p O O
. O O
o O O
. O O
and O O
15 O O
. O O
0 O O
( O O
10 O O
. O O
2 O O
- O O
23 O O
. O O
7 O O
) O O
mg O O
/ O O
kg O O
, O O
p O O
. O O
o O O
. O O
, O O
respectively O O
, O O
while O O
that O O
of O O
flunarizine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
34 O O
. O O
0 O O
( O O
26 O O
. O O
0 O O
- O O
44 O O
. O O
8 O O
) O O
mg O O
/ O O
kg O O
, O O
p O O
. O O
o O O
. O O

This O O
resulted O O
in O O
an O O
increased O O
incidence O B_MEASURE
of O O
seizures O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O O
90 O B_DISEASE
% O I_DISEASE
( O O
P O B_MEASURE/B_LOCATION
< O I_MEASURE/I_LOCATION
. O O
01 O B_MEASURE
) O O
, O O
and O O
death O B_DISEASE
, O O
100 O B_TIME[MEASURE]/B_LOCATION
% O I_TIME[MEASURE]/I_LOCATION
( O O
P O B_MEASURE
< O I_MEASURE
or O O
= O O
. O O
01 O B_MEASURE
) O O
, O O
compared O O
with O O
group O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
4 O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O O

This O O
also O O
resulted O O
in O O
an O O
increased O O
incidence O B_MEASURE
of O O
seizures O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O O
90 O B_DISEASE
% O I_DISEASE
( O O
P O B_MEASURE
< O I_MEASURE
or O O
= O O
. O O
01 O B_MEASURE
) O O
, O O
and O O
death O B_DISEASE
, O O
90 O B_MEASURE
% O I_MEASURE
( O O
P O B_MEASURE
< O I_MEASURE
or O O
= O O
. O O
05 O B_MEASURE
) O O
, O O
compared O O
with O O
group O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
4 O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
. O O

Studies O O
were O O
performed O O
to O O
examine O O
the O O
mechanisms O O
for O O
the O O
protective O O
effects O O
of O O
free O O
radical O O
scavengers O O
on O O
gentamicin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
( O O
GM B B_ORGANIZATION/B_PROTEIN[GENE]
) O O
- O O
mediated O O
nephropathy O O
. O O

Superoxide B B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
dismutase O O
( O O
SOD O O
) O O
or O O
dimethylthiourea B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
( O O
DMTU B B_LOCATION/B_ORGANIZATION
) O O
significantly O O
lessened O O
the O O
GM B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
induced O O
decrement O O
in O O
CIn O O
. O O

These O O
results O O
suggest O O
that O O
1 O O
) O O
both O O
SOD O O
and O O
DMTU B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
have O O
protective O O
effects O O
on O O
GM B B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
mediated O O
nephropathy O O
, O O
2 O O
) O O
the O O
mechanisms O O
for O O
the O O
protective O O
effects O O
differ O O
for O O
SOD O O
and O O
DMTU B B_LOCATION/B_ORGANIZATION
, O O
and O O
3 O O
) O O
superoxide B B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
anions O O
play O O
a O O
critical O O
role O O
in O O
GM B B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
induced O O
renal O O
vasoconstriction O O
. O O

An O O
anti O O
- O O
cephalothin B B_VIRUS[BIO]/B_DISEASE
IgG O O
antibody O O
was O O
detected O O
in O O
the O O
patient O O
' O O
s O O
serum O O
and O O
in O O
the O O
eluates O O
from O O
her O O
erythrocytes O O
. O O

Careful O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
investigation O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
drug O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
induced O O
hemolytic O B_DISEASE_ADJECTIVE[DISEASE]
anemias O I_DISEASE_ADJECTIVE[DISEASE]
reveals O O
the O O
complexity O B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
the O O
immune O B_DISEASE_ADJECTIVE[DISEASE]
mechanisms O I_DISEASE_ADJECTIVE[DISEASE]
involved O O
. O O

A O O
survey O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
15 O B_MEASURE/B_BIO
independent O I_MEASURE/I_BIO
inbred O I_MEASURE/I_BIO
strains O I_MEASURE/I_BIO
of O O
mice O B_SPECIES[BIO]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
revealed O O
that O O
ventricular O B_MEASURE/B_PERSON
cardiomyocyte O B_MEASURE/I_PERSON
nuclear O B_MEASURE/I_PERSON
number O B_MEASURE/I_PERSON
ranged O O
from O O
3 O B_NUMBER[MEASURE]
to O O
13 O B_MEASURE
% O I_MEASURE
mononucleate O I_MEASURE
, O O
suggesting O O
that O O
cardiomyocyte O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
terminal O B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
differentiation O B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
is O O
influenced O O
directly O O
or O O
indirectly O O
by O O
genetic O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
background O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
. O O

The O O
purpose O O
of O O
the O O
present O O
study O O
was O O
to O O
compare O O
influence O O
of O O
central O O
arginine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
vasopressin I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
( O O
AVP B B_LOCATION/B_PROTEIN[GENE]
) O O
and O O
of O O
atrial O O
natriuretic O O
peptide O O
( O O
ANP O O
) O O
on O O
control O O
of O O
arterial O O
blood O O
pressure O O
( O O
MAP O O
) O O
and O O
heart O O
rate O O
( O O
HR O O
) O O
in O O
normotensive O O
( O O
WKY O O
) O O
and O O
spontaneously O O
hypertensive O O
( O O
SHR O O
) O O
rats O O
. O O

Sensitivity O O
of O O
cardiac O O
component O O
of O O
baroreflex O O
( O O
CCB O O
) O O
, O O
expressed O O
as O O
a O O
slope O O
of O O
the O O
regression O O
line O O
was O O
determined O O
from O O
relationships O O
between O O
systolic O O
arterial O O
pressure O O
( O O
SAP O O
) O O
and O O
HR O O
period O O
( O O
HRp O O
) O O
during O O
phenylephrine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
Phe B B_LOCATION/B_PERSON
) O O
- O O
induced O O
hypertension O O
and O O
sodium B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
nitroprusside I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
SN B B_LOCATION/B_ORGANIZATION
) O O
- O O
induced O O
hypotension O O
. O O

In O O
SHR O O
but O O
not O O
in O O
WKY O O
administration O O
of O O
ANP O O
, O O
AVP B B_LOCATION/B_GENE
and O O
ANP O O
+ O O
AVP B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
decreased O O
CCB O O
during O O
Phe B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
- O O
induced O O
MAP O O
elevation O O
. O O

No O O
prophylaxis O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O O
antilymphocyte O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
globulin O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
used O O
. O O

Widespread O B_DISEASE_ADJECTIVE[DISEASE]
cognitive O I_DISEASE_ADJECTIVE[DISEASE]
disorders O I_DISEASE_ADJECTIVE[DISEASE]
, O O
such O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
as O O
delirium O B_DISEASE/B_LOCATION
, O O
have O O
not O O
been O O
previously O O
linked O O
with O O
high O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
blood O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
levels O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
of O O
SSRIs O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
. O O

Left O O
atrial O O
and O O
left O O
ventricular O O
papillary O O
muscle O O
contractile O O
responses O O
to O O
isoproterenol B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O O
reduced O O
compared O O
to O O
controls O O
in O O
groups O O
treated O O
with O O
clentiazem B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
alone O O
, O O
but O O
combined O O
with O O
epinephrine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
clentiazem B B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
restored O O
left O O
atrial O O
responses O O
and O O
enhanced O O
left O O
ventricular O O
papillary O O
responses O O
to O O
isoproterenol B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

This O O
effect O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
on O O
the O O
renal O B_BODY_PART_OR_ORGAN_COMPONENT/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
function O I_BODY_PART_OR_ORGAN_COMPONENT/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
could O O
be O O
prohibited O O
by O O
the O O
administration O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
a O O
peripheral O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
dopa O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
decarbodylase O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
inhibitor O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

The O O
results O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
indicate O O
that O O
this O O
new O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
model O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
is O O
very O O
sensitive O B_DISEASE_ADJECTIVE[DISEASE]
and O O
enables O O
monitoring O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
the O O
development O B_DISEASE_ADJECTIVE[DISEASE]/B_ORGANISM_FUNCTION
of O O
cardiotoxicity O B_DISEASE
with O O
time O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
. O O

The O O
NMS O B_DISEASE/B_GENE
- O O
like O B_DISEASE
encephalopathy O I_DISEASE
that O O
develops O O
in O O
association O B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O O
the O O
use O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_ORGANISM_FUNCTION
of O O
antidepressants O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
indicates O O
that O O
NMS O B_LOCATION
and O O
SS O B_DISEASE
are O O
spectrum O B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
disorders O I_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
induced O O
by O O
drugs O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
with O O
both O O
antidopaminergic O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
serotonergic O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
effects O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

The O O
hemorrhagic O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
F2 O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
pituitaries O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
were O O
all O O
among O O
the O O
most O O
massive O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
, O O
indicating O O
that O O
some O O
of O O
the O O
genes O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
regulate O O
both O O
phenotypes O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
. O O

Chemical O O
cystitis O O
was O O
induced O O
by O O
cyclophosphamide B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
( O O
CYP B B_PROTEIN[GENE]/B_LOCATION
) O O
which O O
is O O
metabolized O O
to O O
acrolein B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
, O O
an O O
irritant O O
eliminated O O
in O O
the O O
urine O O
. O O

The O O
effect O O
of O O
recombinant O O
human O O
insulin O O
- O O
like O O
growth O O
factor O O
- O O
I O O
on O O
chronic O O
puromycin B B_DISEASE_ADJECTIVE[DISEASE]
aminonucleoside I I_DISEASE_ADJECTIVE[DISEASE]
nephropathy O O
in O O
rats O O
. O O

We O O
recently O O
demonstrated O O
that O O
recombinant O O
hGH O O
exacerbates O O
renal O O
functional O O
and O O
structural O O
injury O O
in O O
chronic O O
puromycin B B_DISEASE
aminonucleoside I I_DISEASE
( O O
PAN B B_DISEASE/B_LOCATION
) O O
nephropathy O O
, O O
an O O
experimental O O
model O O
of O O
glomerular O O
disease O O
. O O

Therefore O O
, O O
we O O
examined O O
whether O O
recombinant O O
human O O
( O O
rh O O
) O O
IGF O O
- O O
I O O
is O O
a O O
safer O O
alternative O O
for O O
the O O
treatment O O
of O O
growth O O
failure O O
in O O
rats O O
with O O
chronic O O
PAN B B_DISEASE_ADJECTIVE[DISEASE]
nephropathy O O
. O O

Urinary O O
protein O O
excretion O O
was O O
unaltered O O
by O O
rhIGF O O
- O O
I O O
treatment O O
in O O
rats O O
with O O
chronic O O
PAN B B_DISEASE
nephropathy O O
. O O

After O O
12 O O
wk O O
, O O
the O O
inulin O O
clearance O O
was O O
higher O O
in O O
rhIGF O O
- O O
I O O
- O O
treated O O
rats O O
, O O
0 O O
. O O
48 O O
+ O O
/ O O
- O O
0 O O
. O O
08 O O
versus O O
0 O O
. O O
24 O O
+ O O
/ O O
- O O
0 O O
. O O
06 O O
mL O O
/ O O
min O O
/ O O
100 O O
g O O
of O O
body O O
weight O O
in O O
untreated O O
PAN B B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
nephropathy O O
animals O O
, O O
p O O
< O O
0 O O
. O O
05 O O
. O O

In O O
rats O O
with O O
PAN B B_DISEASE
nephropathy O O
, O O
administration O O
of O O
rhIGF O O
- O O
I O O
increased O O
IGF O O
- O O
I O O
and O O
GH O O
receptor O O
gene O O
expression O O
, O O
without O O
altering O O
the O O
steady O O
state O O
level O O
of O O
IGF O O
- O O
I O O
receptor O O
mRNA O O
. O O

Nefiracetam B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
( O O
DM B B_MEASURE/B_PROTEIN[GENE]
- I I_MEASURE/I_PROTEIN[GENE]
9384 I I_MEASURE/I_PROTEIN[GENE]
) O O
reverses O O
apomorphine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
induced O O
amnesia O O
of O O
a O O
passive O O
avoidance O O
response O O
: O O
delayed O O
emergence O O
of O O
the O O
memory O O
retention O O
effects O O
. O O

A O O
case O O
of O O
phenytoin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
( O O
DPH B B_DISEASE/B_PROTEIN[GENE]
) O O
encephalopathy O O
with O O
increasing O O
seizures O O
and O O
EEG O O
and O O
mental O O
changes O O
is O O
described O O
. O O

Human O O
corticotropin B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- O O
releasing O O
hormone O O
and O O
thyrotropin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
- O O
releasing O O
hormone O O
modulate O O
the O O
hypercapnic O O
ventilatory O O
response O O
in O O
humans O O
. O O

In O O
a O O
placebo O B_LOCATION/B_PERSON
- O O
controlled O O
, O O
single O B_NUMBER[MEASURE]/B_LOCATION
- O O
blind O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
study O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
we O O
aimed O O
to O O
clarify O O
if O O
both O O
peptides O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
act O O
by O O
altering O O
central O B_DISEASE
chemosensitivity O I_DISEASE
. O O

The O O
results O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
indicate O O
an O O
additive O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
effect O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
both O O
releasing O O
hormones O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O O
the O O
hypercapnic O B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
ventilatory O B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
response O B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
in O O
humans O B_SPECIES[BIO]/B_DISEASE
, O O
presumably O O
independent O B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
of O O
central O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
chemosensitivity O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
. O O

Lamivudine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O O
effective O O
in O O
suppressing O O
hepatitis O O
B O O
virus O O
DNA O O
in O O
Chinese O O
hepatitis B B_DISEASE
B I I_DISEASE
surface I I_DISEASE
antigen I I_DISEASE
carriers O O
: O O
a O O
placebo O O
- O O
controlled O O
trial O O
. O O

We O O
performed O O
a O O
single O O
- O O
blind O O
, O O
placebo O O
- O O
controlled O O
study O O
to O O
assess O O
its O O
effectiveness O O
and O O
safety O O
in O O
Chinese O O
hepatitis B B_DISEASE
B I I_DISEASE
surface I I_DISEASE
antigen I I_DISEASE
( O O
HBsAg B B_DISEASE/B_GENE
) O O
carriers O O
. O O

Forty O O
- O O
two O O
Chinese O O
HBsAg B B_DISEASE
carriers O O
were O O
randomized O O
to O O
receive O O
placebo O O
( O O
6 O O
patients O O
) O O
or O O
lamivudine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
orally O O
in O O
dosages O O
of O O
25 O O
mg O O
, O O
100 O O
mg O O
, O O
or O O
300 O O
mg O O
daily O O
( O O
12 O O
patients O O
for O O
each O O
dosage O O
) O O
. O O

The O O
drug O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
given O O
for O O
4 O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
weeks O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
. O O

There O O
was O O
no O O
change O B_MEASURE
in O O
the O O
hepatitis O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
B O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
e O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
antigen O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
status O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
or O O
in O O
aminotransferase O B_DISEASE
levels O I_DISEASE
. O O

In O O
conclusion O O
, O O
a O O
4 O O
- O O
week O O
course O O
of O O
lamivudine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
was O O
safe O O
and O O
effective O O
in O O
suppression O O
of O O
HBV O O
DNA O O
in O O
Chinese O O
HBsAg B B_DISEASE/B_PERSON
carriers O O
. O O

The O O
suppression O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
was O O
> O B_DISEASE_ADJECTIVE[DISEASE]
90 O I_DISEASE_ADJECTIVE[DISEASE]
% O I_DISEASE_ADJECTIVE[DISEASE]
but O O
reversible O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
. O O

BACKGROUND O O
: O O
Four O O
studies O O
published O O
since O O
December O O
, O O
1995 O O
, O O
reported O O
that O O
the O O
incidence O O
of O O
venous O O
thromboembolism O O
( O O
VTE O O
) O O
was O O
higher O O
in O O
women O O
who O O
used O O
oral B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
contraceptives I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
( O O
OCs B B_LOCATION/B_ORGANIZATION
) O O
containing O O
the O O
third O O
- O O
generation O O
progestagens B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
gestodene B I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
or O O
desogestrel B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
than O O
in O O
users O O
of O O
OCs B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
containing O O
second O O
- O O
generation O O
progestagens B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
. O O

All O O
women O B_PERSON
who O O
had O O
a O O
recorded O O
diagnosis O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
deep O B_LOCATION/B_DISEASE
- O O
vein O B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
thrombosis O I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
, O O
venous O B_DISEASE
thrombosis O I_DISEASE
not O O
otherwise O O
specified O O
, O O
or O O
pulmonary O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
embolus O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
during O O
the O O
study O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
period O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
, O O
and O O
who O O
had O O
been O O
treated O O
with O O
an O O
anticoagulant O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
were O O
identified O O
as O O
potential O B_PERSON/B_DISEASE
cases O I_PERSON/I_DISEASE
of O O
VTE O B_DISEASE
. O O

Scopolamine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
and O O
pentobarbital B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
blocked O O
the O O
pilocarpine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
induced O O
electrographic O O
seizure O O
, O O
MK B B_LOCATION
- I I_LOCATION
801 I I_LOCATION
treatment O O
augmented O O
the O O
electrographic O O
seizure O O
induced O O
by O O
pilocarpine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

5 B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Fluorouracil I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
plus O O
folinic B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
acid I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
paclitaxel B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
Taxol B B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
; O O
Bristol O O
- O O
Myers O O
Squibb O O
Company O O
, O O
Princeton O O
, O O
NJ O O
) O O
are O O
effective O O
salvage O O
therapies O O
for O O
metastatic O O
breast O O
cancer O O
patients O O
. O O

TFL O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
is O O
an O O
active O B_DISEASE_ADJECTIVE[DISEASE]
, O O
well O O
- O O
tolerated O O
regimen O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
metastatic O B_DISEASE/B_BIO
breast O I_DISEASE/I_BIO
cancer O I_DISEASE/I_BIO
. O O

The O O
tuberoinfundibular O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
dopaminergic O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
( O O
TIDA O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
system O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
is O O
known O O
to O O
inhibit O O
prolactin O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
( O O
PRL O B_PROTEIN[GENE]/B_LOCATION
) O O
secretion O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
. O O

In O O
young O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ENT
animals O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ENT
this O O
system O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ENZYME[GENE]
responds O O
to O O
acute O B_DISEASE_ADJECTIVE[DISEASE]
elevations O I_DISEASE_ADJECTIVE[DISEASE]
in O O
serum O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
PRL O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
by O O
increasing O O
its O O
activity O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
. O O

The O O
purpose O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O O
this O O
study O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
to O O
induce O O
hyperprolactinemia O B_DISEASE
in O O
rats O B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O O
extended O B_TIME[MEASURE]/B_LOCATION
periods O I_TIME[MEASURE]/I_LOCATION
of O O
time O B_TIME[MEASURE]
and O O
examine O O
its O O
effects O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O O
dopaminergic O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
systems O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
the O O
brain O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
. O O

After O O
6 O O
months O O
of O O
hyperprolactinemia O O
, O O
dopamine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
DA B B_LOCATION
) O O
concentrations O O
in O O
the O O
median O O
eminence O O
( O O
ME O O
) O O
increased O O
by O O
84 O O
% O O
over O O
the O O
control O O
group O O
. O O

There O O
was O O
no O O
change O O
in O O
the O O
levels O O
of O O
DA B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
, O O
norepinephrine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
( O O
NE B B_LOCATION/B_ORGANIZATION
) O O
, O O
serotonin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
5 B B_LOCATION
- I I_LOCATION
HT I I_LOCATION
) O O
, O O
or O O
their O O
metabolites O O
in O O
the O O
arcuate O O
nucleus O O
( O O
AN O O
) O O
, O O
medial O O
preoptic O O
area O O
( O O
MPA O O
) O O
, O O
caudate O O
putamen O O
( O O
CP O O
) O O
, O O
substantia O O
nigra O O
( O O
SN O O
) O O
, O O
and O O
zona O O
incerta O O
( O O
ZI O O
) O O
, O O
except O O
for O O
a O O
decrease O O
in O O
5 B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
hydroxyindoleacetic I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
acid I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
( O O
5 B B_LOCATION/B_ORGANIZATION
- I I_LOCATION/I_ORGANIZATION
HIAA I I_LOCATION/I_ORGANIZATION
) O O
in O O
the O O
AN O O
after O O
6 O O
- O O
months O O
of O O
hyperprolactinemia O O
and O O
an O O
increase O O
in O O
DA B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
concentrations O O
in O O
the O O
AN O O
after O O
9 O O
- O O
months O O
of O O
hyperprolactinemia O O
. O O

A O O
case O O
of O O
acute O O
renal O O
failure O O
, O O
due O O
to O O
occlusion O O
of O O
renal O O
vessels O O
in O O
a O O
patient O O
with O O
acute O O
promyelocytic O O
leukemia O O
( O O
APL O O
) O O
treated O O
with O O
all B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
trans I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
retinoic I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
acid I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
ATRA B B_ORGANIZATION/B_LOCATION
) O O
and O O
tranexamic B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
acid I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
has O O
been O O
described O O
recently O O
. O O

After O O
10 O B_TIME[MEASURE]/B_ENT
days O I_TIME[MEASURE]/I_ENT
of O O
treatment O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
, O O
he O O
developed O O
acute O B_DISEASE
renal O I_DISEASE
failure O I_DISEASE
that O O
was O O
completely O O
reversible O B_DISEASE_ADJECTIVE[DISEASE]
after O O
complete O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
remission O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
of O O
APL O B_DISEASE
was O O
achieved O O
and O O
therapy O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
discontinued O O
. O O

Pupillary O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
changes O B_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
associated O O
with O O
the O O
development O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
stimulant O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
induced O O
mania O B_DISEASE/B_LOCATION
: O O
a O O
case O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
report O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
. O O

Such O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
medication O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
- O O
associated O O
changes O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
in O O
the O O
total O B_MEASURE
power O I_MEASURE
of O O
pupillary O B_DISEASE/B_PROTEIN[GENE]
oscillation O B_DISEASE/I_PROTEIN[GENE]
might O O
be O O
of O O
utility O B_LOCATION/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
identifying O O
persons O B_PERSON/B_LOCATION
at O O
risk O B_DISEASE_ADJECTIVE[DISEASE]
for O O
manic O B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
like O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
adverse O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
effects O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
during O O
the O O
medical O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_ORGANISM_FUNCTION
use O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_ORGANISM_FUNCTION
of O O
psychomotor O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
stimulants O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
or O O
sympathomimetic O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
agents O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

In O O
view O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
the O O
risks O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
to O O
both O O
mother O B_PERSON/B_BIO
and O O
fetus O B_PERSON
in O O
women O B_PERSON
with O O
prosthetic O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
cardiac O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
valves O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
it O O
is O O
recommended O O
that O O
therapeutic O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
abortion O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
be O O
advised O O
as O O
the O O
first O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
alternative O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

The O O
negative O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
mucosal O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
potential O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
: O O
separating O O
central O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
and O O
peripheral O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
effects O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
of O O
NSAIDs O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
man O B_PERSON/B_BIO
. O O

OBJECTIVE O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
: O O
We O O
wanted O O
to O O
test O O
whether O O
assessment O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
both O O
a O O
central O B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
pain O B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
- O O
related O O
signal O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
( O O
chemo O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_BODY_PART_OR_ORGAN_COMPONENT
- O O
somatosensory O B_BODY_PART_OR_ORGAN_COMPONENT/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
evoked O O
potential O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
, O O
CSSEP O B_LOCATION/B_DISEASE
) O O
and O O
a O O
concomitantly O O
recorded O O
peripheral O B_DISEASE/B_MEASURE
signal O I_DISEASE/I_MEASURE
( O O
negative O B_LOCATION
mucosal O I_LOCATION
potential O I_LOCATION
, O O
NMP O B_LOCATION/B_DISEASE
) O O
allows O O
for O O
separation O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
central O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
and O O
peripheral O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
effects O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
of O O
NSAIDs O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
. O O

For O O
this O O
purpose O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
experimental O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
conditions O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O O
created O O
in O O
which O O
NSAIDs O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
had O O
previously O O
been O O
observed O O
to O O
produce O O
effects O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
on O O
phasic O B_DISEASE_ADJECTIVE[DISEASE]
and O O
tonic O B_DISEASE/B_ORGANISM_FUNCTION
pain O I_DISEASE/I_ORGANISM_FUNCTION
by O O
either O O
central O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
or O O
peripheral O B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
mechanisms O B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
. O O

Based O O
on O O
the O O
similar O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
behaviour O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O O
CSSEP O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
NMP O B_DISEASE
, O O
it O O
was O O
concluded O O
that O O
the O O
pharmacological O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
process O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
underlying O O
this O O
phenomenon O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
was O O
localised O O
in O O
the O O
periphery O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
. O O

By O O
means O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
the O O
simultaneous O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
recording O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O O
interrelated O B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
peripheral O B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
and O O
central O B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
electrophysiologic O B_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
correlates O B_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
of O O
nociception O B_DISEASE
, O O
it O O
was O O
possible O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
separate O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
central O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
and O O
peripheral O B_LOCATION
effects O I_LOCATION
of O O
an O O
NSAID O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

The O O
major O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
advantage O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O O
this O O
pain O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
model O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
is O O
the O O
possibility O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
of O O
obtaining O O
peripheral O B_DISEASE_ADJECTIVE[DISEASE]
pain O I_DISEASE_ADJECTIVE[DISEASE]
- O O
related O O
activity O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
directly O O
using O O
a O O
non O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
- O O
invasive O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
technique O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
in O O
humans O B_PERSON/B_SPECIES[BIO]
. O O

Dehydrated O O
rats O O
regularly O O
develop O O
acute O O
renal O O
failure O O
following O O
single O O
injection O O
of O O
aminoglycoside B B_NUMBER[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
antibiotics O O
combined O O
with O O
dextran O O
or O O
of O O
antibiotics O O
only O O
. O O

D B B_PERSON
- I I_PERSON
Glucarates I I_PERSON
had O O
the O O
ability O O
to O O
prevent O O
renal O O
damage O O
but O O
not O O
to O O
cure O O
it O O
. O O

CNA O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
was O O
administered O O
for O O
a O O
mean O B_MEASURE/B_LOCATION
of O O
11 O B_MEASURE
+ O I_MEASURE
/ O O
- O O
10 O B_TIME[MEASURE]
hr O I_TIME[MEASURE]
. O O

He O O
gave O O
a O O
five O O
- O O
year O O
history O O
of O O
polyuria O O
and O O
polydipsia O O
, O O
during O O
which O O
time O O
urinalysis O O
had O O
been O O
negative O O
for O O
glucose B B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
. O O

RESULTS O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
: O O
All O O
dosage O B_PERSON/B_ORGANIZATION
groups O I_PERSON/I_ORGANIZATION
consisted O O
of O O
three O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_NUMBER[MEASURE]
women O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_NUMBER[MEASURE]
, O O
except O O
those O O
with O O
100 O B_MEASURE
microg O I_MEASURE
( O O
n O B_OTHER/B_MEASURE
= O O
6 O B_MEASURE
) O O
and O O
200 O B_MEASURE
microg O I_MEASURE
( O O
n O B_OTHER/B_MEASURE
= O O
18 O B_MEASURE
) O O
. O O

The O O
majority O B_MEASURE
of O O
additional O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
administration O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
oxytocics O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
( O O
4 O B_MEASURE
/ O O
5 O B_MEASURE
) O O
and O O
blood O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
transfusion O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
( O O
3 O B_MEASURE
/ O O
5 O B_MEASURE
) O O
occurred O O
in O O
the O O
dose O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
groups O I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
200 O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
microg O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
. O O

CONCLUSION O O
: O O
The O O
MTD O O
was O O
calculated O O
to O O
be O O
at O O
200 O O
microg O O
carbetocin B B_LOCATION
. O O

Sumatriptan B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
succinate I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
, O O
a O O
serotonin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O O
1 O O
( O O
5 B B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
- I I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
hydroxytryptamine I I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
- O O
1 O O
) O O
receptor O O
agonist O O
, O O
is O O
an O O
antimigraine O O
drug O O
that O O
is O O
reported O O
to O O
act O O
by O O
selectively O O
constricting O O
intracranial O O
arteries O O
. O O

Clinical O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
assessment O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
as O O
well O O
as O O
blinded O O
ratings O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
Unified O B_DISEASE
Parkinson O I_DISEASE
' O I_DISEASE
s O I_DISEASE
Disease O I_DISEASE
Rating O I_DISEASE
Scale O I_DISEASE
( O O
UPDRS O B_DISEASE
) O O
scores O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O O
carried O O
out O O
pre O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
and O O
postoperatively O O
. O O

Gamma O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
Knife O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
pallidotomy O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
is O O
as O O
effective O B_DRUG_ADJECTIVE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
as O O
radiofrequency O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
pallidotomy O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O O
controlling O O
certain O B_DISEASE_ADJECTIVE[DISEASE]/B_NUMBER[MEASURE]
of O O
the O O
symptoms O B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
Parkinson O B_DISEASE
' O I_DISEASE
s O I_DISEASE
disease O I_DISEASE
. O O

It O O
may O O
be O O
the O O
only O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
practical O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
technique O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
available O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O O
certain O B_PERSON/B_LOCATION
patients O I_PERSON/I_LOCATION
, O O
such O B_DISEASE_ADJECTIVE[DISEASE]/B_TIME[MEASURE]
as O O
those O O
who O O
take O O
anticoagulants O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
have O O
bleeding O O
diatheses O B_DISEASE_ADJECTIVE[DISEASE]
or O O
serious O B_DISEASE
systemic O I_DISEASE
medical O I_DISEASE
illnesses O I_DISEASE
. O O

Effects O O
of O O
17alpha B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
ethinylestradiol I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
( O O
EE B B_LOCATION/B_ORGANIZATION
) O O
on O O
the O O
neutral O O
and O O
acidic O O
biosynthetic O O
pathways O O
of O O
bile B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
salt I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
( O O
BS B B_LOCATION
) O O
synthesis O O
were O O
evaluated O O
in O O
rats O O
with O O
an O O
intact O O
enterohepatic O O
circulation O O
and O O
in O O
rats O O
with O O
long O O
- O O
term O O
bile O O
diversion O O
to O O
induce O O
BS B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
synthesis O O
. O O

This O O
study O O
shows O O
that O O
17alpha B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
ethinylestradiol I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
( O O
EE B B_LOCATION/B_ORGANIZATION
) O O
- O O
induced O O
intrahepatic O O
cholestasis O O
in O O
rats O O
is O O
associated O O
with O O
selective O O
inhibition O O
of O O
the O O
neutral O O
pathway O O
of O O
bile B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
salt I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
BS B B_LOCATION/B_ORGANIZATION
) O O
synthesis O O
. O O

The O O
effects O O
of O O
helodermin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
, O O
a O O
basic O O
35 O O
- O O
amino B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
acid I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
peptide O O
isolated O O
from O O
the O O
venom O O
of O O
a O O
lizard O O
salivary O O
gland O O
, O O
on O O
arterial O O
blood O O
pressure O O
and O O
heart O O
rate O O
were O O
examined O O
in O O
the O O
rat O O
, O O
focusing O O
on O O
the O O
possibility O O
that O O
activation O O
of O O
ATP B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
sensitive O O
K B B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
+ O O
( O O
K B B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
ATP B B_PROTEIN[GENE]/B_LOCATION
) O O
) O O
channels O O
is O O
involved O O
in O O
the O O
responses O O
. O O

The O O
results O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
were O O
also O O
compared O O
with O O
those O O
of O O
vasoactive O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
intestinal O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
polypeptide O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
( O O
VIP O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
. O O

Helodermin B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
produced O O
hypotension O O
in O O
a O O
dose O O
- O O
dependent O O
manner O O
with O O
approximately O O
similar O O
potency O O
and O O
duration O O
to O O
VIP O O
. O O

These O O
findings O O
suggest O O
that O O
helodermin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
- O O
produced O O
hypotension O O
is O O
partly O O
attributable O O
to O O
the O O
activation O O
of O O
glibenclamide B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O O
sensitive O O
K B B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
+ O O
channels O O
( O O
K B B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
ATP B B_PROTEIN[GENE]/B_LOCATION
) O O
channels O O
) O O
, O O
which O O
presumably O O
exist O O
on O O
arterial O O
smooth O O
muscle O O
cells O O
. O O

